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A bstract 
Abstract 
Cardiovascular disease is the most common cause of premature death in the developed 
world and is responsible for 39% of all mortalities in the UK. Three quarters of these 
deaths are a consequence coronary heart disease and stroke, conditions that often 
occur as a result of platelet aggregation and thrombus formation causing ischaemia- 
inducing vascular blockages. Currently the prevention of coronary occlusion in high- 
risk patients involves the inhibition of platelet aggregability, however, reducing the 
number of circulating platelets, which are produced by megakaryocytes, remains 
unexplored. Megakaryocytopoiesis is tightly regulated by a spectrum of cytokines 
ensuring differentiation and circulating platelet numbers remain within normal 
physiological restraints. Recently, it was identified that megakaryocytes express 
NMDA-type glutamate receptors and subsequent studies implied a role for the 
glutamate signalling in megakaryocytic cell line differentiation. This thesis 
characterises the expression and role of the megakaryocytic NMDA receptor in both 
cell lines and primary human cells. MEG-O1 and HEL cell lines in addition to primary 
megakaryocytes express a range of regulatory NR2 and NR3 receptor subunits as well 
as the PSD proteins Yotiao and PSD-95. Blockade of the NMDA receptor ion channel 
with MK-801 reduced ERK 1 /2 activation and inhibited primary megakaryocyte 
differentiation. Formation of proplatelets in vitro was dramatically inhibited by MK- 
801 treatment, as were normal ultrastructural characteristics including a-granule 
formation and the expansion of demarcation membrane. It was also demonstrated that 
megakaryocytes express the vesicular glutamate transporter protein VGLUT2, whilst 
MEG-01 cells spontaneously release glutamate, providing a plausible glutamate source 
for NMDA receptor activation. It was also established that transgenic mice with 
significantly lowered levels of the NR1 subunit demonstrated a 5-fold increase in 
bleeding time compared to wildtype control. In the future, therapeutic manipulation of 
the megakaryocytic NMDA receptor may enable a greater level of control over platelet 
production by the modification of megakaryocyte differentiation. 
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Chapter 1 
Introduction 
1.1 Cardiovascular disease 
The human body relies on the circulatory system, driven by the heart, for the supply of 
oxygen and nutrients to its tissues. Breakdowns in this system, usually involving 
narrowing or blockages of the blood vessels or failure of the heart muscle, are often 
catastrophic. 
The British Heart Foundation's 2002 statistics confirm that the main cause of death in 
the UK remains diseases of the heart and circulatory system (cardiovascular disease or 
CVD) (Fig. 1.1). CVD resulted in 235,000 UK deaths in 2000,39% of all mortalities. 
Coronary heart disease (CHD; disease of the heart and blood vessels supplying the 
heart) and stroke (interruption of blood supply to areas of the brain) are the main 
forms of CVD, accounting for three quarters of mortalities. Although CVD-induced 
death increases dramatically with old age, it also causes one quarter (73,000) of 
premature mortalities (deaths before 75 years). 
Worldwide, incidences of CHD are decreasing, a statistic mirrored in the UK (Fig. 1.2). 
However, the death rate from CHD in the UK remains amongst the highest in the world. 
Apart from Eastern and Central European countries, where CHD mortalities are 
increasing dramatically, only Ireland and Finland have a higher CHD death rate than the 
UK (Fig. 1.3). Although the death rates are decreasing in the UK, this is not at the same 
rate as other European counties, especially Scandinavia. 
In the UK, CHD mortalities remain higher in males than females, although death rates 
in younger males (45-54) are decreasing more than in females of the same age. 
Incidences of CHD mortalities show a greater decrease in younger age groups. Death 
rates from stroke have also been falling throughout the last century and by 20"o in the 
last 10 years (Fig. 1.4). As well as differences between sexes, there are also worrying 
variations between regions in the UK. Premature death rates in Scotland are 50% and 
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Figure 1.1. Causes of death in the UK in the year 2000. Cardiovascular 
disease (including CHD, stroke and other CVD) accounts for more deaths than 
any other cause, numbering 235,000, equivalent to 39% of all fatalities (taken 
from British Heart Foundation CHD statistics 2002; www. bhf org. uk). 
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Figure 1.2. Percentage decrease in total incidences of CHD mortalities in 
selected countries worldwide from 1986 to 1996. Death rates have generally 
decreased, apart from many Eastern European countries which show worrying 
increases in the number of CHD deaths (taken from British Heart Foundation 
CUD statistics 2002; www. bhf. org. uk). 
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Figure 1.4. Age specific death rates in males and females / 100,000 population in the UK 
of C'Vl) from 1968-1998. The death rates are higher in males and is significantly more prevalent 
in older age groups. Fatalities have decreased in all age groups, especially amongst the younger 
generations (taken from British Heart Foundation CHD statistics 2002. , Nw-w. bhf. org. uk). 
Chapter 1 
80% higher in men and women respectively than those living in East Anglia and CHD 
mortalities are also significantly higher in the North of England and Northern Ireland 
than Wales and Southern England. Notably. the highest mortality rates are localised to 
large urban areas. 
The prevalence of CVD in the UK is reflected by its cost to the health services. CHD 
alone is thought to cost the health care system £1.600 million per annum (p. a. ). the 
majority of which is spent on hospital inpatient care and drug administration. This 
total is over twice the amount of all other diseases. In addition to the costs to the health 
care system, CVD also costs the UK economy in the order of £ 11.000 million p. a. in 
production losses, due to working time lost and informal care, usually provided by 
families. However, the most recent study investigates only selected diseases and does 
not include cancer. The cost to the UK economy is preventable as the majority of risk 
factors leading to CVD are avoidable. These include smoking, poor diet, lack of 
physical activity, obesity, raised blood pressure and raised blood cholesterol. 
1.1.1 Current therapies for CVD 
The treatment of CVD has increased dramatically over the last 20 years. The number 
of operations, including coronary artery bypass surgery and angioplasty have increased 
5-fold since 1980. However, these procedures are extremely invasive and health 
services are focusing on administration of CVD preventative drugs. Diuretics have 
been the most common prescription drugs used in the prevention of CVD in the last 20 
years. Over this time however, other preventative treatments have emerged, most 
notably from the increased use of prescriptive drugs aimed at preventing clotting in the 
blood by anticoagulants and antiplatelet drugs (Fig. 1.5). Platelets are the smallest 
component of blood and are responsible for the formation of a thrombus (clot), 
preventing excessive bleeding following vascular injury (for in-depth platelet review, 
see Introduction 1.2). Platelets are activated at sites of injury, therefore any damaged 
vascular area, especially major and coronary arteries, is at risk of thrombus formation 
(Topol. 1998). Platelet activation and aggregation subsequently causes a positive 
feedback mechanism, resulting in the release of components promoting 
N'asoco>istriction and further platelet aggregation (Verheugt and Gersh. 2002). 
Blockages of blood vessels caused by the formation of clots, reduce the supply of 
6 
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oxygen to the heart and the brain (ischaemia). often causing severe damage by 
ischaemic heart disease and stroke. 
Aspirin is currently the most widely used anticoagulant and consistently reduces the 
incidence of ischaemic attack in high-risk patients (Theroux et al., 1988; The Risc 
Group, 1990) and is also beneficial when combined with low molecular weight heparin 
(The Frisc Study Group, 1996; Cohen et al., 1997; Harding et al.. 2002). Aspirin acts 
as an anticoagulant by inhibiting the production of the aggregation promoting 
thromboxane A2 by platelets (Fig. 1.6). Consequently, platelets exposed to aspirin do 
not respond to the pro-thrombotic agents collagen and adenosine diphosphate (ADP) 
(O'Brien, 1968; Zucker and Rothwell, 1978). Aspirin is cheap and as a preventative, 
greatly lowers the incidence of CVD in high-risk patients (Antithrombotic Trialists' 
Collaboration, 2002). However, recent evidence indicates an increase in aspirin 
resistance and fatal post-operative bleeding (Cambria-Kiely and Gandhi, 2002; 
Howard, 2002), leading to the development of improved therapies for modulating 
platelet function. 
The use of antiplatelet therapies in the UK has increased nearly 60-fold in the last 20 
years (Fig. 1.5). Antiplatelet drugs function by inhibiting the activation of the 
glycoprotein (GP) IIb/IIIa receptor on platelets, the role of which is to initiate the final 
stages of platelet aggregation (Harding et al., 2002) (Fig. 1.6). Intravenous 
administration of antibodies raised against GPIIb/IIIa, especially abciximab, has 
provided very positive results in numerous clinical trials (The CAPTURE 
Investigators, 1997; The PRISM Investigators, 1998; The PURSUIT Trial 
Investigators, 1998; The PARAGON Investigators, 1998; Chew and Moliterno, 2000, 
The GUSTO IV-ACS Investigators, 2001). Similar to aspirin, these antagonists create 
the potential to provoke major haemorrhage and are also extremely expensive 
(Verbeugt and Gersh, 2002). Orally administered GPIIb/IIIa antagonists have proved 
significantly less successful. A recent report indicates that these drugs have no effect 
on ischaemic events and actually increase in the number of mortalities (Chew et at.. 
2001). 
F he control of ischaernic disease is currently managed by a combination of the 
previously mentioned therapeutics. How ever, the "all-or-nothing" irre` ersible effect 
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Figure 1.6. Diagram summarising the action of aspirin and GPIIb/IIIa inhibiting drugs 
on thrombus formation. Aspirin inhibits the actions of ADP and thromboxane A2, whilst the 
GPI Ibi Il la inhibitors prevent the binding of activated platelets to fibrinogen. The methods of 
both drugs successfully reduce the occurrence of CVD, but can complicate the process of 
coagulation, especially following surgery. 
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on all platelets causes subsequent detrimental effects. Rather than ensure that the 
circulating platelets do not function. a more effective mechanism of preventing 
ischaemia would be to tightly modulate the total number of circulating platelets. This 
would ensure that the risk of clotting would decrease, but haemorrhage would be less 
likely to occur. This demands a clear understanding of the cellular mechanisms that 
culminate in platelet production from its "precursor cell", the megakary, ocyte. 
1.2 The Megakaryocyte and Platelet Production 
In 1890, W. W. Howell described the "formation of the giant cells of the marrow" and 
was the first to name these cells megakaryocytes. Sixteen years later, J. H. Wright 
identified the megakaryocyte as the source of blood platelets (Wright, 1906). 
Megakaryocyte research stagnated after these discoveries until the 1970's, when 
molecular and in vitro research provided insight to different stages of normal and 
abnormal megakaryocyte development (megakaryocytopoiesis) and the effects of 
cytokines acting on megakaryocytes. 
1.2.1 Megakaryocytopoiesis 
Megakaryocytes reside in a number of tissues. Predominantly these are the main 
locations of blood cell production, bone marrow and spleen. It is also notable that 
megakaryocytes have also been identified in the lung (Martin et al., 1983; Slater et al., 
1983; Trowbridge et al., 1988) and whole cells passed from the bone marrow to the 
circulation (Tavassoli and Aoki, 1981). In the foetus, the megakaryocyte appears first 
in the yolk sac and then the liver before appearance in the spleen and marrow during 
embryogenesis (Gilman. 1942). The vast majority of megakaryocyte research focuses 
on cells within the bone marrow. Bone marrow fills the cylindrical cavities of long 
bones such as the femur and ulnae and is comprised of fatty "yellow" marrow and 
haematopoietic "red" marrow. Although only 0.5% of cells within the bone marrow 
are megakaryocytes, they are easily recognisable due to their size. A fully matured 
megakaryocyte is several-times the size of any other cell within the bone marrow, 
within the region of 30 µm in diameter. 
10 
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Haematopoiesis is the process by which all mature blood cells are produced from 
multipotent haematopoietic stem cells (HSCs). HSCs are a small subset of blood cells 
with the potential to self-renew and in the relevant conditions, differentiate to all 
components of the haematopoietic system (Fig. 1.7). The HSC differentiates to the 
myeloid lineage, from which the megakaryocyte lineage-committed progenitor cell is 
derived (for review see Bruno and Hoffman, 1998). The earliest megakaryocyte- 
restricted progenitor cell to develop in vitro from the adult bone marrow is the burst 
forming unit megakaryocyte (BFU-MK) (Long et al., 1985; Brindell et al., 1989), 
followed by the colony forming unit megakaryocyte (CFU-MK) (Brindell et al., 1990), 
both of which contain only megakaryocytes. However, some mixed colonies do form, 
the most common is the BFU-erythroid/megakaryocyte (BFU-E / MK). The single 
BFU-E / MK cell has bi-potentiality and after 12 days in culture, mixed erythroblasts 
/megakaryocyte colonies form (Debili et al., 1996). This demonstrates just one of the 
associations between the differentiation of the megakaryocyte and the erythrocyte. 
The CFU-MK is the most differentiated megakaryocyte progenitor cell. The later 
stages of differentiation are essentially characterised by morphological differences 
(Long, 1998). The immature megakaryocyte (or megakaryoblast) has a sparse 
cytoplasm and high nucleus to cytoplasm ratio, due to the large amount of protein 
synthesis at this stage. The nuclear and cytoplasm size both increase at the 
promegakaryocytic stage, in addition to the appearance of platelet-specific particles. 
Megakaryocyte development culminates in cytoplasmic maturation and nuclear 
endoreplication (see Chapter 1.2.2. ). Platelets are then shed into the circulation, 
although the exact means of this remains unknown (see Chapter 1.2.3. ). 
During differentiation, megakaryocytes and their precursor cells express certain cell 
surface markers at stages of differentiation. All haematopoietic progenitor cells 
express CD 34 during the early stages of differentiation. The expression of CD34 
declines during megakaryocytopoiesis and is absent in the terminally differentiated 
cells. Cells of the megakaryocyte lineage express the specific lineage marker CD41 
(also known as platelet dgl coprotein or (GP)Ilb), from the CFI 1-MK stage through to 
maturity. CD61 (GPIIIa) is expressed during early megakaryocyte 
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differentiation, and CD42a (GPIX) expression is limited to terminally differentiated 
cells (Lepage et al., 2000). 
1.2.2 Megakaryocytic Endomitosis 
Megakaryocyte differentiation is characterised by the formation of a polyploid nucleus 
by endomitosis (reviewed in Zimmet and Ravid, 2000). This is a process in which 
nuclear replication takes place in the absence of cellular replication, leading to a large 
number of repeated chromosomes compared with the normal diploid (2N) cell. 
Endomitosis is not exclusive to megakaryocytes in the mammal. Cardiac myocytes 
(Sandritter and Scomazzoni, 1964), hepatocytes (Kudryavtsev et al., 1993) and arterial 
smooth muscle cells (Owens and Schwartz, 1983) all become polyploid at some point 
during normal cellular development as well as smooth muscle cells during pregnancy 
(Heiden and James, 1975) and thyroid cells in hyperthyroidism (Auer et al., 1985). 
Abnormalities in chromosome number are also common in malignant cells. However 
this is a condition known as aneuploidy, in which specific chromosomes are deleted or 
replicated. Quantification of aneuploid cells is now used in prognosis of prostate, 
colon and breast cancers (Barlogie, 1984). However, megakaryocyte polyploidisation 
is unique, as the cell becomes highly polyploid during normal differentiation. The 
immature megakaryocyte is a diploid (2N) cell and in this state is able proliferate at a 
high rate (Zimmer and Ravid, 2000). When the cell differentiates and undergoes 
endomitosis, the cell no longer divides and undergoes further endomitotic cycles, 
leading to cells of 4,8,16,32,64 and even 128N, with the mode being 16N. Polyploid 
megakaryocytes would therefore be able to produce much greater amounts of mRNA 
and protein than a normal diploid cell, enabling the megakaryocytes to perform the 
unique process of platelet production. 
The exact mechanism by which the megakaryocyte achieves such high levels of 
polyploidy is a subject of ongoing research. It appears that the megakaryocvte 
undergoes a quiescent stage following cycles of nuclear division (Odell et al., 1968, 
Zhang et al.. 1996). Previously, it was thought that during mitosis, polyploid 
megakarg ocytes proceed normally up to anaphase A. but do not proceed with anaphase 
B. telophase or cytokinesis (Fig. 1.8) (Nagata, 1997). A more recent publication did 
however identif the characteristics of anaphase (DNA condensation, nuclear 
13 
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membrane breakdown and formation of a mitotic spindle). suggesting that only 
cytokinesis was absent in megakaryocytes compared to normal nuclear replication 
(Vitrat, 1998). It would therefore appear that the formation of a polyploid nucleus is 
due to abortive mitosis. The mechanisms underlying abortive mitosis in the 
megakaryocyte appears to involve the cell cycle regulator cyclin B-dependent cdc2 
kinase (Datta et al., 1996; Zhang et al., 1996; Garcia and Cales, 1996, Carow et al., 
2001). Cyclins are proteins synthesised during interphase of the cell cycle and 
degraded at the end of mitosis (Patel et al., 1999). Lowered levels of cyclin B1 causes 
megakaryocytic cells to undergo polyploidisation (Zhang et al.. 1996) and ubiquitin- 
mediated degradation of cyclin B1 allows re-entry to the S-phase of the cell cycle 
without completing anaphase (Zhang et al., 1998). Datta and co-workers demonstrated 
that polyploidy in megakaryocytic cells is actually associated with increases in levels 
of cyclin B and cdc2, but it is the down regulation of the phosphatase cdc25-C (cdc2 is 
only active in a phosphorylated state) that causes the subsequent inactivity of cdc2 
(Datta et al., 1996). However, considering the rarity of the megakaryocyte, combined 
with the fact that only 1% of megakaryocytes at anytime are undergoing mitosis, the 
exact mechanism of megakaryocytic polyploidisation may remain elusive for some 
time. The reason for megakaryocytes becoming polyploid appears to be important in 
the production of platelets. Idiopathic thrombocytopenic purpura (ITP) is an inducible 
immunologic condition in which platelet number is greatly reduced. This causes an 
increase in levels of megakaryocyte polyploidy as well as increases in megakaryocyte 
number and size, suggesting that the megakaryocyte endomitosis is responding to low 
platelet numbers (Mazur et al., 1988; Tomer et al., 1989). When circulating platelet 
number becomes normal, the level of megakaryocyte ploidy reverts to its normal modal 
score of 16N. Other reports also suggest that high levels of ploidy in megakaryocytes 
have a direct non-linear relationship with mean platelet mass (platelet volume x 
number) (Bessman, 1984). Atherosclerotic patients often display abnormally high 
ploidy megakaryocytes and it is postulated that as platelets produced from these cells 
are larger and more easily activated, they may have a causative effect on this condition 
(Brown et al., 1997). Work by Kuter and Rosenberg conclusively demonstrated the 
existence of a "feedback loop" between the number of circulating platelets and 
megakaryocyte ploidy (Kuter and Rosenberg. 1990). Thrombocvtopenia induced in 
mice by application of anti-platelet serum correlates with increases in megakar` ocv'te 
ploidv. which is reduced by platelet transfusion. Therefore, in response to changes in 
15 
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platelet number. megakaryocyte ploidy varies inversely with and proportionally to 
platelet change. The mediators of this feedback loop remain unclear. However. 
following the finding that circulating platelets actively bind TPO (Fielder et al, 1996). 
it seems likely that platelets can regulate the plasma TPO levels directly by its binding. 
1.2.3 Platelet Production 
Once the megakaryocyte develops a highly polyploid nucleus, the cytoplasm also 
undergoes a unique maturation process. Firstly, the cytoplasm develops a demarcation 
membrane system (DMS), the origin of which remains unknown. In immature 
megakaryocytes, the DMS is concentrated to local areas of the cell, but as the cell 
matures, the DMS is present in the vast majority of the cytoplasm. At this stage, 
primitive platelets begin to form within the cytoplasm of the megakaryocyte (known as 
platelet territories) and the DMS dilates to eventually fragment the cytoplasm and 
release the matured platelets (Nurden et al., 1997). During this process, platelet- 
specific proteins are expressed and small dense bodies known as a-granules, form. 
These contain substances vital for the function of the mature platelet, such as von- 
Willebrand factor (vWF), ADP, GPIIb/IIIa, serotonin and ß-thromboglobulin (Long, 
1998). a-Granule disorders, such as von Willebrand disease type III, Glazmann 
thrombasthenia and Gray platelet syndrome, although quite rare, often result in 
decreased platelet number and aggregation causing clotting abnormalities (Smith et al., 
1997). 
As previously eluded, the major function of the megakaryocyte is in the formation and 
release of mature, functional platelets. The various stages of differentiation ensure that 
the mature megakaryocyte cytoplasm is weak and easily ruptured and the platelets 
which are already formed can be released into the circulation. The process by which 
platelets are released from the mature megakaryocyte is termed thrombocytopoiesis. 
l'ach megakaryocyte can form between 1,000 and 5,000 platelets, which are 
subsequently released into the circulation, but the process by which this is achieved is 
poorly understood. The widely accepted process, hypothesised by Wright in 1910, is 
that megakarvocytes produce platelets from the bone marrow by forming long thin 
cytoplasmic structures known as proplatelets. As mature megakarvocv-tes in the bone 
16 
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marrow are often observed in close proximity to blood-filled sinusoids (Tavassoli. 
1980), it has been suggested that the proplatelet structures are able to invade the 
sinusoid and the circulating blood pressure will cause the proplatelet to disintegrate, 
resulting in platelet release in the sinusoid lumen. Scanning electron microscope 
(SEM) pictures have supported this idea (Ihzumi et al., 1977; Radley and Scurfield. 
1980; Handagama et al., 1984), with the identification of such cytoplasmic extensions 
observed in the canine marrow sinusoid. It is also possible that entire intact 
megakaryocytes can enter circulation via the sinusoid, entailing transendothelial 
migration through parajunctional areas of the sinusoid, approximately 6µm in diameter 
(Tavassoli and Aoki, 1981). The other plausible method of platelet release is by 
passage of whole megakaryocytes from the marrow through the microcirculation of the 
lungs causing cytoplasmic disintegration with pulmonary macrophages destroying the 
released nuclei (Martin et al., 1993; Zucker-Franklin and Philipps, 2000). It is believed 
that splenic megakaryocytes only contribute to thrombocytopoiesis following complete 
bone marrow ablation (Layendecker and McDonald, 1982). The contribution of each 
site to circulating platelet number is far from clear, owing to major experimental 
problems with these investigations. 
Apoptosis is the process of programmed cell death, often induced by extracellular 
signals such as a death signal or withdrawal of factors vital for cell survival. This 
process takes place in virtually all cells during development, to control cell number and 
eradicate senescent or unhealthy cells. The differentiated megakaryocyte however, is 
able to undergo apoptosis completely of its own accord, in the absence of extracellular 
stimuli (for review see Li and Kuter, 2001). Bcl-x is a member of the Bcl-2 family of 
potent antiapoptotic proteins and is expressed at very high levels almost throughout 
megakaryocytopoiesis. Bcl-x expression has however been shown to decrease 
dramatically in large terminally differentiated megakaryocytes on the verge of 
producing platelets (Sanz et al., 2001). Transgenic mice overexpressing Bcl-x in 
rnegakarv ocvtes showed, as expected, a reduction in the number of megakaryocv tes 
undergoing apoptosis, although the majority of these cells were unable to form 
proplatelets in culture and lacked normal DMS morphology (Kaluzhny et al., 2002). 
ON-erexpression of Bcl-' results in a 2-fold reduction in the number of circulating 
platelets, although nlegakarvocvte number remains unchanged (O`gilv'y' et al.. 1999). 
17 
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More recently a family of proteases, known as caspases. which are activated during 
apoptosis have also been implicated in the formation of proplatelets from bone 
marrow-derived megakaryocytes (De Botton et al., 2002). Cleavage and subsequent 
activation of procaspase-3 and -9 occurs in megakarvocytes undergoing proplatelet 
formation and caspase inhibition with the specific inhibitor z-VAD. fmk. inhibited 
proplatelet formation from mature megakaryocytes. When z-VAD. fmk is added to 
cells already undergoing platelet formation, it has no effects. These results are 
consistent with the theory that platelet formation occurs through a process similar to 
that of apoptosis. 
18 
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1.3 Regulation of Megakaryocytopoiesis 
A wide range of different cytokines regulates the proliferation. survival and 
differentiation of progenitor cells to mature platelet-producing megakaryocytes 
(summarised in Fig. 1.9). The majority of the cytokines identified so far are positive 
regulators, promoting the differentiation of the haematopoietic stem cells down the 
megakaryocyte lineage and a few have been identified that inhibit megakaryocyte 
differentiation (reviewed in Wendling and Han, 1997). This ensures that the number of 
circulating platelets is tightly regulated. Although effects of several different classes of 
cytokines are important in megakaryocytopoiesis, most of which will be mentioned 
here, the most potent effects appear to be mediated by thrombopoietin (TPO). 
1.3.1 Thrombopoietin 
The exact nature of TPO remained a mystery from when it was first named as the 
humoral substance responsible for platelet production in 1958 (Kelemen et al., 1958) 
until it was characterised and cloned in 1994 (de Sauvage et al., 1994; Lok et al., 1994, 
Kaushansky et al.; 1994; Wendling et al., 1994). TPO was identified as a polypeptide 
of 353 amino acids, presumed to consist of two domains due to its homology with the 
major regulator of erythrocyte development, erythropoietin (EPO). The 155 residues at 
the amino-terminal have 46 percent sequence similarity to EPO and binds to the TPO 
receptor, c-Mpl (Bartley et al., 1994). The carboxy-terminal has no homology to any 
haematopoietic cytokines and the deletion of this domain has no overall effect on 
thrombopoietin activity (Hokom et al., 1995). It is clear that TPO affects nearly every 
aspect of megakaryocyte development. TPO, in conjunction with other cytokines 
involved in cell proliferation, supports HSC survival and promotes entry to the 
megakaryocyte lineage (Kaushansky. 1995a; Ku et al., 1996; Sitnicka et al., 1996). 
TPO then stimulates expression of platelet-specific markers associated with 
megakaryocyte differentiation, such as CD61 (Kaushansky et al., 1994), causes the 
development of a polyploid nucleus by endomitosis (Debili et al., 1995) and triggers 
the maturation of the cytoplasm (Choi et al., 1995: Cramer et al.. 1997). The profound 
effects TPO has on megakaryocytes in vitro, lead to the development of transgenic 
mice lacking the genes 
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for c-Mpl (c-Mpl-/-) (Gurney et al.. 1994; Alexander et al.. 1996) or TPO (TPO-`-) (de 
Sauvage et al., 1996). In c-Mpl-/- mice, both megakaryocyte and platelet numbers are 
reduced by approximately 90% compared to c-MpF and c-Mpl+/- without affecting 
any other blood cell lineages. In addition, the mean platelet volume is significantly 
increased in the knockout animals. TPO-"- mice also display a 90% reduction in 
megakaryocyte and platelet numbers and show a decrease in the levels of polyploidy in 
the knockouts compared to wild-types. The TPO-'- mice differ from the c-Mpl-/-, as 
the TPO gene appears to work in a dose-dependant manner with heterozygous mice 
(TPO+/-) with megakaryocyte and platelet counts intermediate of knockout and wild- 
type. However, in c-Mpl+'- mice, megakaryocyte and platelet counts are not 
significantly to wild-types. These data identify that TPO is the major regulator of 
megakaryocytopoiesis, acting through c-Mpl. The actions of TPO although most 
profound in megakaryocytes, are not restricted only to this lineage. TPO also enhances 
the proliferation and expansion of erythroid progenitors (Kaushansky et al., 1995b). 
CFU-granulocyte-macrophage (CFU-GM) lineage in normal mice (Kaushansky et al., 
1996) and the proliferation of human and murine HSCs (Young et al., 1996, Kobayashi 
et al., 1996; Sitnicka et al., 1996). 
The commercial availability of recombinant TPO has enabled the characterisation of 
signalling events induced by its interaction with c-Mpl. On binding TPO, c-Mpl 
becomes a homodimer resulting in the activation of numerous downstream signalling 
events (reviewed in Fig. 1.10). Janus kinases (JAK) are already bound to the 
cytoplasmic domain of the receptor and following dimerisation, the increase in local 
JAK concentration causes cross phosphorylation and subsequent activation (Miyazaki 
et al., 1994). There are four members of the JAK family, JAK 1,2,3 and TYK2. Of 
these JAK2 is the most important in c-Mpl mediated signal transduction as it is the 
only one of the family activated in the presence of TPO (Tortolani et al., 1995: \1u et 
at.. 1995). Once activated, JAK2 phosphorylates tyrosine residues located on the 
cytoplasmic domain of the receptor enabling the receptor to activate independent 
pathways (Drachman et al., 1999). as well as directly activating other signalling 
mechanisms. In nlegakarvocytes, the most studied substrate of J: \K is the signal 
transducers and activators of transcription (STATs) family, of which STAT3 and 5 are 
activated almost immediately following binding of TPO to c-Mpl. STATs bind to 
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Chapter I 
phosphotyrosines situated on the receptor and are themselves then activated by JAK. 
The phosphorylated STATs form homodimers and translocate to the nucleus causing 
transcriptional activation (Dorsch et al.. 1997). The adaptor proteins Grb2. SOS and 
Shc, the GTP exchange protein Vav and the phosphatase SHP-2 are also activated by 
JAK2 on c-Mpl almost immediately on binding TPO (Miyakawa et al., 2001). These 
proteins activate the mitogen activated protein kinase (MAPK) pathway, also 
culminating in the activation of transcription factors (Rojnuckarin et al.. 1999). 
Another c-Mpl-activated pathway of great importance to megakaryocyte development 
is phosphoinositide-3-kinase (P13-K). Activation of c-Mpl induces the regulatory 
domain of P13-K to undergo a conformational change and recruits the P13-K kinase 
domain. Activated P13-K can then activate the MAPK pathway, members of the 
protein kinase C (PKC) family and also AKT (also known as protein kinase B (PKB)) 
(Sattler et al., 1997; Geddis et al., 2001; Rojnuckarin et al., 2001; Majka et al., 2002). 
The c-Mpl-mediated activation of MAPK is thought to promote megakaryocyte 
proliferation and differentiation, whilst AKT, via its downstream targets NFKB, ß- 
catenin, forkhead transcription factor and Bad, influences cell survival in addition to 
differentiation (Rojnuckarin et al., 2001; Majka et al., 2002). 
TPO is clearly essential for correct megakaryocyte development. However its 
influence appears to be restricted to megakaryocyte progenitor cell proliferation and 
ploidy. C-Mpi-'- and TPO-/- mice although thrombocytopenic, do not bleed 
spontaneously as would be expected if TPO signalling were the single most important 
cytokine in platelet production. Bunting and co-workers (1997) showed that the 
remaining megakaryocytes and platelets from c-Mpl-/- and TPO-/- mice have normal 
ultrastructural morphology compared to wild-type. Functional studies demonstrated 
that platelets from these mice respond as normal to agonists such as ADP and 
fibrinogen. This suggests that the c-Mpl / TPO system is not solely responsible for the 
production of normal megakaryocytes and platelets. In vitro. mature megakaryocytes 
isolated from mouse bone marrow. do not disintegrate into platelets following 
administration of TPO, but instead require the presence of serum (Kaushanskv, 
personal communication). This observation confirms in vivo studies using baboons 
injected for a 28-day period with human recombinant TPO. in which a 7-day delay in 
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increased platelet numbers was observed after the first administration of TPO (Harker 
et al., 1996). This work also suggests that the role of TPO is predominantly 
megakaryocyte proliferation rather than megakaryocyte differentiation and platelet 
production. 
1.3.2 Other Positive Regulators of Megakaryocytopoiesis 
As previously mentioned a wide range of cytokines, in addition to TPO, have positive 
effects on megakaryocyte differentiation. These remaining cytokines are however 
much less megakaryocyte-specific than TPO and influence the production of nearly all 
cells during haematopoiesis. Stem cell factor (SCF; also known as steel factor and C- 
kit) in conjunction with interleukin (IL)-3 and granulocyte macrophage colony- 
stimulating factor (GM-CSF) has profound effects on megakaryocyte progenitor 
proliferation, greatly increasing colony size (Brindell et al., 1991). Transgenic mice 
lacking either the gene for SCF or its receptor show a decrease in total megakaryocyte 
number, although platelet numbers do not decrease due to a concomitant increase in 
megakaryocyte size and consequently, the ability to produce more platelets (Hunt et al., 
1992). These findings suggest that SCF primarily regulates progenitor cell 
proliferation. IL-3 appears to have a greater effect on megakaryocytopoiesis than GM- 
CSF, with IL-3 treatment increasing platelet numbers in both primates and humans 
(Farese et al., 1993) whilst GM-CSF has no significant effect on platelet number, but 
instead increases the number of CFU-MK colonies (Vannucchi et al., 1990; Stahl et al., 
1991). A greater increase in platelet number has been demonstrated when IL-3 and 
GM-CSF were used in conjunction, compared to independent application 
(O'Shaughnessy et al., 1995). 
The role of IL-6 family of cytokines, comprising of IL-6, Leukaemia inhibitory factor 
(LIF), IL-11, oncostatin M, ciliary neurotrophic factor (CNTF) and cardiotrophin-1 
(CT-1) has been the subject of extensive research in megakaryocytopoiesis. The 
majority of these studies have focused on IL-6. which promotes megakaryocyte 
development, increasing the number and size of cells, as well as endomitosis and 
proplatelet formation (Ishibashi et al.. 1989; Debili et al.. 19933). Increased serum IL-6 
concentrations in rheumatoid arthritis usually results in reactive thrombocvtosis (over- 
active nmegakaryocytopoicsis). indicating that IL-6 may be a cause of pathological 
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megakaryocytopoiesis (de Benedetti et al.. 1991: Hollen et al.. 1991). Doubt was cast 
on these findings however, when the IL-6 knockout mouse was shovm to have no 
platelet number abnormalities (Kishimoto et al., 1994). IL-11 and LIF have similar 
effects to each other, both inducing the maturation of immature megakaryocytes in 
vitro. Mice treated with IL-11 or LIF show a 1-2 fold increase in the circulating 
platelet number, without increasing the overall number of megakaryocytes (Burstein et 
al., 1992; Teramura et al., 1992). This is believed to be due to IL-11 and LIF 
increasing the megakaryocyte ploidy levels. Phase I clinical trials using IL-11 have 
proved disappointing, having no effect on patients suffering from chemotherapy- 
induced thrombocytopenia (Gordon et al., 1996). 
Other factors promoting megakaryocytopoiesis include EPO, which has a proliferative 
action on the bi-potential BFU-E/M cells. Mice treated with low levels of EPO show a 
small increase in platelet number, although chronic EPO treatment causes 
thrombocytopenia (Macdonald et al., 1987), presumably due to the majority of bi- 
potential cells being forced down the erythrocyte lineage (Broudy et al., 1995). 
Granulocyte colony stimulating factor (G-CSF) and fibroblastic growth factor ß 
(FGF3) also stimulate megakaryocyte development, possibly by working in 
conjunction with IL-3 (Glapsy and Golde, 1992). 
1.3.3 Negative Regulators of Megakaryocytopoiesis 
The majority of megakaryocytopoiesis research has focused on positive regulation. 
lowever, it is becoming increasingly apparent that negative regulation is a vital control 
mechanism for platelet release. The majority of these factors are actually released by 
megakaryocytes and platelets, inducing a negative feedback mechanism, inhibiting 
differentiation (Caen and Han. 1995; Gewirtz et al., 1995). Transforming growth 
factor ß1 (TGF31) has the greatest inhibitory effect on megakaryocyte development 
and is extremely potent, with picogram amounts irreversibly affecting both human and 
mouse megakaryocyte progenitors in vitro (Keller et al., 1991; Kuter et al., 1992, Xi et 
al.. 1996) (Fig . 
1.9). Subcutaneous injection of TGFß 1 for a 14-day period decreased 
platelet number (Carlino et al.. 1990) but also increased the number of macrophages 
and granulocytes (Bursuker et al.. 1992). indicating that TGFI 1 may have a bi- 
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directional effect on haematopoiesis. Platelet factor 4 (PF4), released from platelet a- 
granules upon activation (Mantovani et al., 1994), has an inhibitory effect on the 
proliferation of megakaryocyte progenitors in vitro and in vivo (Gerwitz. 1989; Han et 
al.. 1990). Heparin-like molecules expressed on the cell surface of megakaryocv tes 
and platelets are essential for the binding of growth factors involved in the positive 
regulation of megakaryocytopoiesis such as IL-3, IL-6, GM-CSF, bFGF (Rider, 1993) 
and possibly TPO. Many of these growth factors need to bind to heparin before they 
can exert any effect on the cell. PF4 has a very high affinity for heparin-like molecules 
and therefore may block the binding site for positive regulators (Sato et al.. 1993). 
Anagrelide is the most common treatment for thrombocythaemic (characterised by 
increased megakaryocyte and platelet number) conditions such as essential 
thrombocythaemia (ET). Anagrelide reduces megakaryocyte and platelet number and 
lowers the level of ploidy from 32N to a modal of 16N in ET-derived megakaryocytes 
(Lane et al., 2001; Tomer, 2002). Anagrelide therefore has the ability to inhibit 
megakaryocyte proliferation and differentiation. The mechanism by which anagrelide 
achieves this is unknown, although it has been shown to affect megakaryocyte post- 
mitosis (Mazur et al., 1992), identifying the possible means by which ploidy levels are 
decreased. 
1.3.4 Transcriptional Regulation of Megakaryocytopoiesis 
The molecular control of megakaryocytopoiesis still in part remains obscure, possibly 
due to the fact that no megakaryocyte "master gene" has been identified. However, 
three transcription factors, GATA-1, FOG-1 and NF-E2, have been implicated as chief 
regulators of megakaryocytopoiesis at distinct stages during differentiation (for review 
see Shivdasani, 2001). 
GATA- I and GATA-2 have been identified as a key erythro-megakaryocyte 
transcription factors with the majority of megakaryocyte-expressed gene containing 
GAT: \ eis-elements (Lepage et al.. 1999). It is possible to identify the effects of 
G; \TA-l on megakaryocytes and platelet production by using trans`genic mice lacking 
the gelle for GATA-l (tihivdasani et al.. 1997) and also human subjects with critical 
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GATA-1 point mutations (Nichols et al., 2000; Freson et al.. 2001). An 85% reduction 
in platelet number. increased bleeding time, increased platelet size and erroneous 
platelet shapes are some of the identifiable differences between knockout and wild-type 
mice and human patients compared to normal (Vyas et al.. 1999). Interestingly. 
megakaryocytes derived from GATA-1-null mice show massively increased levels of 
proliferation, although the resulting cells are small and do not display any mature 
morphology. It could therefore be hypothesised that GATA-1 inhibits proliferation and 
initiates aspects of megakaryocyte differentiation. 
FOG (Friend Of GATA)-1 is a co-factor of GATA-1. The megakaryocyte phenotypes 
of mice completely lacking GATA-1 are very similar to humans with point mutations 
preventing interaction between GATA-1 and FOG-1. It could therefore be a distinct 
possibility that the characteristics of GATA-1 ablation could be due to the lack of 
FOG-1 function (Nichols et al., 2000). However, mice deficient in only FOG-1 show a 
complete lack of megakaryocyte progenitors, implicating a role in earlier 
megakaryocyte development (Tsang et al., 1998). Consequently, FOG-1 may be a 
positive regulator of megakaryocyte progenitor proliferation and differentiation. So it 
would appear that FOG-1 acts independently of GATA-1 during early megakaryocyte 
differentiation and again in conjunction with GATA-1 in later megakaryocytopoiesis. 
The NF-E2 transcription factor is comprised of two domains. The 45kDa domain is 
expressed exclusively in haematopoietic cells whilst the other 18kDa domain is 
expressed in a wide range of cells. The role of the NF-E2 was initially investigated in 
erythrocyte differentiation, when its role in platelet production was identified. NF-E2 
gene ablation results in mild erythrocyte phenotype (Shivdasani et al., 1995a), whilst 
platelet number was profoundly reduced (Shivdasani et al., 1995b). Apart from the 
great reduction in platelet number, the megakaryocytes differentiate normally, forming 
cells with a mature cytoplasm and high levels of polyploidy. The terminally mature 
megakaryocytes appear not to be able to form and release platelets in vivo and NF-E2 
mutated mice completely lack circulating platelets. The transcriptional targets of NF- 
E2 would therefore appear to be involved in the final stages of platelet release. A 
likely target is ß1 tubulin, which is restricted to haematopoietic cells and limited to 
only mature cells in the megakar -ocyte lineage. Expression of ß1 tubulin is reliant on 
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NF-E2 and localises to the proplatelet shafts during in vitro thrombopoiesis (Lecine et 
al., 2000) and mice lacking 31 tubulin do not produce platelets (Schwer et al., 2001). 
This certainly provides a feasible answer as to why NF-E2-null mice are so severely 
thrombocytopenic, although other genes involved in the extracellular matrix 
reorganisation of platelet production may be under the control of NF-E2. 
The effective control of normal and pathological megakaryocyte development relies 
upon a greater understanding of cellular and molecular events during differentiation. 
The identification of TPO as a principle regulator of megakaryocytopoiesis has 
certainly been the most promising advance in the understanding of megakaryocyte 
biology since the discovery of their function. However, TPO fails to complete the 
story of megakaryocytopoiesis by leaving out the final chapter. Cytokines regulating 
platelet release remain a mystery. 
1.4 Megakaryocytes and the Bone Marrow Microenvironment 
The bone marrow is tightly packed with numerous cell types, most of which will 
constantly interact in the regulation of differentiation and function. The 
megakaryocyte is no exception and has been shown to modulate and be modulated by 
numerous different neighbouring cell types within the bone marrow microenvironment. 
One such interaction currently the subject of intensive study is the role of the 
megakaryocyte in bone remodelling (for review see Compston, 2002). 
Bone and bone marrow can be considered as one concurrent tissue. Not only are they 
adjacent, they share blood supply, as marrow sinuses receive blood from arteries 
supplying nutrients to bone. The process of bone remodelling is effectively a balance 
between osteoblasts which form the calcified bone and the osteoclast, which resorbs 
hone (for review see Seeman, 2002). A disruption in this balance results in 
pathological conditions, the most common of which is osteoporosis. Osteoclasts are 
derived from narrow HSCs ('Teitelbaum, 2000), whilst osteoblasts differentiate from 
stromal stem cells, also present in the marrow (Owen, 1988). Me`gakary-ocytes express 
I'GFI and TGFI receptors (Bord et al.. 2001), osteonectin, osteocalcin (Kelm et al.. 
1992; Thiede et al., 1994), oestrogen receptors (Bord et at., 2001) and RANK ligand 
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(Kartsogiannis et al.. 1999). all of which regulate bone remodelling. implying a role for 
megakaryocytes in bone remodelling. TPO has profound effects on normal bone 
remodelling by inhibiting osteoclastogenesis (Wakikawa et al., 1997) and causing 
osteoporosis in mouse models in which TPO is over-expressed (Yan et al., 1996). 
Postmenopausal women undergoing high-dose oestrogen replacement therapy to 
prevent excessive bone-loss by osteoporosis, display a significant increase in 
megakaryocyte number (Bord et al., 2000), presumably due to activation of the 
megakaryocytic oestrogen receptor. Osteopetrosis, a condition characterised by 
excessive bone formation, has been induced in transgenic rats. These animals known 
as "toothless" (tl/tl) are thrombocytopenic, but do however show an increase in 
megakaryocyte number and size (Thiede et al., 1996). In addition, hyperproliferative 
megakaryocyte conditions such as myelofibrosis often occur in conjunction with the 
bone hardening disease, osteosclerosis (Poulsen et al.. 1998). Only speculative 
conclusions can be drawn on the role of the megakaryocyte in bone remodelling, but it 
certainly appears that dysfunctional bone conditions nearly always coincide with 
changes in megakaryocyte number and function. 
Megakaryocyte differentiation can also be modulated via interactions with both 
endothelial and stromal cells present in the bone marrow. HSCs cocultured either in 
direct contact with or in the presence of bone marrow endothelial cells (BMEC) tend to 
differentiate to the myeloid lineage, especially megakaryocytic (Rafii et al., 1995). 
After 14 days of coculture, in the absence of any exogenous cytokines, 80% of HSCs 
were myeloid (CD 15 or CD 14 positive) and 20% were megakaryocytes (CD61 or 
CD41 positive). BMECs are able to produce IL-6, SCF, G-CSF and GM-CSF without 
stimulation, all of which are able to initiate and support megakaryocytopoiesis. 
Conversely it appears that bone marrow stromal cells (BMSC) can regulate 
megakaryocyte differentiation (Zweegman et al., 2000). In vitro coculture of HS( -s in 
direct contact with BMSCs differentiated to BFU-MK and CFU-MK, but did not 
differentiate past that point. However, HSCs grown in the presence of, but not in direct 
contact with BMSCs did become large, polyploid, mature megakaryocytes. It would 
therefore appear that the interactions between megakaryocvtes and numerous different 
cell types could affect cellular differentiation and function. 
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1.5 Megakaryocytic Disorders 
The majority of megakaryocytic diseases come under the heading of the 
myeloproliferative disorders (MPD), in which excessive proliferation of abnormally 
developed megakaryocytes results in very high platelet numbers and myelofibrosis (for 
reviews see Briere et al., 1997; Cripe and Hromas, 1998). Three of the most common 
malignant megakaryocytic diseases are essential thrombocythaemia (ET). 
polycythaemia vera (PV) and agnogenic myeloid metaplasia (AMM). 
ET is usually diagnosed incidentally, by the presentation of high platelet number 
following blood sample examination. ET bone marrow trephines are characterised by 
profoundly elevated in numbers of enlarged megakaryocytes that usually cluster in 
small groups (Georgii et al., 1996). Although platelet number is increased, the platelets 
can either be over-reactive causing thrombosis, or under-reactive resulting in 
haemorrhage. At first it was thought that the discovery of TPO function and the 
cloning of c-Mpl, would lead to a greater understanding of all MPDs and especially 
ET. However, there is no evidence of c-Mpl mutations, a reduction in level of c-Mpl 
expression, differences in serum TPO levels or c-Mpl-mediated signalling in ET 
patients (Kiladjian et al., 1997; Horikawa et al., 1997). This suggests strongly that the 
c-Mpl/TPO signalling pathway is not altered in ET. The prognosis of ET patients is 
good. There is no significant decrease in lifespan (Fenaux et al., 1990) and only 10% 
of patients suffer from haematological events (Cortelazzo et al., 1990), 13% of which 
are haemorrhage (Hehlmann et al., 1988), the remaining cases being vascular 
thrombotic disorders. However, 4.5% of patients suffering from ET do develop acute 
leukaemia as a direct cause, possibly due to hydroxyurea treatment (Sterkers et al., 
1998). 
FT can also develop into another megakaryocytic MPD. PV (Murphy et at.. 1997). PV 
is similar in many aspects to ET. Megakaryocyte number and size are both increased 
as well as platelet number although not to the same extent as ET. The difference to ET 
is the increase in erythrocyte number and morphology and the development of 
nlvelotibrosis. l'stvelofibrosis results from dramatic increases in the levels of platelet- 
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derived growth factor (PDGF) and TGF-ß from the malignant megakaryocytes. This 
stimulates the bone marrow fibroblasts and causes the production of fibronectin and 
collagen, resulting in fibrous outgrowths into the marrow (Ross et al.. 1986). 
Myelofibrosis in ET is extremely rare, but by approximately 4 years after presentation, 
20% of PV patients develop bone marrow fibrosis (Georgii et al.. 1996). Myelofibrosis 
is the prominent abnormality in AMM, with over 50% of bone marrow being fibrotic 4 
years after presentation. The large amount of fibrotic tissue in the marrow cavity and 
subsequent loss of progenitor cells results in splenomegaly, enlargement of the spleen 
due to increase blood cell production and extramedullary haematopoiesis. 
Extramedullary haematopoiesis can also occur in the central nervous system, such as 
the brain or spinal column or in the pleural and peritoneal cavities. This results in the 
enlargement of these tissues causing haemorrhage or possible seizures. 
Thrombocytopenic conditions caused by dysfunctional megakaryocytopoiesis are less 
common than the previously mentioned malignant conditions. X-linked 
thrombocytopenia is believed to be due to a 2-base mutation on the X-chromosome 
leading to the substitution of a single amino acid. This substitution inhibits the 
interaction between GATA-1 and FOG-1, resulting in severe thrombocytopenia and 
large platelets (macrothrombocytes) (Mehaffey et al., 2001). Amegakaryocytic 
thrombocytopenia is present at birth and develops into other haematopoietic cell 
cytopenias during childhood. This is the only known megakaryocytic disease thought 
to be as a direct result of abnormal TPO/c-Mpl signalling (Muraoka et al., 1997; Ihara 
et al., 1999; Ballmaier et al., 2001). Patients' megakaryocyte colony formation does 
not respond to TPO treatment and point mutations have since been discovered in the c- 
Mpl gene in all patients in the studies. It has therefore been concluded that this 
condition is caused by the absence of response to TPO by c-Mpl. The finding that 
defective TPO signalling is the single cause only of this very rare disease suggests that 
other factors are involved in the pathogenesis of other megakaryocyte disorders. One 
such factor recently implicated in megakaryocyte differentiation is glutamate signalling 
(Genever et al.. 1999a). 
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1.6 Glutamate Signalling in the Central Nervous System 
The central nervous system (CNS) is subtly regulated by excitatory and inhibitory 
neurotransmission with almost the entirety of the former being mediated by the amino 
acid glutamate. Glutamatergic synaptic activity can essentially be divided into four 
stages; 1. The passage of an action potential along the axon of the pre-synaptic cell 
causes the vesicular release of glutamate into the synaptic cleft. 2. Released glutamate 
diffuses across the synaptic cleft where it binds to glutamate receptors located in the 
extracellular membrane of the post-synaptic cell. 3. Binding of the glutamate agonist 
to the receptor results in receptor activation, leading to an influx of charged ions such 
as Ca 2+ and Na+ or activation of coupled G-proteins in to the post-synaptic cell, causing 
depolarisation, continuing the action potential and the activation of a wide range of 
downstream signalling events. 4. The termination of synaptic transmission by the 
removal of glutamate from the synaptic cleft, via glutamate transporter expressing 
neighbouring neuronal and glial cells (Fig. 1.11). Abnormal glutamate signalling has 
been implicated in a range of neurological conditions, including epilepsy, ischaemic 
brain damage, Huntingdon's chorea, Alzheimer's, Parkinson's disease and 
amyotrophic lateral sclerosis (reviewed in Choi and Rothman, 1990; Lee et al., 1996). 
Glutamate-containing vesicles translocate to the area of the pre-synaptic neuron termed 
the active zones. Following stimulation, the vesicles dock with the plasma membrane 
and the vesicular membrane fuses with the pre-synaptic plasma membrane, releasing 
the vesicular glutamate into the synaptic space. The process of tethering the vesicle to 
the plasma membrane requires the interaction of specific proteins, known as the 
SNARE (soluble N-ethyl maleimide-sensitive factor attachment protein receptors) 
hypothesis, present on both the vesicle and the plasma membrane. The vesicle 
(v)-SNARE proteins bind with the target (t)-SNARE proteins on the plasma membrane 
resulting in the fusion of the membranes and subsequent glutamate release. 
1.6.1 Nletabotropic Glutamate Receptors 
Glutamate receptors can be classified into two main groups: ionotropic. those with an 
integral ion channel and metabotropic, which are coupled to (J-proteins. The finding 
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that glutamate was able to activate inositol phosphate metabolism in striatal and 
cerebellar granule cells (Sladeczek et al.. 1985: Nicoletti. 1986) was supported by the 
discovery that Xenopus oocytes injected with cerebral mRNA develop Cl- oscillations 
when stimulated with glutamate, due to inositol-1,4.5-triphosphate (IP3)-mediated 
release of intracellular Ca 2+ (Sugiyama et al., 1987; Murphy and Miller, 1988). 
Resulting studies identified the existence of a family of metabotropic glutamate 
receptors (mGluR), ranging from mGluR-1 through to mGluR-8 (for review see Oza\ti-a 
et al., 1998). The family subtypes are structurally related. but have different selective 
agonists and activate different downstream signalling events. The mGluR family have 
also been divided into three groups depending on amino acid sequence, agonist 
response and subsequent signalling activation. mGluR-1 and mGluR-5 are members of 
group I, mGluR-2 and mGluR-3 group II and mGluR-4 and 6-8 are members of group 
III. The structure of different mGluR subtypes are however similar, consisting of an 
N-terminal approximately 550 amino acid residues in size, a 250 amino acid 7 
transmembrane spanning domain and a C-terminal domain the length of which depends 
on subtype (for review see Hollmann and Heinemann, 1994, Dingledine et al.. 1998). 
The mGluR subtypes that are members of the same group show similar signal 
transduction characteristics. Group I receptors stimulate Ca 2+ release from intracellular 
stores via phospholipase C (PLC)-mediated formation of IP3 (Masu et al., 1991). The 
mGluR-1 receptor also activates the signalling molecules cyclic adenosine 
monophosphate (cAMP) and arachidonic acid (Aramori and Nakanishi, 1992), whilst 
mGluR-5 does not. The group II and III mGluRs function by inhibiting adenylate 
cyclase and as a consequence reduces the formation of cAMP (Tanabe et al., 1992; 
Tanabe et al., 1993). 
The mGluRs function in numerous neuronal actions, including neuronal excitability by 
the inhibition of K+ currents resulting in depolarisation (Charpak et al., 1990), 
suppression of presynaptic neuroligand release (Nakanishi, 1994) and synaptic 
plasticity in the cerebellar cortex (Ozavv-a et al., 1998). 
1.6.2 lonotropic Glutamate Receptors 
In contrast to the mGluRs, ionotropic glutamate receptors (iG1uR) are ligand-gated ion 
channels, which on activation cause an influx of ions into the cell directly through the 
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receptor (for reviews see Hollmann and Heinemann. 1994: Ozawa et al.. 1998: 
Dingledine et al., 1999). Three families of iGluRs exist. all of which are named after 
their pharmacological agonist. These families are: a-amino-3-hydroxyy-5-methyl-4- 
isoxazole propionate (AMPA), N-methyl-D-aspartate (NMDA) and kainate. AMPA 
receptors are found ubiquitously throughout the CNS, although different regions do 
show varying levels of expression (Monaghan et al., 1984). Kainate receptors 
demonstrate similar local expression patterns to AMPA receptors, although strong 
levels are observed in hippocampal regions (Represa et al., 1987). NMDA receptors 
are found throughout the brain but are primarily located in the forebrain (Monaghan et 
al., 1989). The iGluRs all have similar structure, consisting of an extracellular N- 
terminal and intracellular C-terminal and three transmembrane spanning domains 
named M 1,3 and 4 as M2 is re-entrant loop that faces the cytoplasm and does not 
transverse the membrane. Amino acid residues within the re-entrant loop are thought 
to manage the ion permeability of each receptor type. The S1 region, located before 
M1 and the S2 region, located after M3 are believed to be the agonist-binding site (see 
Fig. 1.12). The primary function of iGluRs lies in the formation of experienced-based 
learning and memory, via a complex molecular mechanism referred to as long-term 
potentiation (LTP). 
1.6.2.1 AMPA and Kainate receptors 
AMPA receptors are present at most synapses in the CNS and trigger fast excitatory 
neurotransmission. Four AMPA subunits have so far been identified. The first, GluR1 
was isolated from a rat brain cDNA library (Hollmann et al., 1989) and lead to the 
discovery of three further structurally related subunits, GluR2,3 and 4, all of which are 
approximately 900 amino acids in size (Hollmann and Heinemann, 1994) which form 
either hetero or homo pentamer receptors. All of the AMPA subunits are able to exist 
as two different variants, termed "flip" and "flop", which are created via alternative 
splicing of aI l5bp extracellular region above the M4 domain (Sommer et al., 1990). 
"l'his feature. in conjunction with other RNA-mediated modifications of subunit amino 
acid sequence, results in the AMPA receptor being exceptionally diverse and able to 
produce a wide range of functional responses. 
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Figure 1.12 The iGluR family. (A) Alignment of the members of the iGluR gene 
family based on amino acid sequence (adapted from Das et al, 1998). (B)The generalised 
structure of iGluR subunits, demonstrating the 3 transmembrane (M 1,3 and 4) and the re- 
entreant loop (M2) and the agonist binding sites (S1 and 2). 
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The diversity of the AMPA receptor is demonstrated by cation permeability. It was 
originally believed that AMPA subunits were permeable only to K' and Na-. and 
impermeable to Cat+. However, AMPA subunit expression studies using Xenopus 
oocytes demonstrated that whilst GluR2 homomeric receptors are Ca 2+ impermeable. 
homomeric GluR1,3 and 4 receptors are permeable to Cat+. Expression of GluR2 with 
GluR 1,3 or 4 greatly reduces Ca 2+ permeability, demonstrating that the G1uR2 subunit 
is dominant in controlling AMPA receptor Ca 2+ influx (for review see Seeburg. 1993). 
Native AMPA receptors are likely to be heteropentamers of G1uRl-4 subunits. As 
GluR2 is widely expressed throughout the CNS, many of the AMPA receptors have 
low permeability to Cat+. However, in certain regions of the brain, especially the rat 
hippocampus and cerebellar glia, highly Ca 2+ AMPA receptors are present (lino et al., 
1990; Burnashev et al., 1992). It can therefore be hypothesised that differences in 
calcium permeability between regions of the brain and even cell-to-cell differences 
may be due to the expression of GluR2 subunits by the AMPA receptor. An increase 
in Ca2+ permeability via the AMPA receptor enables it to mediate synaptic plasticity, 
especially during long-term potentiation (LTP) (Jia et al., 1996). 
Both AMPA and kainate act as AMPA receptor agonists, although AMPA has a 
desensitisation effect, which is considered to be due to the subunit composition of the 
receptor. For example, a G1uR4 flop homopentamer receptor channel has the quickest 
desensitisation time, whilst G1uR3 flip is the slowest. Heteropentamers comprised of 
subunits in the flop variation tend to desensitise quicker than flip, demonstrating that 
alternative splicing of AMPA receptor subunits control the receptor kinetics 
(Mosbacher et al., 1994). The differences in AMPA receptor desensitisation. which are 
determined by subunit composition, can have profound effects on the excitatory 
postsynaptic current (ESPC). The time it takes for the ESPCs to decay varies between 
neuronal cell types, depending on their function. It is believed that the differences in 
ESPCs are due to desensitisation, possibly via AMPA receptor subunit structure 
(Barbour. 1994). 
The kainate family of receptors are composed of five subunits GluR5,6.7. KAI and 
KA2, of which alternative splicing of the G1uR5 subunit and mRNA editing of GluR5 
and (iluR(' occurs. increasing the receptor diversity (for review see 1-lollmann and 
I leinenlann. 1994). The fact that kainate elicits an affect on AMPA receptors has 
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resulted in lack of understanding of the kainate receptors functional properties. 
However, recent advances in the field of pharmacological AMPA antagonists have 
ensured that the physiological properties of the kainate receptor can now be 
investigated. Similar to the AMPA receptor. the native kainate receptor composed of 
heteromers of the five subunits, also desensitises rapidly. although it is highly 
permeable to Ca2+ (Egebjerg et al., 1991; Kohler et al.. 1993). The role of the kainate 
receptor in the CNS would appear to be in slow glutamatergic neurotransmission 
(Vignes and Collingridge, 1997), though it also regulates presynaptic neurotransmitter 
release (Malva et al., 1995; Chittajallu et al.. 1996). 
1.6.2.2 The NMDA receptor 
The NMDA receptor was initially considered to be composed of five receptor subunits, 
comprising a selection of NMDA receptor (NR) 1 and NR2A-D, until the discovery of 
two NR3 subunits A and B (previously referred to NMDAR-L or )(-1) (for reviews see 
Hollmann and Heinemann, 1994; Ozawa et al., 1998; Dingledine et al., 1999). All of 
these receptor subunits are encoded from three genes, each of which is present on a 
different chromosome. The stoichiometry of the subunits that form the native NMDA 
receptor remains a point of contention. The NR I subunit is fundamental to receptor 
function (Moriyoshi et al., 1991) and is able to form homomeric channels with NMDA 
receptor characteristics, but display reduced amplitude current responses compared to 
receptors in vivo. This indicated that the NR1 subunit co-localises with the other 
subunits when forming functional receptor channels. It remains unclear as to whether 
the NMDA receptor consists of four (tetrameric) or five (pentameric) subunits and how 
many NR 1 subunits are present in this receptor (Fig. 1.13 ). By co-expressing NR 1 and 
NR2 subunits in Xenopus oocytes and measuring the number of different conductances, 
Behe and co-workers (1995) concluded that the NMDA receptors were tetramers. 
composed of two NR I subunits and two NR2 subunits. Premkumar and Auerbach 
(1997) then carried out the same experiments, only to hypothesise the formation of 
pentamers made up from three NRl subunits and two NR2 subunits. The finding that 
post-translational subunit changes affecting receptor conductance may lead to an over- 
exaggeration of subunit number has further complicated these ideas (Laube et al.. 
1998). 
38 
Chapter 1 
Original in colour 
C, 
C 
'-(U) 
VV 
II II 
Cu: 
.:! a. 
-- 
G 
I& 
U 
Q 
Cl) 
0 
z c 
-_ _--- -_ ý. 
ýý Z 
r 
ý 
ý`\ Z 
2 
U) 
co 
0 z 12- 
N 
f> Y 
ir- W 
O 
ÖVE 
QUO "ý 
U C_ ý 
C) 
zýUO 
0 
,Z 
c3 U 
> 44 
C '- Ö 
8-U QU 
L 
,ýC 
OU 
NC 
03 O ß" O cz 
b, A 
ý+ C v) 
ýZO 
yý (ý O 
oýUýw 
än`ß > 
CC Uu . r. 
FS. 
ýOÜ 
ý. ý. . ~c 
UOt cC 
39 
Chapter I 
A number of characteristics of the NMDA receptor differ to that of the AMP A and 
kainate receptors. One difference is ion permeability, as the NMDA receptor is highly 
permeable to Cat+, whilst a similar cation, Mg 2+ actually blocks the receptor channel 
(Mayer and Westbrook, 1987; Ascher and Nowak, 1988). The binding of Mg 2+ to and 
subsequent blocking of the NMDA receptor is a voltage-dependant mechanism. At 
resting membrane potential, Mg 2+ blocks the NMDA receptor. preventing the action of 
the receptor at the synapse. When the membrane becomes depolarised, possibly via 
activation of AMPA, on the post-synaptic cell, the Mg 2+ block is removed and 
subsequent calcium influx occurs. This may explain NMDA and AMPA receptor co- 
localisation, as AMPA shows an almost immediate activation on agonist binding 
followed by desensitisation and subsequent long-lasting effect of NMDA receptor 
activation. The NMDA receptor-mediated calcium influx has profound effects on the 
cell by activating a wide range of signalling cascades, generating changes in neuronal 
cell function. Another unique characteristic of the NMDA receptor is the fact that 
glycine acts as a co-agonist with glutamate and is a requirement for NMDA receptor 
activation (Johnson and Ascher, 1987; Kleckner and Dingledine, 1988). The glycine- 
binding site appears to be located on the NR1 subunit, whilst glutamate binds to NR2, 
which possibly explains the reason behind the reduced conductance of the homomeric 
NR1 receptors compared to heteromeric NR1/NR2 receptors (Sucher et al., 1996). The 
fact that the NMDA receptor conductance increases as glutamate and glycine bind to 
their relative subunits provides an acceptable explanation as to the slow activation and 
desensitisation kinetics. 
NR3 is a distant relation to the other NMDA receptor subunits and is the most poorly 
understood and its function is unlike any other. NR3A co-immunoprecipitates with 
other NMDA receptor subunits and when co-expressed with NR1 and NR2A in 
Xenopus oocytes, whole cell (Ciabarra et al.. 1995) and single channel (Das et al., 
1998) conductances and Ca 2+ influx were markedly reduced. Das and co-workers 
confirmed these findings by generating NR3 knockout mice that displayed a 3-fold 
increase in channel current. These results identified the NR 3 subunit as a modulator of 
NMDA receptor function. acting as a "volume control" by reducing the activity of the 
receptor. the only ligand-gated ion channel known to do so. Parkinson's disease is 
believed to be due to NN1D. \ receptor hyper-activation due to excessive amounts of 
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extracellular glutamate. Therefore the NR3 subunit. acting to reduce this level of 
activation, may have pertinent therapeutic implications. 
NMDA receptor subunit composition determines the properties of the receptor channel. 
greatly increasing its functional diversity (for review see Cull-Candy et al., 2001). 
NMDA receptor heteromers composed of NR1 and one of the four NR2 subunits 
demonstrate a great diversity in receptor desensitisation time, ranging from 
milliseconds (NR1/NR2A) to seconds (NRI/NR2D) (Wyllie et al., 1998. Vicini et al., 
1998). NR2A and B are also more sensitive to the blocking action of Mg 2+ compared 
to NR2C and D (Momiyama et al., 1996) and although differences in Ca 2 permeability 
are negligible (Burnashev et al., 1995), disparity in Mg 2+ sensitivity is likely to affect 
Ca 2+ conductance. During postnatal development, the NR2B subunit is replaced by 
NR2A, resulting in faster desensitisation and subsequently quicker NMDA-mediated 
ESPC decay, which plays a role in synaptic plasticity (Constantine-Paton and Cline. 
1998). NR1/NR2C receptors also exist, participating in synaptic plasticity via long- 
term depression (LTD), the process opposing LTP, mainly in cerebellar granule cells 
(Hrabetova et al., 2000), however NR1/NR2D heteromers do not exist in the synapse 
(Cull-Candy et al., 1998). 
The effect of Ca 2+ influx via the activated NMDA receptor regulates the action of 
intracellular kinases and phosphatases controlling numerous cellular events. NMDA- 
mediated activation of downstream signalling molecules, of which the most important 
are Cat+/calmodulin-dependent protein kinase II (CaMKII), PKC and PKA (for review 
see Dingledine et al., 1998; Kennedy, 2000), underlie cellular responses at the CNS 
synapse. These molecules in-turn are able to phosphorylate serine and threonine 
residues situated on the NMDA receptor, enhancing its function by decreasing Mg 2+ 
affinity and opening probability (Chen and Huang, 1992; Leonard and Hell, 1997). It 
therefore becomes possible to understand how the NMDA receptor is able to initiate 
LTP by protein phosphorylation, rather than longer-term gene transcription. 
Signalling molecules are organised as a protein complex at the membrane of the 
postsv naptic cell, called the postsY naptic density (PSD). which is visible by 
transmission electron microscopy (TENT) (Gray, 1959). It is likely that the components 
of the P, --, D vary between synapses, however some signalling molecules are highly 
abundant in the protein complex. the identification and function of which shall be 
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discussed in a later chapter. The MAPK pathway culminates in gene transcription and 
protein phosphorylation of fundamental importance to LTP (English and Sww eatt. 1997, 
Sweatt et al., 2001). NMDA-mediated MAPK activation is considered to be via 
several signalling proteins, the most important of which is CaMKII (Kurino et al.. 
1995; Xia et al., 1996; Perkinton et al., 2002). CaMKII inhibits SvnGAP. a synaptic 
Ras GTPase-activating protein. SynGAP is believed to inactivate GTP-ras. the major 
positive regulator of the MAPK pathway (Scheffzek et al.. 1996). Therefore, CaMKII 
releases the SynGAP-mediated constraints on the MAPK pathway by SynGAP 
inactivation (Chen et al., 1998). The NMDA receptor-mediated increase in 
intracellular Ca 2+ also leads to the activation of PKC and PKA, both potent activators 
of downstream signalling events. Other signalling molecules involved in LTP appear 
to be CaMKII-dependent, including the transcription factor cAMP response element 
binding protein (CREB) and nitric oxide (NO), the latter being activated by way of 
neuronal nitric oxide synthase (nNOS) (Fig. 1.13). 
The signalling mechanisms utilised by glutamate receptors during processes such as 
synaptic plasticity, are by no-means specific to the CNS. Indeed, the presence of 
glutamate receptors on any cell type is likely to have profound effects on all aspects of 
cell function. 
1.7 Glutamate Signalling in Peripheral Tissues 
The identification of glutamate receptors expressed by cells outside of the CNS, raises 
new possibilities of glutamate-mediated cellular functions in numerous diverse tissues 
(for reviews see Skerry and Genever, 2001, Gill and Pulido, 2001). Compelling 
evidence exists for the function of GluRs in bone, skin and pancreas, whilst glutamate 
receptors have also been identified in the heart, thymus, testis, taste buds, liver, kidney 
and gastro-intestinal tract. iGluRs appear also to function in plant cells, as mediators 
of light signal transduction (Lam et al., 1998), raising the possibility that the 
mammalian glutamate receptor may have evolved from a more primitive receptor type. 
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1.7.1 Glutamate signalling in bone 
Bone is perhaps the most widely accepted and understood location of peripheral 
glutamatergic signalling. This signalling process was first hypothesised on the basis of 
a differential RNA display, in which changes in the expression of the glutamate 
transporter GLAST-1 following in vivo bone loading (Mason et al.: 1997). This 
transporter was identified in osteocytes (bone matrix cells) and osteoblasts but not 
osteoclasts, leading to further studies focusing upon the discovery of other components 
associated with glutamate-mediated signalling. These investigations proved to be 
extremely productive, identifying a range of glutamate receptors expressed by bone 
cells in vivo, by primary cells and cell lines (Patton et al.; 1998: Chenu et al., 1998). In 
vitro, bone cells treated with the specific non-competitive NMDA receptor antagonist 
MK-801 resulted in the reduction of osteoblastic bone formation (Dobson et al., 2000: 
Taylor et al.; 2000), whilst inhibiting osteoclastic-mediated bone resorption (Peet at al, 
1999). AMPA receptor antagonism also resulted in increased adipocytic lineage 
commitment from marrow stromal cells compared to osteoblast differentiation. The 
ability of glutamate signalling to determine cell lineage from primitive multipotent and 
progenitor cells has not currently been investigated and may prove extremely exciting. 
Attempts to demonstrate glutamate receptor function in bone by agonist-mediated 
response has proved less conclusive. However, electrophysiological studies on 
osteoblastic cell lines and primary cells has demonstrated glutamate receptor-like 
gating characteristics, but similarity of these results to the CNS glutamate receptor 
remains a point of controversy (Laketic-Ljubojevic et al.; 1999; Gu et al.; 2000). Patch 
clamping experiments also identified the existence of NMDA receptor currents in 
osteoclasts (Peet et al.; 1999; Espinosa et al.; 1999). 
It has been established recently that osteoblasts also express components required for 
glutamate release in the CNS synapse. These include SNAREs and associated proteins 
involved in presv naptic vesicle docking and glutamate release. Osteoblasts also 
demonstrate regulated and spontaneous glutamate exocytosis. prevention of which 
leads to inhibition of cell survival and differentiation (Bhangu et al.. ? 001; Genever 
and Skerry, 2001). Further examination of osteoblastic glutamate signalling has 
revealed all the necessary components required 1or LTP in the CNS posts\ naptic cell 
41, 
Chapter I 
(G. J. Spencer, personal communication). These include many of the structural and 
signalling proteins present in the PSD of which CaMKII is particularly prevalent. 
Treatment of osteoblastic cells with glutamate resulted in CaMKII activation. 
inhibition of which reduced osteoblastic differentiation and mineralisation in vitro. 
1.7.2 Glutamate signalling in other tissues 
A high level of NR1 expression by proliferative cells in the resting basal epidermis of 
skin, raises the possibility that the NMDA receptor is involved in the differentiation of 
keratinocytes. MK-801 inhibition of human keratinocyte NMDA receptors induced the 
cells to differentiate (Morhenn et al., 1994; Genever et al., 1999b). In addition to 
NMDA receptors, the G1uR2/3 family of AMPA receptors are localised to the basal 
surfaces of rat keratinocytes, which also express the glutamate transporters GLT-1 and 
EAAC-1 and various mGluRs (Genever et al., 1999b). NMDA receptor expression in 
migrating epidermal cells is reduced during re-epithelialisation following wounding, 
implying that glutamate signalling is involved in the process of skin development. The 
supply of glutamate in skin remains unknown, although there are several possible 
sources, including the possibility of keratinocyte glutamate recycling and release 
(Davidson et al., 1997) and glutamate containing nerves that are present in skin 
(Kinkelin et al., 2000). 
Pancreatic cells express glutamate receptors of the NMDA, AMPA and kainate 
families. Electrophysiological patch clamp experiments revealed that the 
characteristics of these receptors were identical to those found in neuronal cells (Gonoi 
et al., 1994; Molnar et al., 1995), with the function of the AMPA and kainate receptors 
possibly determining insulin secretion from pancreatic cells. Glutamate receptor 
expression has been demonstrated throughout the gastro-intestinal tract especially 
NR1, which is present in the oesophagus, stomach mucosa and mast cells (Gill and 
Pulido, 2001). Glutamate-mediated activation of NMDA receptors present in ileum 
results in smooth muscle contraction, a process responsible for gastro-intestinal 
motility (Shannon and Sawyer, 1989), which is blocked by Mgand MK-801. The 
presence of glutamate receptor types and function in other tissues is summarised in 
Figure 1.14. 
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Figure 1.14. Glutamate signalling in selected peripheral tissues. Numerous human 
tissues of widely varying function express glutamate receptors. In these tissues, 
glutamate signalling appears to play fundamental roles in their function (for review see 
Skerry and Genever, 2001) 
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1.8 The Megakaryocytic Glutamate Receptor 
Many of the physiological actions of platelets depend upon the concentration of 
intracellular calcium ([Ca2+]I), including activation and aggregation. The discovery of 
the platelet NMDA receptor raises the possibility of this receptors' involvement in 
platelet [Ca2+]; (Franconi et al., 1996). The addition of arachidonic acid (AA) to 
platelet rich plasma (PRP) is known to induce platelet aggregation. However, AA 
application in conjunction with glutamate or NMDA prevents platelet activation. This 
effect is shown to be NMDA receptor-specific, as MK-801 addition prior to AA and 
glutamate/NMDA application prevented the anti-aggregative effects. Addition of 
glutamate or NMDA in the absence of AA had no effect on platelet function. Similar 
dose-dependent effects were observed with other pro-aggregation agents, ADP and 
platelet-activating factor (PAF). There responses were not expected as activation of 
the NMDA receptor should increase [Ca2+]1, therefore promoting platelet activity. 
However, this effect may be explained by the fact that NMDA also caused an increase 
in intracellular cAMP concentration, known to inhibit platelet activation (Bushfield et 
al., 1985), an effect that was absent in Cat+-free medium. 
Further study from the same group investigated the effect of NMDA receptor 
activation on Ca 2+ influx and thromboxane B2 (TxB2) synthesis (Franconi et al., 1998). 
NMDA increased [Ca2+]; in a dose-dependent manner whilst completely inhibiting the 
synthesis of the pro-aggregation agent TxB2, providing more evidence of the anti- 
aggregation effect of NMDA. The significant therapeutic potential of these findings 
was demonstrated by combining NMDA with aspirin. Aspirin (20µM) alone decreased 
AA-mediated human PRP aggregation to 54% from 84%. However, aspirin combined 
with I OOnM NMDA reduced maximum aggregation to around I%. These results are 
certainly compelling and warrant further investigation. 
The megakaryocytic NMDA receptor was first identified in 1999 (Genever et al., 
1999). However, it seems surprising that Franconi and co-workers' discovery of the 
functional platelet NMDA receptor in 1996 did not lead to a logical investigation of 
megakaryocytic glutamate signalling. Immunohistochemical staining of bone marrow 
with an antibody raised against the cytoplasmic domain of the NRI subunit identified 
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strong expression by megakaryocytes in rat bone marrow. Further studies revealed 
NR1 expression by human megakaryocytes and the megakaryocytic cell line MMEG-01. 
NRI protein expression was confirmed firstly by RT-PCR of rat bone marrow mRNA 
and MEG-O1 cells. using gene specific primers to rat and human brain NR1 
respectively. RT-PCR also amplified products in rat marrow and MEG-01 cells that 
corresponded to the brain NR2D subunit, but not NR2A. B or C. Interestingly, western 
blot analysis of NRl expression by MEG-O1 cells with and without the differentiation- 
promoting agent phorbol myristate acetate (PMA), confirmed that the subunit \\*as in a 
deglycosylated state compared to brain control. This finding is of particular 
significance, as glycosylation is known to provide NMDA receptor membrane stability, 
allowing for orientation only in specific areas of the postsynaptic cell. However, 
deglycosylated receptors would probably distribute evenly over the cell surface, as 
seen in the megakaryocyte. Human megakaryocytes derived from CD34+ umbilical 
cord blood cells were also shown to express NR1 by northern blot analysis of total 
RNA. All acetylcholinesterase (AChE)-positive cells, a megakaryocyte lineage 
marker, in rat bone marrow also expressed NR1, indicating that the receptor is present 
at all stages of megakaryocyte maturation. 
By treating animals with radiolabelled MK-801 ([3H]-MK-801), which selectively 
binds to and blocks open NMDA receptor channels followed by autoradiographic 
examination of bone marrow, it was identified that NMDA receptor subunits formed 
functional channels in l'ivo. This binding was significantly reduced when animals were 
pre-treated with an excess of non-radioactive MK-801. The function of the 
megakaryocytic NMDA receptor was ascertained by treating megakaryocytic cell lines, 
with MK-801. PMA-mediated increases in cell size and expression of the 
inegakaryocyte-specific marker CD41 were significantly reduced following MK-801 
application compared to controls. MK-801 also inhibited cellular adhesion by 
approximately 50% compared to controls, without affecting cell viability. The changes 
in cellular adhesion were also observed following application of a non-competitive 
NNIDA receptor antagonist D-(-)-2-amino-5-phosphonopentanoic acid (D-APS) and 
using another megakaryoblastic cell line CNIK. 
These data provided compelling evidence of a functional N\ IDA receptor in 
mc akaryohlastic cells and identified the presence of this receptor on me`gakar\ ocvteý 
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in vivo. Taken in conjunction with the finding that a number of uncharacterised cells in 
the bone marrow express the glutamate transporter GLT-1 (Mason et al., 1997). 
enabling the termination of paracrine glutamate signalling. It is possible to theorise an 
entire glutamatergic signalling system within the bone marrow microenvironment. The 
effect of NMDA receptor inhibition on megakaryoblastic differentiation supports the 
identification of a previously unrecognised megakaryocyte signalling system. At these 
relatively premature stages, this work does however ask more questions than it 
answers. This thesis aims to answer some of these questions. 
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1.9 Primary aims 
9 To determine the NMDA receptor subunit and associated proteins expression 
by megakaryocytic cell lines and human primary megakaryocytes. 
" Establish the function of the megakaryocytic NMDA receptor on human 
primary cells and megakaryocytic cell line differentiation by using the specific 
NMDA receptor antagonist MK-801. 
e Investigate possible sources of glutamate within the bone marrow 
microenvironment with which to stimulate the megakaryocytic NMDA 
receptor. 
" Determine the intracellular signalling cascades mediated by the NMDA 
receptor in the modulation of megakaryocyte differentiation. 
" To determine any changes in megakaryocyte number and possible bleeding 
abnormalities in NR1 hypomorphic mice compared to wild types. 
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General Materials and Methods 
2.1 Cell Culture 
2.1.1 Cell culture plasticware and reagents 
Tissue culture plasticware and reagents were purchased from Life Technologies 
(Paisley, UK) unless stated otherwise. Cells were maintained in a humidified 
atmosphere at 37°C in 5%CO2/95% air. All media was supplemented \vith 100U/ml 
penicillin, 100µg/m1 streptomycin and 2mM L-glutamine unless otherwise stated. 
2.1.2 Cell line culture 
MEG-O1 and human erythroleukaemia (HEL) human clonal megakaryoblastic cell 
lines were cultured according the standard ATCC protocol, in RPMI 1640 medium 
with 10% foetal bovine serum (FBS). For experiments investigating responses to 
glutamate, cells were incubated overnight in glutamate-free NeurobasalTM media with 
serum replacement N2 supplement (Gibco). Both cell lines are non-adherent and 
media was changed every 3 days, and passaged by centrifugation (400g, 5 min) and 
replated at lx 105 cells/ml. To induce megakaryocyte differentiation, both cell lines 
were treated with I OOnM phorbol myristate acetate (PMA; dissolved in ethanol) for 72 
hours. In non-PMA treated samples, equivalent volume of ethanol was added. 
2.1.3 Human CD34-positive-derived megakaryocytes 
Umbilical cord blood was obtained from the umbilical cord and placenta from pre- 
term mothers giving birth by caesarean section. Blood was collected into heparinised 
tubes, a maximum of 5 minutes after birth. Approximately 50-100ml was extracted 
from each placental preparation. Blood was only taken after the mothers granted 
informed consent, at least 1-1 hours before surgery. CD34-positive (CD 34') cell 
separation took place within 1 hour of blood collection. Umbilical cord blood was 
diluted 2: 1 vol/vol. with Hanks buffered saline solution (11BSS) and overlaid on Ficoll 
paque (Fischer. Loughborough. UK). The preparation was centrifuged at 400U for 35 
minutes and the mononuclear cells removed from the Ficoll interface and washed 
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twice by resuspending cell pellet in IOml cold "buffer A" (phosphate buffered saline 
(PBS) containing 2% bovine serum albumin (BSA) (Sigma) and 5mM EDTA). 100µl 
of cells were taken for purity anal`'sis at this stage and remaining cells were 
centrifuged at 400g for 10 minutes at 4°C. CD34+ cells were isolated using a magnetic 
immunoselection protocol (Miltenyi Biotec GMBH, Germany). Washes were 
performed by adding l Oml of buffer A to the cells followed by centrifugation at 400g 
for 10 minutes at 4°C. Mononuclear cells were suspended in 100µl of IgG blocking 
reagent and 100µl mouse anti- human CD34+ primary antibody against the Q-BEND 
isotype and incubated at 4°C for 15 minutes. After washing, l00µ1 of mouse anti- 
human CD34+- fluorescein isothiocyanate I (FITC) conjugated antibody against 
HPCA-1 isotype was added and incubated for 15 minutes at 4°C and washed. The cell 
pellet was resuspended in 400µl buffer A and 100µl of magnetic anti-hapten 
secondary antibody, incubated at 4°C for 15 minutes and washed. The cells were 
resuspended in 500µ1 of buffer A and passed through a MS+ immunoselection column 
attached to the magnetic base unit (Miltenyi Biotec) and 3x500µ1 of buffer A passed 
through the column to remove the CD34-negative (CD34-) populations. The column 
was removed from the magnetic source and the CD34+ population collected by 
flushing 1 ml of buffer A through the column. 25µl of cells were taken from both 
CD34+ and CD34- for purity analysis by flow cytometry. Average purity of CD34+ 
cells was 91%, ranging from 85.3% to 94.7% (see Fig. 2.1). CD34+ cells were 
cultured in Iscove's modified Dulbecco's medium (IMDM; supplied containing 500µM 
L-glutamate) supplemented with 2mM glutamine, 2mg/ml sodium pyruvate, 1% 
Minimum Essential Medium vitamin solution, I% non-essential amino acids, 0.1 mM 
3-mercaptoethanol and 2mg/ml L-asparganine. The medium was also supplemented 
with 10% cord blood plasma, 0.2% BSA and 25ng/ml thrombopoietin (TPO) 
(Calbiochem, Nottingham, UK). Cord blood plasma was isolated from undiluted 
umbilical cord blood, centrifuged at 800g for 35 minutes at 4°C and the supernatant 
plasma fraction removed. Cells were plated at 5x104 cells/ml in 24-well plates and 
replated at this concentration following 7 days in culture. An additional 25ngi ml TPO 
was added at this point, and the cells were cultured for a further 7 days in culture. 
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Figure 2.1. Purity analysis of isolated CD34+ haematopoietic cells following 
MACS separation from umbilical cord blood. CD34' cells were labeled with a 
mouse anti-human CD34 antibody prior to MACS separation. Following separation, 
CD34- effluent was collected prior to CD34' flow-through and both samples tested 
for purity by flow cytometry. CD34-positivity typically ranged from 85-92% (blue 
filled peak) compared to CD34- (red peak) and antibody control (black peak). 
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2.2 Immunolocalisations 
2.2.1 Cytospin preparations 
A Cytospin 3 cytocentrifuge (Shandon Scientific Ltd, Runcorn, UK) «-as used for all 
cytospin preparations. Polylysine slides (BDH) were cleaned in alcohol, labelled and 
placed under a slide filter card in the sample chamber and placed in the cytospin head. 
Cells were removed from media and washed 3 times with PBS. The cell concentration 
was altered to lx 105 cells/ml and 200µ1 of cell suspension added to the sample 
chamber. Cells were spun for 5 minutes at 100g, "LO" acceleration and the slides 
removed from the slide clip, immediately fixed in 4% paraformaldehyde and kept at 
4°C until use. 
2.2.2 Fluorescent immunocytochemistry 
Cells were fixed in 4% paraformaldehyde for 5 minutes at room temperature and 
washed 3 times with PBS. The cells were then incubated in 10% goat serum (Sigma) 
for 30 minutes at room temperature and excess serum removed. Cells were incubated 
with primary antibody or control IgGs for either 1 hr at room temperature for cytospin 
preparations, or overnight at 4°C for fibronectin bound cells. Excess primary antibody 
was removed, washed 3 times for 5 minutes with PBS and incubated with either FITC 
or tetramethyl rhodamine isothiocyanate (TRITC) secondary antibodies (Sigma) at 
1: 100 dilution for 45 minutes in the dark at room temperature. Excess secondary 
antibody was removed and cells were washed 3 times with PBS for 10 minutes. 
Specimens were then mounted in Vectorshield (Vector Laboratories) and viewed using 
a Leica DMLA microscope (Leica) under U. V illumination. 
2.2.3 Im munohistochemistry 
?.?. 3.1 Tissue collection and cryosectioning 
Spleen, tibiae and femora were removed from adult mice and rats and immediately 
frozen in liquid nitrogen and store at -80°C until use. Specimens were mounted in 
Crvo-m-bed embedding compound (Bright. UK) on brass chucks and frozen in chilled 
isopentane. Frozen sections were cut using a Bright OTF500 cryostat (Bright) fitted 
with a tungsten carbide tipped knife, collected on poly lysine slides and stored at -20°C 
until required. 
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2.2.3.2 Peroxidase immunolocalisations 
Sections were fixed in 4% paraformaldehyde for 5 minutes before the depletion of 
endogenous peroxidase activity with 3% hydrogen peroxide (Sigma) for 30 minutes. 
Non-specific avidin binding to endogenous biotin was prevented using the Vector 
Avidin / Biotin Blocking Kit (Vector Laboratories) according to the manufacturer's 
protocol. For sections incubated in non-mouse raised primary antibodies, 10% 
blocking serum was applied to the tissue sections, chosen to match the species in 
which the secondary antibody was raised. Sections were incubated with primary 
antibody for 30 minutes, followed by exposure to biotinylated IgG secondary 
antibodies (1: 200; Vector Laboratories). Avidin-biotinylated-peroxidase reagent 
(Vectastain Elite ABC reagent, Vector Laboratories, 1: 50 dilution) was then applied to 
the specimens and incubated for 20 minutes followed by incubation with DAB tablets 
(0.5mg/ml 3,3'-diaminobenzidine and 0.3% hydrogen peroxide; Sigma) dissolved in 
dH2O, for 2 minutes. The sections were counterstained with haematoxylin before 
mounting in 90% v/v glycerol/PBS and viewed using a Leica DMLA microscope. 
Antibody negative controls received identical treatment apart from the application of 
normal mouse IgGs (Vector Laboratories; 1µg/ml) instead of the primary antibody. 
All incubations were performed at room temperature with 3x5 minute PBS washes 
between incubations. 
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Megakaryocytic NMDA Receptor Expression 
3.1 Introduction 
NMDA receptor subunit organisation has a profound effect on receptor activity and 
conductance (see chapter 1.6.2.2). The functional importance of NMDA receptor 
subunit diversity is indicated by organisational changes during development. mRNA 
taken from the developing rat brain, demonstrates that NR2D expression is restricted 
to the brainstem and diencephalons (region of forebrain underlying cerebral 
hemispheres), whilst NR2B is expressed throughout the brain (Monger et al., 1994). 
Shortly after birth, NR2A is found in most regions of the brain, whilst NR2C 
expression is limited to the cerebellum. It appears therefore that in the CNS, NR2B 
expression is of greatest importance in the early embryo, which decreases during 
development to be superseded by the NR2A subunit (Akazawa et al., 1994). This 
occurrence is believed to underlie the speed of NMDA receptor-excitatory 
postsynaptic currents (EPSC), the phenomenon linked with memory forming synaptic 
plasticity (Constantine-Paton, 1998). 
Alterations in NMDA receptor subunit composition are not however limited only to 
regions of the brain. Indeed, single cells also display differences in subunit 
organisation. One such example is again, the NR2A: NR2B ratio in relation to NMDA 
receptor-EPSC. Receptors composed of mainly NR2A subunits will display rapidly 
decaying EPSC compared to cells composed mainly of NR2B subunits. The 
functional importance of this is explained by studies of rat visual cortex NMDA 
receptor-EPSCs. Animals reared in the dark and subsequently exposed to light, results 
in the rapid insertion of new NMDA receptors with an increased NR2A: NR2B ratio, 
reducing sensitivity by decreasing the time taken for NMDA receptor-EPSC decay 
(Quinlan et al., 1999). 
As previously mentioned (chapter 1.6.2.2). evidence exists for the participation of 
NR2A-. NR-'B- and NR-'C' containing heteromeric NMIDA receptors at the C'NS 
jý 
Chapter 3 
synapse. The NR1/NR2D receptors have not however been identified at the CNS 
synapse, even though recombinant data indicted that they would be easy to identify by 
their extremely slow deactivation kinetics (Cull-Candy et al., 1998). This theory was 
confirmed by patch-clamp experiments on Purkinje cells (neuronal cells that carry 
output from the cerebellum) expressing pure NR 1 /NR2D receptors. as glutamate- 
mediated receptor activation leads to extremely slow deactivation (Misra et al., 
2000a). Although other cells express NR2D, NMDA receptor-EPSC remains fast. 
demonstrating the lack of pure NR1/NR2D receptors at the synapse (Misra et al., 
2000b). This does not however rule out the existence of triheteromeric receptors, such 
as NR1/NR2B/NR2D that are found in the midbrain (Dunah et al., 1998), which would 
not display pure NR1/NR2D kinetics. 
The above findings clearly reveal that NMDA receptor subunit composition results in 
functionally different receptors. These are subsequently expressed at different times 
during the development of the embryonic CNS and by different regions of the adult 
brain. It is therefore apparent that the structure of the NMDA receptor is directly 
correlated with its required function on the cell by which it is expressed. 
In addition to NMDA receptor subunit composition contributing to its function and 
subsequent downstream effects, proteins binding to the receptor can regulate its 
localisation and its signalling. As previously mentioned, NMDA receptor activation 
underlies the process of synaptic plasticity, by LTD (reduction of synaptic efficacy) 
and LTP (increase of synaptic efficacy) (chapter 1.6.2.2). These mechanisms are 
achieved by changes in synaptic strength, which is in turn achieved by modifications 
in postsynaptic NMDA receptor sensitivity and clustering on the postsynaptic 
membrane, activation of silent receptors and transcriptional changes (Bliss and 
Collingridge, 1993: Bear and Malenka, 1994). The molecules involved in these 
synaptic changes are organised into the post-synaptic density (PSD). The first and 
most abundant protein identified at these peripheral condensations was PSD-95 (also 
known as synaptic associated protein-90 (SAP-90)). PSD-95 belongs to a conserved 
cytoskeletal protein family known as membrane associated guanylate cyclases 
(MAGUKs). of which other principle members are chaps, ' n-110'PSD-9 3. SAP 102 and 
S; AP97%hDlg. All NIAGUKs contain characteristic domains known as PDZ 
(PSD-95'Dlg, ZO-1) and SH3. which mediate protein-protein interactions forming cell 
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membrane protein scaffolds (Craven et al.. 1998). PSD-95 binds to the long 
C-terminus of NR2 subunits (Kornau et al.. 1995; O'Brien et al., 1998) via one of its 
three PDZ domains (for review see Fujita and Kurachi. 2000; Sheng. 2001). PSD-95 
has a variety of multi-faceted roles in NMDA receptor function, including localisation 
of the receptor in the PSD (Steigerwald et al.. 2000), anchoring the receptor to the 
postsynaptic membrane (Sheng et al., 2000) and receptor-mediated activation of 
associated signalling pathways, of which the MAPK pathway is amongst the most 
critical in synaptic plasticity (Migaud et al., 1998). PSD-95 is able to modulate the 
MAPK pathway by interacting with CaMKII, which inhibits the synaptic GTPase 
activating protein SynGAP (Komiyama et al., 2002). In addition to PSD-95, another 
member of the MAGUK family, chapsyn-110, has been implicated in the coupling of 
nNOS to the NMDA receptor (Harris and Lim, 2001). Chapsyn-110 facilitates the 
nNOS activation by linking nNOS to the vicinity of the NMDA receptor, which is 
subsequently activated by the calcium influx resulting from receptor activation. 
Although these four MAGUK proteins account for the majority of the PSD, novel 
PDZ domain-containing MAGUKs have recently been identified. MALS, the 
mammalian homologue of the Caenorhabditis elegans LIN-7 protein (Simske et al., 
1997), contains a single PDZ domain and associate to the NMDA receptor / PSD-95 
complex, possibly also to the c-terminal of the NR2 subunit (Jo et al., 1999). Jo and 
co-workers suggest that MALS is likely to participate in the clustering of NMDA 
receptors and possibly other glutamate receptors in the PSD. Another novel MAGUK 
protein is CASK, the mammalian homologue of the Caenorhabditis elegans protein 
LIN-2. The PDZ domain of CASK binds to numerous other PSD proteins, but also 
specifically to the transmembrane adhesion protein syndecan (Cohen et al., 1998). 
Interestingly, CASK also contains two guanylate kinase (GUK) motifs, neither of 
which possesses enzymatic activity. However, a recent study discovered that CASK 
could translocate from the plasma membrane to the nucleus, and associates via its 
Gt IK domain to the transcription factor T-brain-1 (Tbr-1) (Hseuh et al., 2000), which 
greatly enhances the transcription of Tbr-l-dependant reporter genes. The capability 
of CASK to directly modulate transcription makes it unique in the PSD-MAGUK 
family. 
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SHANK (SH3 domain ankryin repeat) is a common protein in the cytoplasmic face of 
the PSD (adverse to PSD-95 which is located toward the membrane side of PSD). a 
location that puts this molecule in prime position to interact with cytoplasmic proteins 
and endoplasmic reticulum. SHANK has also shown to bind to interact with the actin- 
binding protein cortactin, raising the possibility that SHANK may be involved in PSD- 
mediated regulation of the cellular cytoskeleton (Naisbitt et al.. 1999). These results 
have since been confirmed by overexpression of SHANK in cultured neurones, which 
results in the enlargement of the dendritic spines (Sheng, 2001). 
The PSD also contains other non-MAGUK proteins that mediate glutamate signalling. 
Yotiao, which gains its name from having a similar coiled structure to a popular 
Chinese breakfast, is highly abundant both at CNS synapses and neuromuscular 
junctions that associates with the c-terminal tail of specific NR1 splice variants (Lin et 
al., 1998). Yotiao expression has been confirmed in several tissues apart from brain. 
Abundant signal was demonstrated in both skeletal muscle and pancreas, whilst lower 
levels of expression were also identified in heart and placenta, suggesting that the 
protein may have alternative non-glutamatergic roles. Very little evidence exists on 
the function of Yotiao. The fact that NR1 subunits are able to cluster in the 
postsynaptic membrane in the absence of NR2 subunits (Ehlers et al., 1995) and 
subsequently lacking well characterised NR2-associated clustering proteins, suggests 
that Yotiao may be involved in NR1 clustering. Lin and colleagues, who 
demonstrated that Yotiao fractionates with cytoskeletal-associated proteins. confirmed 
this hypothesis, therefore providing the link between NR1 and the cytoskeleton (Lin et 
al., 1998). Yotiao has also been revealed as being responsible for recruiting PKA and 
protein phosphatase 1 (PP 1) to the NMDA receptor and appear to counteract each 
other in the modulation of NMDA receptor channel conductance. In normal 
conditions, PP 1 is continually active, inhibiting the activity of the receptor channel. 
However, increases in cellular cAMP results in PKA phosphorylation of the receptor, 
conferring an increase in receptor channel activity (Westphal et al., 1999). Therefore 
the function of the Yotiao protein is one of NR1 receptor subunit clustering and 
receptor channel modulation. 
It is evident that the presence of the many multi-functional proteins in the PSD gives a 
different picture of the NMD: \ receptor at the CNti synapse. Rather than sinule 
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receptor channels acting independently to increase intracellular calcium concentration. 
NMDA and other glutamate receptors are present and linked to a mass of various 
scaffold and signalling proteins, which together modulate synaptic plasticity. The aim 
of this chapter is to investigate the expression of the regulatory NR2 and NR3 subunits 
and PSD proteins are expressed by megakaryocytes using yell-characterised 
megakaryocytic cell lines and primary human megakaryocytes. This would provide a 
greater understanding of how the NMDA receptor may function in the megakaryocvte 
compared to its neuronal counterpart. 
Basic exploratory research is often performed on megakaryocytic cell lines, two of the 
most common being used during this research are MEG-01 and human 
erythroleukaemia (HEL) cells (for review see Saito, 1997). Megakaryocytic cell lines 
are often derived from the bone marrow of patients with leukaemia and display many 
of the characteristics of megakaryocytopoiesis and differentiated human primary 
megakaryocytic cells. MEG-0l cells were derived from a patient suffering with 
megakaryoblastic crisis of chronic myeloid leukaemia (CML), whilst marrow taken 
from a patient with acute myelogenous leukaemia resulted in the development of HEL 
cells. In an undifferentiated state HEL cells possess features common to macrophages, 
erythrocytes and megakaryocytes (Long et al., 1990). However when stimulated by 
low concentration doses of PMA, the HEL cell gains a more megakaryocytic 
phenotype including expression of the megakaryocyte-specific markers CD41 and 
CD42a, as well as the typical cytoplasmic maturation and the formation of a polyploid 
nucleus. These changes are believed to be due to PMA-mediated activation of PKC, 
which controls the switch between megakaryocyte and erythrocyte lineage (Hong et 
al., 1996), whilst stimulation of HEL cells with erythropoietin (EPO) results in 
crythrocyte development (Chu et al., 1998). These characteristics make the HEL cell 
line a useful model in lineage determination studies. 
The MEG-01 cell line exhibits megakaryocytic properties (CD41, CD61, CD42a, von 
Willebrand factor (\'WF)) whilst lacking markers for other lineages (Ogura et al., 
1985). Fxpression of CD41, CD42a and vNNT by NIFG-O1 cells is increased by P NIA 
stimulation, which also induces a highly differentiated morphology (Ogura et al.. 
1989). Some reports indicate that ? SIEG-0l cells produce platelet-like particles that are 
ot-similar sue and display other features of circulating platelets (Takeuchi et al., 
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1998). Unlike HEL cells, MEG-01 cells do not express the TPO receptor c-NIpl. 
Therefore, PMA is the only known differentiation-promoting agent for NIEG-01 cells. 
whilst HEL cells can be stimulated to differentiate by culture in the presence of TPO 
(Matsumura et al., 1996). 
It is important at this point to consider the potential problems of using phorbol esters 
to induce differentiation of megakaryocytic cell lines. Prolonged exposure to phorbol 
esters causes the almost complete depletion of certain PKC isoforms by proteolysis 
(Hug and Sarre, 1993). Therefore, by following the standard protocol of treating the 
cell lines for 72 hours in the presence of I OOnM PMA to ensure total differentiation 
(see section 2.1.2), it is not surprising that many of the PKC isoforms are 
down-regulated following their activation. PMA treatment of MEG-O1 cells, although 
rapidly activating the majority of PKC isoforms, subsequently leads to the 
down-regulation of the PKC-a, -c and -0 isoforms following 1-2 hours of treatment. 
However, the P1 and II PKC isoforms are down regulated very slowly, suggesting that 
the activation of PKC-a, -c and -0 initiate differentiation whilst PKC-ßI and 131I are 
important in the maintenance of differentiation (Nagata et al., 1996). 
Recently, other signalling molecules have been identified as having phorbol ester 
binding sites, namely chimaerins, protein kinase D (PKD)-1, Ras guanyl-releasing 
protein (GRP), DAG kinase-y and Munc 13 (for review see Brose and Rosenmund, 
2002). These signalling molecules can regulate a range of downstream events, such as 
the MAPK pathway, which are able to stimulate megakaryocyte differentiation. The 
existence of these phorbol ester-binding molecules makes it important to take into 
account that non-PKC molecules may also be mediating PMA-induced megakaryocyte 
cell line differentiation. However, considering that the PKC antagonists GF-109203X 
and Ro-3 1-8220 prevent PMA-mediated megakaryocytic cell line differentiation 
(which may not however be specific PKC inhibitors (Alessi, 1997)). it appears that 
PKC remains the primary activator of megakaryocyte cell line differentiation 
(Lumelskv and Schwartz. 1997). 
The development of stem cell separation techniques combined with the commercial 
availability of human recombinant TPO has meant that C D3-ß haematopoietic cells 
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can now be promoted to form large numbers of differentiated megakaryocytes in vitro. 
There are three main sources of human CD34t cells, umbilical cord blood (UCB). 
bone marrow and peripheral blood (for review see Majka et al.. 2001). Although 
peripheral blood is the most accessible source of these cells, the megakar`-oblast 
recovery after 11 days of culture is significantly less than the other sources. 
Megakaryoblast recovery is greatest in bone marrow, however collection of this tissue 
is invasive and restrictive. Consequently, due to its accessibility and availability. UCB 
is the most widely used source for generating megakaryocytes following CD34' 
separation. CD34+-derived megakaryocytes exhibit numerous characteristics of 
mature bone marrow megakaryocytes, including; expression of the megakaryocyte and 
platelet-specific markers CD41, CD61, CD42a and CD62P. TPO receptor c-Mpl and 
PDGF receptor (Gewirtz, 1995; Majka et al., 2000). 
The megakaryocytic cell lines and primary cells were used to determine the expression 
of NMDA receptor subunits and PSD proteins. 
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3.2 Materials and Methods 
3.2.1. RNA isolation 
Cells were washed twice with PBS before total RNA was extracted by adding 1 ml 
TRIzoi (GibcoBRL) / 5x106 cells, transferred to a 1.5m1 Eppendorf tube and 
incubated for 5 minutes at room temperature. 200 µl of chloroform (Sigma) was 
added to the TRIzol® preparation and samples vortexed for 15 seconds before 
centrifugation at 12,000g for 20 minutes at 4°C. The upper aqueous phase was 
removed and placed into a new 1.5ml Eppendorf containing 500µ1 of isopropanol and 
incubated at -20°C for 20 minutes. RNA was precipitated in the isopropanol and 
pelleted by centrifugation at 12,000g for 10 minutes at 4°C and supernatant removed. 
The RNA pellet was washed in 70% v/v ethanol, centrifuged at 4°C for 5 minutes at 
7,500g, air-dried and resuspended in 11 µl RNase free H2O (Life Technologies). RNA 
quality and yield was quantified by using an Ultraspec 2000 spectrophotometer by 
adding 1µl of purified RNA to 99µl of RNase free H2O at 260nm and RNA quality 
analysed by running samples on a 1% TBE agarose electrophoresis gel. All RNA 
samples were stored at -80°C until use. 
3.2.2 cDNA synthesis from total RNA 
Genomic DNA was removed from RNA samples by using the DNA-free TM DNase 
digestion kit (Ambion) according to the manufacturers protocol. Briefly, total RNA 
was incubated with 0.1 volume of l Ox DNase buffer and 1µl of DNase I for 30 
minutes at 37°C. 0.1 volumes of DNase activation reagent was then added to the RNA 
samples and incubated at room temperature for 2 minutes, before the DNase activation 
reagent was pelleted by centrifugation at 12,000g for 1 minute. cDNA was 
synthesised from 10µg of DNase treated total RNA using the SuperScript II RT-PCR 
system (Life Technologies). l µl oligo (dT)12_18 was added to the RNA, the volume 
adjusted to 12µl using RNasc-free H2O and denatured at 70°C for 3 minutes. A 
master-mix preparation was prepared containing lOx first strand synthesis buffer, 
2ýmNl MgCl-,. 10mM dNTP mix. 0.1M DTT, 200U/µl SuperScript II and RNase-free 
H2O. added to the RNA and incubated at 42°C for 1 hr. The reaction was terminated 
by heating to 80°C for 5 minutes and RNA digested by treating with RNase H for 2() 
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minutes at 37°C. cDNA samples were diluted 1: 5 in RNase-free H2O and stored at 
-20°C until use. cDNA integrity was confirmed by performing a reverse transcriptase 
polymerase chain reaction (RT-PCR) for glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). 
3.2.3 RT-PCR 
R"1T-PCR master mix was prepared containing 0.5U Platinum Taq polymerase, Ix PCR 
buffer, 0.2mM dNTP mix, 1.5mM MgC12,0.2µM forward and reverse primers 
(Genosys) and 5 t1 of 1: 5 diluted cDNA. The final reaction mix was adjusted to a 
volume of 50µl/reaction using RNase-free H2O. The sequence, position, size of 
product and annealing temperatures for each specific primer pair are listed in Table 1. 
RT-PCR reactions were performed in a DNA engine PTC200 thermal cycler (M. J. 
Research) and 10µl of PCR reaction product analysed by gel electrophoresis using a 
1% agarose gel containing 0.2µg/ml ethidium bromide and visualisation by a U. V. 
lamp. 
3.2.4 Northern blot analysis 
3.2.4.1 Denaturing gel electrophoresis and northern transfer 
10µg of total RNA samples were denatured at 65°C for 10 minutes before loading in 
l 0µl of formamide, 3.5µl formaldehyde (37% v/v) and 1µl ethidium bromide. 
Samples were then fractionated on 0.8% denaturing gels containing 1x MOPS 
(3-[N-morpholino] propanesulphonic acid) and 3.7% v/v formaldehyde. Following 
electrophoresis, gels were washed twice in lOx SSC and RNA transferred by capillary 
blotting on to Hybond N+ nylon membrane (Amersham Biosciences, Amersham, UK) 
overnight in l Ox SSC. The nylon membrane was subsequently washed twice in 2x 
SSC and the RNA permanently fixed to the membrane by U. V. irradiation using a 
UVC-508 Ultraviolet Crosslinker (Ultra Lum) and stored at room temperature until 
required. 
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Primer Sequence Position Size Tm 
Cycle 
number 
2953-3368 415bp 65°C 35 NM DAR 1 F-5'-GGAAGGCGCCCCCCAGAAGC-3' R-5'-CGAAGCCCGAGCGGAAAAACAGC-3' 
NMDAR2A F-5'-CCGGCCTGGGTTGCTCTTC-3' ' ' 2875-3332 457bp 68°C 35 R-5 -AGTTCGCTTTGGATTCTGTGCCTCA-3 
P. M DAR2B F-5'-CTGCCGGACATCACCACCACAACA-3' ' ' 4283-4727 441 bp 65°C 33 R-5 -CATCACGCGACCCACAGCCTTACC-3 
NMDAR2C F-5'-GAACGGCATCATTGGGGAGGTGTA-3' ' ' 1629-2088 459bp 68°C 35 R-5 -CGTGTAGCTGGCGAGGAAGATGAC-3 
NMDAR2D F-5'-CCGCCGTGTGGGTGATGATGTTCG-3' ' ' 1836-2310 474bp 65°C 35 R-5 -ACGCGGGGCTGGTTGTAG-3 
NMDAR3 F-5'-CTGCCGGACATCACCACCACAACA-3' ' ' 1836-2310 474bp 65°C 35 -CATCACGCGACCCACAGCCTTACC-3 R-5 
Yotiao F 5'-AAGGGAAGAAGAATTTGGTGTTGA 3' ' ' 629-1034 405bp 
° 60 C 37 R-5 -TGAGGATCTGTTGTTTGGCTTGTA-3 
- PSD 95 
F-5'-ACGGCGGGTTGAGCGACGAGAGT-3' 
' ' 2461-2953 492b p 68°C 
37 
-CAGGGAGCGGGGGCGGATGAA-3 R-5 
Oh as n-110 
F-5', GCTCGGCTGTATGTGCGTTAGAAG-3' py 
' 
805-1306 501 bp 60°C 36 R-5 -GAGGCCTGGTGTAGTCGTCGTC-3 
MALS F-5'-CCACCCCCGCCCCAATCT-3' ' ' 143-647 504bp 76°C 36 -CTCTTTTGAGGCCTCCGTGTCTTTGCAG-3 R-5 
CASK F-5'-GCACTACTAGCCGCTGTGTCAAGTCAC-3' 
' ' 946-1439 493bp 65°Cj 35 -TCGCCGTTTAAATAGGGAGAGGTG-3 R-5 
SHANK F-5'-AGGACCGGGGACTTCTTGATTGAG-3' 
' ' 239-664 425bp 68°C 37 -GATTCCTTGGCGTTOGTACACAGAGTT-3 R-5 
GAPDH T ' 
3' 
' 33-552 519bp 630C 34 R5 GGTCATGAGYCCT CCACGAT3 
Table 1. Primer sequence, gene position, product size, annealing 
temperature and cycle number used by RT-PCR analysis. 
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3.2.4.2 Probe synthesis and hybridisation 
RT-PCR of RNA derived from MEG-01 and HEL cells was used to generate templates 
for the labelling reaction. Radiolabelled probes were synthesised from l Ong of 
template cDNAs in 10mM TRIS HCl (pH 8.0), 1mM EDTA by incubating in random 
prime labelling mix (RediprimeTMI1, Amersham Biosciences) containing 50pCi a', P- 
dCTP at 37°C for 20 minutes. Gel filtration (G-50 sephadex spin column. Boehringer 
Mannheim, (Roche, Basal, Switzerland)) was used to remove radiolabelled probes 
from unincorporated a32P-dCTP and mixed with 100µ1 sheared salmon sperm DNA 
(10mg/ml, Boehringer Mannheim, (Roche)). Northern blots were incubated in 12m1 
Quickhyb buffer (Stratagene, CA) for 20 minutes at 68°C and probes. previously 
denatured at 95°C for 2 minutes, added to the blot. Hybridisation was performed at 
68°C for 1 hour and membranes then washed twice in 2x SSC, 0.1 % v/v SDS at room 
temperature and twice in 0. lx SSC, 0.1% v/v SDS at 60°C. BioMAX films (Kodak) 
were exposed to the northern blots with two intensifying screens (Kodak) for a 
minimum of 18 hours at -80°C. Films were developed using a X-ograph automated 
developer. 
3.2.5 Immunolocalisation 
Cytospin preparation and immunocytochemistry of MEG-O1 cells in the absence and 
presence of PMA were performed as previously described (chapter 2.1.2). Cytospins 
were incubated with anti-NMDARI monoclonal antibody (Pharmingen; 1 µg/ml) for 
30 minutes followed by FITC-conjugated goat anti-mouse secondary antibody (Sigma; 
1: 500 dilution). Antibody-negative controls were incubated with non-specific mouse 
IgGs (Santa Cruz; 1µg/ml) in the place of primary antibody. Stained preparations 
were mounted in Vectorshield (Vector Laboratories) and fluorescence viewed 
immediately using a Leica DMLA microscope (Leica) 
3.2.6 Laser microdissection and single cell RT-PCR 
Rat tibiae were removed and snap frozen in chilled isopropanol. Specimens were 
mounted in Cryo-m-bed embedding compound (Bright. UK) on brass chucks and 
frozen in chilled isopentane. Slide frames and foils (Leica) were U. V. irradiated for 
)0 minutes using a LVC-508 Ultraviolet Crosslinker (Ultra Lum) to remove all 
residual RN: \ses and to reduce the electrostatic charge of the foil. 7µ'ß'I thick frozen 
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sections were collected on slide foils, using a Bright OTF500 cryostat (Bright) fitted 
with a tungsten carbide tipped knife and used immediately. Specimens were air-dried 
and stained with 0.1 % toluidine blue. U. V. laser microdissection (LMD) was 
performed using a Leica DMLA light microscope fitted with a Leica . AS 
LMD 
microdissection unit (Leica). A single megakaryocyte, identified by size. morphology 
and multilobed nucleus was excised from rat bone and collected in a 200µl Eppendorf 
containing 12 µl of lysis buffer (50mM IRIS HC1 (pH 8.0). 100mM NaCl. 5mNI 
MgCl2,0.5% Triton X-100,1mM DTT and 100 units RNAse out (Invitrogen)). 
Samples were centrifuged at 12,000g, 4°C for 10 minutes, chilled rapidly on dry ice 
and stored at -80°C until use. Synthesis of cDNA and RT-PCR master mix 
preparation was performed as previously described in this chapter. Identical primers 
(see Table. 1) were also used to amplify products by single cell RT-PCR. with cycle 
number increased to 50. 
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3.3 Results 
3.3.1 mRNA expression of NMDA receptor subunits and associated proteins by 
megakaryocytic cell lines 
3.3.1.1 mRNA expression of NMDA receptor subunits by megakaryocytic cclls 
RT-PCR was used to confirm expression of NR2D by MEG-O1 cells in the absence 
and presence of PMA (Fig. 3.3.1). However, the expression of other NMDA receptor 
subunits was also identified. In MEG-O1 cells, RT-PCR identified expression of 
NR2A (+PMA only), NR2C (weakly +/- PMA), NR2D (+/- PMA) and NR3 (-PMA 
only). Expression of NR2B by MEG-01 cells was not detected. These findings would 
insinuate expression of specific NMDA receptor subunits only, levels of which appear 
to change during differentiation. 
Parallel investigation of NMDA receptor subunit expression by HEL cells by RT-PCR 
also confirmed the expression of select subunits during PMA-mediated differentiation 
(Fig. 3.3.1). Similar to MEG-01 cells, NR2B expression was not detected, whilst 
NR2C mRNA expression was identified in PMA-treated and untreated cells, with an 
apparent increase in NR2C expression following PMA exposure and a similar pattern 
of NR2D expression was also identified. In HEL cells, NR2A expression was not 
detected, contrasting to MEG-O1 cells. It was also found that HEL cells lacked NR3 
subunit expression at both immature and differentiated stages. All subunits were 
expressed by human foetal forebrain positive controls. Water controls were carried 
out in parallel to the above experiments and no products were amplified. 
Northern blot analysis was used to quantify expression of NR2D by HEL cells during 
differentiation. 10µg of total HEL RNA resulted in the identification expression of a 
4.7 kb species in both PMA-treated and untreated samples (Fig. 3.3.2). Expression of 
NR2D increased following PM: \ treatment by approximately 45% when analysed by 
densitometrv, normalising \vith 28S RNA. 
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Figure 3.3.1. Expression of NMDA receptor subunits by megakaryoblastic cell 
lines in the absence and presence of PMA. RT-PCR was used to demonstrate 
mRNA expression of NR2A-D and NR3 receptor subunits by HEL and MEG-0l 
megakaryocytic cell lines in the absence and presence of PMA. Human foetal 
forebrain (FB) was used as a positive control and expressed all NMDA receptor 
subunits. Control reactions were performed in parallel, in the absence of cDNA 
(11.0). Results are representative of 2 independent experiments. 
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Figure 3.3.2. Northern blot analysis of NR2D expression by HEL cells. Northern 
blot analysis of HEL total RNA (10µg) in the absence and presence of PMA was used 
to identify relative expression of NR2D rnRNA. A single 4.7 kDa mRNA species was 
identified. which corresponds in size to the NR2D subunit previous identified in 
human brain. NR2D expression was increased following PMA treatment. Equal 
loading was demonstrated by comparing total RNA. Experiment was performed 
once. 
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3.3.1.2 mRNA expression of N_l1DA associated proteins by megakarv. cocyytic cell lines 
Similar studies using RT-PCR and northern blot analysis were performed on MEG-01 
and HEL cells with and without PMA. to compare mRNA expression of specific 
NMDA receptor associated protein (Fig. 3.3.3). Using RT-PCR, products identical in 
size to those found in human forebrain PSD-95 were amplified in both HEL and 
MEG-01 samples. PSD-95 expression appeared to be independent of differentiation in 
HEL cells, whereas it appeared to be more abundantly expressed by PMA-treated 
MEG-01 cells compared to control untreated cells. Other proteins associated with 
NMDA receptor function and signalling, Yotiao and chapsyn-110, were not detected 
by RT-PCR as being expressed by either MEG-O1 or HEL cells. Human foetal 
forebrain positive control identified expression of chapsyn-110, PSD-95 and Yotiao. 
Water controls were carried out in parallel to the above experiments and no products 
were amplified. 
Northern blot analyses were performed to confirm mRNA expression of PSD-95 and 
Yotiao by HEL and MEG-01 cells (10µg total RNA each; Fig. 3.3.4). PSD-95 
expression was demonstrated in both MEG-0l and HEL cells, with an abundant signal 
identified at 4.2 kb and weak signals present at 6.2 and 8.3 kb. These signals of 
varying sizes may correspond to three of the four known splice variants of the PSD-95 
homologue, which have been identified in numerous tissues (Stathakis et al., 1997). 
Whilst PSD-95 expression appeared to be constant in HEL cells, expression was 
increased in MEG-01 cells treated with PMA compared to relative levels of 28S RNA. 
Northern blot analysis was also used to demonstrate expression of Yotiao by HEL 
cells, even though no product was amplified by RT-PCR (Fig. 3.3.5). Northern blot 
analysis revealed a species of approximately 11 kb, corresponding to that found in 
brain and other tissues (Lin et al., 1998). Although Yotiao appeared to be weakly 
expressed by HEL cells, expression was also notably increased by exposure of HEL 
cells to PMA when compared to relative intensity of 28S RNA. 
The above results confirmed identification of NR2D expression and provided evidence 
of NR2 and NR3 subunit expression by megakaryocytic cells lines. 
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Figure 3.3.3. Expression of NMDA receptor associated proteins by 
megakaryoblastic cell lines in the absence and presence of PMA. RT-PCR was 
used to determine expression of NMDA receptor-associated protein mRNA expression 
by MEG-O1 and HEL cells in the absence and presence of PMA. HEL cells were 
shown to express PSD-95 with and without PMA treatment, whilst MEG-01 cells 
only in the presence of PMA exhibited weak PSD-95 expression. Expression of 
Chapsyn-110 and Yotiao was not detected in HEL and MEG-01 cells. Human foetal 
forebrain (FB) was used as a positive control and expressed all NMDA receptor 
subunits. Control reactions containing were performed in parallel, in the absence of 
cDNA (I LO). Results are representative of two independent experiments. 
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Figure 3.3.4. Northern blot analysis of PSD-95 expression by HEL and MEG-O1 
cells. Northern blot analysis of total RNA (10µg) was used to demonstrate expression 
of PSD-95 by both HEL and MEG-0l cells. PSD-95 expression by MEG-0l cells, 
when compared to total RNA, appears to increase slightly by treating cells with PMA, 
whilst very little difference is observed in between treatment of HEL cells. Experiment 
was performed once. 
ýý_ 
ý. 
. 
72 
PS D-95 
Chapter 3 
HEL 
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Figure 3.3.5 Northern blot analysis of Yotiao expression by HEL cells. Northern 
blot analysis of total RNA (10µg) was used to demonstrate expression of Yotiao by 
both HEL cells. Yotiao expression by HEL cells was shown to have increased 
following PMA treatment. determined by comparing Yotiao expression to total RNA. 
l xperiment was performed once. 
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3.3.2 Localisation of NR1 in MEG-O1 cells 
Immunocytochemistry of MEG-O1 cell cytospin preparations was used to determine 
the localisation of the NR1 subunit in MEG-O1 cells cultured in the absence and 
presence of l 00nM PMA for 72 hours (Fig. 3.3.6). Anti-NR1 antibodies (1µg/ml) 
were used in conjunction with a FITC-secondary antibody in order to accurately 
localise subunit expression (green positive staining). Nuclei were counterstained with 
DAPI (blue) to identify the location of the nucleus. Cells were examined by 
fluorescent microscopy at a magnification of x40 and results shown illustrate 
representative staining patterns. NR1 expression was restricted usually to a single 
small cytoplasmic area in untreated MEG-O1 cells. PMA-treatment of MEG-O1 cells 
resulted in the characteristic increases in cytoplasm to nucleus ratio, cell size and 
nuclear volume. Following PMA-mediated MEG-01 differentiation, NR1 was 
distributed evenly throughout the cytoplasm and was not restricted to any particular 
cytoplasmic locations. Control samples, in which non-specific mouse IgGs were used 
in place of the anti-NRl primary antibody, exhibit the level of background staining. 
3.3.3 NMDA receptor subunit and associated protein mRNA expression by 
human primary megakaryocytes 
The development of cell separation and culture techniques has made it possible to 
investigate large numbers of human primary megakaryocytes, derived from UCB. 
This technique was utilised to establish the expression of the essential NR1 subunit by 
northern blot analysis (Genever et al., 1999). This section aims to ascertain if primary 
human megakaryocytes express mRNA for the regulatory NR2 subunits and NMDA 
receptor associated proteins. 
RT-PCR analysis was used to determine expression of NR2 subunits and NMDA 
receptor associated proteins by human primary megakaryocytes. derived from CD34+ 
UCB cells, following exposure to 25ng/ml TPO for 14 days. Gene-specific primers to 
human brain NR2: A-D, Yotiao, PSD-95, chapsvn-110. CASK, MALS, and SHANK 
and RT-PCR programmes used in these experiments were identical to those previousl\ 
described in chapter 3.3.1.1 and listed in Table 1. Products from primary human 
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Original in colour 
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-PMA 
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Figure 3.3.6. Immunolocalisation of NRl in MEGOl cells in the absence and 
presence of PMA. Cytospin preparations of WG-Ol cells cultured in the absence or 
presence of PMA for 72 hours. Untreated MEG-01 cells expressed NR 1 (green 
staining) which was localised at distinct cytoplasmic regions, whilst NRI was 
prominently expressed throughout the cytoplasm of PMA-treated MEG-01 cells. 
Nuclei were stained blue (DAPI). The experiment was performed once. 
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megakaryocytes identical in size to those found in human foetal cerebellums were 
amplified for NR2A and NR2D. No product was observed for NR2B and C (Fi`g. 
3.3.7 A). Human foetal cerebellum was used as a positive control all four subunits. 
RT-PCR amplified products for the receptor scaffold and signalling proteins Yotiao 
and PSD-95 only (Fig, 3.3.7 B). mRNA expression of other NMDA receptor 
associated proteins, chapsyn-110, CASK, MALS and SHANK were identified in 
human foetal cerebellum only. Water controls were carried out in parallel to the above 
experiments and no products were amplified (data not shown). 
3.3.4 mRNA expression of NMDA receptor subunits by a single ex vivo rat bone 
marrow megakaryocyte 
The recent development of microdissection technology has enabled the excision of 
target tissue from histological samples. Accurate laser microdissection facilitates the 
removal of different sized specimens, from a single cell to large cellular groups, 
identified by high power microscopy and sterile excision allows subsequent 
expression analyses such as single cell RT-PCR. This method was utilised for the 
removal of a single megakaryocyte, identified by the cells large size, morphology and 
multilobed nucleus compared to other cells in the rat bone marrow for subsequent 
analysis of NMDA receptor subunit expression by RT-PCR (Fig. 3.3.8 A). 
Single cell RT-PCR analysis (chapter 3.2.3) using primers specific to NR1, NR2A 
and NR2D genes in human brain (Table 1), identified weak mRNA expression of 
NR2A only (Fig. 3.3.8 B). Products for NR1 and NR2D were amplified in human 
foetal forebrain only. In control reactions lacking reverse transcriptase, no products 
were amplified. 
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Figure 3.3.7. Expression of NMDA receptor subunits and associated proteins by 
human primary megakaryocytes. RT-PCR was used to amplify products for NR2A 
and NR2D from human CD34+-derived megakaryocytes (MK), whilst NR2B and C 
were identified in human foetal cerebellum (CB) only (A). RT-PCR was also 
identified expression of NMDA receptor associated proteins Yotiao and PSD-95 (B). 
Other associated proteins, chapsyn-110, CASK, MALS and SHANK were amplified 
in human foetal cerebellum only. Results are representative of three independent 
experiments. 
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Figure 3.3.8. RT-PCR analysis of NMDA receptor expression of a single 
megakaryocyte removed by laser dissection microscopy from rat bone marrow. 
Laser dissection microscopy (LMD) was used to extract a single megakaryocyte from 
toluidine blue stained rat bone marrow (A). Total RNA was extracted from the 
megakaryocyte and RT-PCR identified weak expression of NR2A. NR 1 and NR2D 
were identified in human foetal forebrain only (FB). In control reactions lacking 
reverse transcriptase (No-RT), no products were amplified. Experiment was 
performed once. 
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3.4 Discussion 
Megakaryocytic cells express functional, channel-forming NMDA receptors. a finding 
confirmed by RT-PCR analysis of MEG-O1 cells and bone marrow, 
immunohistochemistry, in vivo studies and northern blot analysis for NR1 expression 
by CD34+-derived primary cells (Genever et al., 1999). However, for a greater 
understanding of NMDA signalling in megakaryocytes, expression of the regulatory 
NR2 and 3 subunits during megakaryocytic cell line differentiation and by primary 
megakaryocytes is required. This chapter addresses the expression of these subunits 
whilst also confirming the expression of proteins identified in the PSD and for the first 
time focuses on the mRNA expression of NMDA receptor subunits by a single rat 
bone marrow megakaryocyte. 
Differences in the expression of NMDA receptor regulatory subunits following PMA 
treatment and between HEL and MEG-O1 cells indicate that the role of the NMDA 
receptor these cells may vary. HEL cells express the NR2C and D subunits, which, if 
expressed as diheteromers with NR1 (there is no evidence that NR1/NR2C/NR2D 
triheteromers exist in the CNS) would confer a "low-conductance" ion channel with a 
lower sensitivity to Mg2+ and slow deactivation (-300ms for NRI/NR2C and -1.7 
seconds for NRI/NR2D; Behe et al., 1999; Momiyama et al., 1996). In the CNS, 
NR 1 /NR2A diheteromers, in contrast to the previously mentioned NR 1 /NR2C or D, 
have extremely high conductance, fast deactivation time (-'50ms; Behe et al., 1999) 
and high sensitivity to Mgt+. The apparent increase in NR2C and confirmed increase 
in NR2D mRNA expression following PMA treatment may influence the function of 
the receptor as the HEL cell undergoes differentiation. MEG-01 cells express NR2A 
following PMA treatment, in addition to NR2C and NR2D, which would provide this 
receptor with a broader activity than the one expressed by HEL cells. It also appears 
that NR2A and NR2C expression is increased by PMA treatment, implying an 
increased role for these receptor subunits either during differentiation or in fully 
differentiated cells, how ever these findings require confirmation by northern blot 
analysis. The lack of NR2B expression by either HEL or MEG-O1 cells may suggest 
that an NNIDA receptor composition of "intermediate" activity is not utilised by the 
mc: gakaryocyte. 
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The functions of various NR2 subunits can be assessed by the use of subunit selective 
pharmacological agonists and antagonists. One such example is the non-competitive 
NMDA receptor channel block, MK-801. which shall be discussed at greater depth in 
chapter 4. Recombinant NR 1 /NR2A has a higher sensitivity to \ IK-801 than 
NR1/NR2B and C (no data exists for recombinant NR1/NR2D: Chazot et al.. 1994). 
which may have implications on the functional studies described in chapter 4, due to 
MK-801 being employed as a pharmacological NMDA receptor antagonist. Many of 
the subunit-specific inhibitors target NR2B-containing receptors, however. 
cis- 1- [phenanthren-2y1-carbonyl] piperaxzin-2,3-dicarboxylic acid (PPDA) 
specifically blocks NR2C and D containing receptors (Hrabetova et al., 2000) and 
N, N, N', N'-tetrakis-[2-pyridmethyl]-ethylenediamine (TPEN) inhibits only NR2A- 
containing NMDA receptors (Paoletti et al., 1997). Electrophysiological experiments, 
which have previously been carried out on megakaryocytes (Thomas et al., 2001). 
could exploit these subunit-specific inhibitors to give a greater idea of megakaryocyte 
receptor composition. 
Expression of the NR3 subunit by non-PMA treated MEG-01 cells further increases 
the diversity of the NMDA receptor in this cell type. This subunit has the ability, 
when co-assembled with the high calcium conductance NRI/NR2A channel (i. e. 
formation of a NR 1 /NR2A/NR3 receptor), to lower calcium influx by five-fold (Das et 
al., 1998; Perez-Otano et al., 2001). The expression of this subunit by MEG-O 1 cells 
only in an undifferentiated state may imply that the receptor is being kept in a 
relatively unresponsive state until the cell becomes differentiated. The reduction in 
NR 
_3' expression 
in addition to apparent increase in the expression in NR2A by the 
differentiated MEG-O1 cell, suggests that the increase in receptor conductance is 
required only in the mature cell type. The lack of NR3 expression by HEL cells may 
be correlated to the absence of NR2A expression, given that. as the receptor would 
already have a low conductance. hence the "volume control" effect of the NR3 subunit 
would have a minimal effect. 
The confirmation of PSD-95 and Yotiao expression by HEL cells and PSD-95 
expression by MEG-01 cells adds to the NNIDA receptor-signallin`g complex in the 
megakaryocytc. PSD-9- provides an association between the functional 
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megakaryocytic NMDA receptor and activation of downstream signalling pathways 
such as MAPK and nNOS. The presence of PSD-95 may also lead to NMDA receptor 
clustering in the megakaryocyte, although whether interaction is essential in 
megakaryocytes as it is for synaptic plasticity in the postsynaptic neurons remains 
unclear. PMA treatment may also result in a small increase in PSD-95 expression by 
MEG-O1 cells, which could be due either to an increase in PSD-95-mediated 
signalling, or directly correlated to increases in NR2 subunit expression. It is also 
noteworthy that both MEG-O1 and HEL cells express three different PSD-95 
transcripts, which may be of functional importance in non-neuronal tissues (Stathakis 
et al., 1997). Only the ubiquitously expressed 4.2kb transcript has been identified in 
brain, whilst expression of both 6.2 and 8.3kb transcripts found in megakaryocytes has 
also been demonstrated in pancreas, prostate, testis and ovary. Stathakis and 
colleagues state no function for PSD-95 in these tissues, however it is interesting to 
note that glutamate signalling was subsequently identified in many of the tissue 
samples they investigated. The PMA-mediated increase in Yotiao expression by HEL 
cells raises the possibility that NMDA receptor activity can undergo greater regulation 
in mature megakaryocytes. Again, whether Yotiao is also implicated in receptor 
clustering, requires further investigation. 
Indeed, a greater level of NMDA receptor clustering following PMA treatment is not 
supported by the findings of NR1 immunolocalisation in MEG-0l cells in the absence 
and presence of PMA. It was demonstrated that NRl expression appeared to be 
evenly distributed throughout the cytoplasm following PMA treatment, and not at 
distinct membrane regions as observed in postsynaptic neurons. NMDA receptor 
clustering to the postsynaptic plasma membrane is vital for correct function. It seems 
confusing therefore that PMA treated MEG-O1 cells display NR1 diffusely distributed 
throughout the cytoplasm. Matsuda and Hirai demonstrated that disrupting actin and 
microtubule organisation in human embryonic kidney (HEK) 293 cells resulted in 
profound rearrangements of NR1 distribution (Matsuda and Hirai. 1999). 
Interestingly, in actin filament-disrupted cells, NR1 localisation shifted from the 
plasma membrane and formed cytoplasmic "macroclusters", akin to those formed in 
non-PN1A treated NIEG-O1 cells. However, in microtubule-disrupted cells. NRI was 
distributed evenly throughout the cytoplasm, comparable to the findings of 
PNIA-treated MEG-Ol cells. The work by Nlatsuda and l lirai reveals the importance 
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of the cytoskeleton in NMDA receptor clustering, however the changes in cytoskeletal 
organisation observed during MEG-01 cell differentiation may alter NR1 localisation. 
However, NR1 immunohistochemistry performed on primary bone marrow 
megakaryocytes indicate a more membrane located receptor distribution (Genever et 
al.. 1999). This may signify differences in cytoskeletal organisation between cell lines 
and primary cells, leading to different receptor localisations. 
RT-PCR analysis for NMDA receptor subunit and PSD mRNA identified expression 
of NR2A, NR2D, PSD-95 and Yotiao by human primary megakaryocytes for the first 
time. Therefore, in a manner similar to the megakaryocytic cell lines described above, 
expression of NR1/NR2A or NRl/NR2D diheteromers would confer receptors of 
different conductance and magnesium sensitivity and again an "intermediate" receptor 
type expressing NR2B or C would not form. These findings also imply that primary 
cell functional studies using the NMDA receptor antagonist MK-801, described in 
subsequent chapters, should have a high affinity for these receptors. Further work 
regarding primary cell subunit expression should focus on northern blot analysis at 
different time pints to identify changes in receptor subunit composition during 
differentiation. The same conclusions can be drawn regarding the expression of 
PSD-95 and Yotiao. Other PSD proteins, chapsyn-110, CASK, MALS and SHANK 
appear not to be expressed or expressed at negligible levels, implying that the primary 
megakaryocytes express only the components for "specialised" NMDA receptor 
signalling. 
Laser microdissection and subsequent single cell RT-PCR analysis is the first example 
of this technology carried out on a bone marrow megakaryocyte. This technique 
confirmed mRNA expression of the NR2A subunit, but unfortunately due to time and 
technical constraints, it was not possible to optimise the single-cell RT-PCR protocol. 
possibly leading to NR1 and NR2D products not being detected. The absence or 
presence of NMDA receptor subunits expressed by bone marrow megakarvocv'tes 
cannot be confirmed until an exact protocol for laser dissected-megakar 'ocyte single 
cell RT-PCR is achieved. Future use of this technique may provide a greater 
understanding of bone marrow megakarvocyte mRNA expression. 
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This chapter has established that many of the components that encompass the N\ IDA 
receptor signalling system in the CNS are expressed by megakarv ocytes. As 
megakaryocyte NMDA receptor research is still in its infancy, it currently has to he 
assumed that the receptors function in a similar manner to those found in the CNS. 
Such assumptions may however be imprudent. Due to the nature of neuronal cells, the 
function of the NMDA receptor in the CNS is highly unlikely to be identical to those 
expressed by megakaryocytes. The presence of regulatory receptor subunits would 
suggest however, that regulation of the receptor activity is of importance, especially 
before, during and after differentiation. I would also propose that megakaryocytic 
PSD-95 acts as a NMDA receptor associated signalling protein rather than distinct 
receptor clustering. This work still requires clarification. This would include analysis 
of the expression of all NMDA receptor subunits and PSD proteins by cell lines and 
by primary cells at various stages of differentiation by northern blot analysis, in 
addition to receptor subunit/PSD protein co-localisations and 
co-immunoprecipitations. However, the exact nature of the receptor will only be 
clarified by electrophysiological investigation of agonist response and receptor 
conductance. Such confirmation would provide a stronger grounding on which to 
tackle the main aim of this research, how this receptor affects Inegakaryocyte function. 
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Function of the Megakaryocytic 
NMDA Receptor 
The formation of spindle-like proplatelet structures on the surface of 
human primary megakaryocytes demonstrated by scanning 
electron microscopy (magnification x 10,000) 
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Function of the Megakaryocytic NMDA Receptor 
4.1 Introduction 
The characterisation of the megakaryocytic NMDA receptor as described in chapter 3, 
confirms the existence of NMDA receptor components required for receptor function. 
These data therefore provoke intriguing questions regarding the function of NMDA 
receptors in megakaryocytes. Exploratory studies by Genever and co-workers 
identified some functions of the NMDA receptor in MEG-O1 cells related to 
PMA-mediated differentiation and adhesion (Genever et al., 1999`). These findings, 
in addition to numerous others directed at determining NMDA receptor function in 
neuronal cells and peripheral tissues, used the specific NMDA receptor antagonist 
dizocilpine, otherwise known as MK-801 (Peet et al., 1999; Genever et al., 1999h, 
Huang et al., 1999; Garcia-Zaragoza, 2000; Sin et al., 2002). By using this antagonist, 
it is possible to identify the effect on a particular cell as a direct consequence of 
aberrant NMDA receptor function. 
NMDA receptor antagonist research has predominantly focused on the ability of these 
compounds to prevent neuronal degeneration in acute brain injury conditions such as 
epilepsy, head trauma and stroke, which are a result of excessive NMDA receptor 
activation (for review see Hickenbottom and Grotta, 1998). The neuroprotective 
actions of the receptor antagonists do however have psychotic side effects, such as 
schizophrenia in humans (Javitt and Zukin, 1991) and neurotoxicity in rats (Olney et 
al., 1991, . 
IeN, Iovic-Todorovic et al., 1998; Farber et al., 2002). Indeed, 
antagonist-induced NMDA receptor hypofunction strongly resembles naturally 
occurring events in the ageing human brain, such as Alzheimer's disease (Olney and 
Farber, 1995; Wozniak et al., 1998). As such, extensive research into the function of 
NMDA receptor antagonists has been able to identify the detailed actions of these 
compounds. 
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MK-801 is an extremely potent, non-competitive antagonist that binds only to NMDA- 
type glutamate receptors (Wong et al., 1986). As a result, MK-801 is a highly 
effective neuroprotectant against extremely high doses of NMDA. but also results in 
extreme psychotic side effects (Woodruff et al.. 1987). MK-801 acts by binding to a 
site within the open NMDA receptor ion channel. thereby blocking receptor-mediated 
calcium entry (DeLorenzo et al., 1998: Ikonomidou et al., 1999). a mechanism that is 
also shared by the common anaesthetic agent ketamine (Stone and Addae, 2002). 
The results of MK-801 treatment on MEG-O1 differentiation as described by Genever 
and co-workers, demonstrated that NMDA receptor inhibition might inhibit the 
PMA-mediated differentiation of these cells. However, other functions of the receptor 
in these cells remain unanswered and will be a subject of this chapter. Although 
immunological, morphological and molecular determination of megakaryocytic cell 
line differentiation is an effective tool by which to start functional investigations, 
certain characteristics of these cell lines are not comparable with primary bone marrow 
megakaryocytes. A more representative in vitro model of megakaryocyte 
differentiation may be achieved by generating primary human megakaryocytes from 
CD34+ HSCs, a technique that has been exploited in this chapter. 
One characteristic of the terminally differentiated CD34+-derived megakaryocyte, 
which is rarely observed in megakaryoblastic cell lines, is the formation of proplatelet 
structures in culture (Haller and Radley, 1983, Cramer et al., 1997; see chapter 1.2.3). 
Identifying the mechanisms regulating platelet production is a key aim of 
megakaryocyte research, therefore the initial events governing the formation of 
proplatelets has recently attracted a significant level of interest. Much study has 
focused on the profound cytoskeletal reorganisation required in the production of these 
structures, although the molecular mechanisms involved in proplatelet production 
remain unclear (Leven and Yee. 1987, Cramer et al., 1997). Microtubule stabilisation 
causes the formation of abnormal proplatelets (Tablin et al.. 1990), whilst disruption 
greatly inhibits proplatelet formation (Handagama et al.. 1987) suggesting a vital role 
for microtubules in the formation of proplatelets. Two tubulin isoforms, (x and ß. 
integrate to form into filaments, which in turn combine to form microtubules 
(I)owning and Nogales. 1998). The X31 tubulin isoty pe is specific to haematopoietic 
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cells, and along with other cytoskeletal components, is considered to be under the 
control of the transcription factor NF-E2 (Lecine et al., 2000). 
The role of actin in proplatelet formation remains confusing as inhibiting actin 
polymerisation causes both the enhancement (Tablin et al.. 1990) and inhibition 
(Handagama et al., 1987) of platelet production in different systems. However. a 
recent study identified that inhibition of PKCa altered the actin dynamics, reducing 
the number of proplatelets formed from TPO-stimulated proplatelet production 
(Rojnuckarin and Kaushansky, 2001). Considering that TPO and other haematopoietic 
cytokines appear to have no control over proplatelet formation, identification of 
NMDA-mediated effects of megakaryocyte platelet production in vitro is a key aim of 
this chapter. 
CD34+-derived megakaryocytes also display comparable characteristics irr Otro to 
bone marrow megakaryocytes. They increase greatly in size during TPO-mediated 
differentiation, with a terminally differentiated cell being around 25-35 µm in 
diameter (see Fig. 1.9). They also express a range of megakaryocyte lineage-specific 
markers including CD61 and CD41, but also express higher levels of platelet-specific 
markers such as CD42a and CD62P at terminal differentiation (Lepage et al., 2000; 
Perez et al., 2001), unlike the currently available cell lines. 
These cells also display similar ultrastructural characteristics to bone marrow 
megakaryocytes (Schmitt et al., 2001). Terminally differentiated primary cells have 
multi-lobed indented nuclei, indicting that normal nuclear maturation has taken place. 
Characteristic cytoplasmic maturation also occurs, with the invasion of dilated 
demarcation membrane and the formation of cytoplasmic a-granules, both of which 
are essential in the process of platelet release and subsequent platelet function. TEM 
and SEM have also previously been used to determine extent of proplatelet formation. 
Such studies have revealed that mature platelets are actually released from the tips of 
proplatelet structures with extensive branching and bending greatly increasing the 
number of proplatelet ends (Italiano et at.. 1999). 
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Although the use of MK-801 to determine the function of the NNIDA receptor is a 
practical and widely used method. it is also important to determine the effect of 
agonist-mediated receptor activation on target cells. NMDA receptor agonist 
responses are regularly studied in neuronal cells (Anderson et al.. 2002. Allgaier. 
2002) and have also been employed in the study of glutamate signalling in bone cells 
(Laketic-Ljubojevic et al., 1999; Gu et al., 2002). NMDA receptor activity in such 
studies is characterised by agonist-induced calcium influx, typically measured using 
the patch-clamp method. However, other methods do exist such as fluorescent-based 
calcium measurements (Pal et al., 1999), as used in this chapter or 
spectrophotometry/microscopy-based calcium imaging which has previously been 
used in the study of calcium oscillations in rat megakaryocytes (Mason et al.. 2000). 
For agonist-mediated NMDA receptor activation to occur, a source of extracellular 
glutamate is required. In the CNS, glutamate is released from presynaptic cells 
following depolarisation, which results in the activation of membrane-bound receptors 
on the postsynaptic cell (see chapter 1.6), whilst keratinocytes and nerve cells have 
been identified as candidates for glutamate release and recycling in skin (Davidson et 
al., 1997; Kinkelin et al., 2000). Glutamate release has also recently been studied in 
osteoblastic cells (see chapter 1.7.1). As previously stated, osteoblasts express the 
functional glutamate transporter molecule GLAST (EAAT1), which has been 
implicated in glutamate uptake in neuronal cells (Mason et al., 1997). As osteoblasts 
have also been shown to express SNARE and other vesicular proteins associated with 
glutamate release in neuronal cells (Bhangu et al., 2001), it is possible to hypothesise 
that the osteoblast may be responsible for glutamate release and recycling in bone. 
A more recent study adds further weight to these claims by demonstrating that several 
osteoblastic cell types spontaneously release glutamate at concentrations comparable 
to neuronal cells (Genever and Skerry, 2001 a). The concentration of glutamate 
released was also significantly increased during differentiation. However, unlike 
neurons, osteoblastic K+-mediated depolarisation inhibited glutamate release, 
suggesting that voltage-mediated osteoblastic calcium entry reduced the level of 
glutamate exocytosis. Treating osteoblastic cells with the glutamate release inhibitor 
riluzole (l -10µm1). reduced the osteogenic differentiation without affecting viability. 
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However. addition of higher concentrations (>_25µM) of riluzole, which usually has no 
effect on neuronal viability. resulted in high levels of osteoblastic cell death and 
apoptotic characteristics. including increased Bax/Bcl-2 ratio. membrane blebbing. 
chromatin condensation and DNA fragmentation (Genever and Skerry, 2001 b). 
The vesicular glutamate transporter characterised as brain-specific Na+-dependent 
inorganic phosphate (Pi) transporter I (BNPI), now referred to as VGLUTI (vesicular 
glutamate transporter 1; Ni et al., 1994) has also recently been identified as being 
expressed by osteoblasts (Hinoi et al., 2002). Although VGLUT 1 does cause an 
increase in Na+-dependent Pi uptake, giving the protein its original name, it is now 
believed that its major role is to load recycling vesicles with glutamate in presynaptic 
glutamatergic axon terminals (Bellocchio et al. 1998; Bellocchio et al., 2000; 
Takamori et al., 2000). VGLUTI-positive immunoisolated vesicles display enhanced 
levels of glutamate uptake, whilst over-expression of VGLUTI in non-glutamatergic 
neurons results in these cells releasing glutamate, indicating that VGLUTI expression 
is sufficient to define glutamatergic phenotype. However, VGLUT I expression was 
not identified in some presynaptic cells demonstrated to be releasing glutamate, 
suggesting the existence of other vesicular glutamate transporters (Bellocchio et at.. 
2000). This lead to the cloning of a VGLUTI homologous protein called 
differentiation-associated BNPI (DNPI; later named VGLUT2), which was 
upregulated in expression when pancreatic cells are stimulated to differentiate in 
neuronal cells (Aihara et al., 2000). Subsequent studies revealed that VGLUT2 was 
also functionally homologous to VGLUTI (Takamori et al.. 2001). VGLUT2 was 
previously thought not to be expressed by osteoblasts (Hinoi et al., 2002) however, 
recent unpublished evidence suggests otherwise (P. G. Genever. personal 
communication). 
These findings demonstrate the intricacies of the glutamate signalling system in bone, 
displaying some of the similarities and differences compared to signalling in the CNS. 
Whether such a system exists in megakarvocytes or the bone marrow 
microenvironment is important to consider, as currently no evidence exists as to the 
source of glutamate for the activation of megakaryocytic N ID. \ receptors. The 
existence of uncharacterised GLT-l positive cells in the bone marrow (Mason et al.. 
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1997) indicates that glutamate recycling in the vicinity of the megakaryocyte is 
feasible although the glutamate source and release mechanisms remain elusive. 
This chapter addresses a number of diverse questions. These include further 
determinations of the functional role of NMDA receptors in megakaryocytic cell line 
differentiation, in addition to expanding the study to the role of the receptor in human 
primary megakaryocytes. This work also includes for the first time. investigations to 
identify the effects on MEG-O1 cells of agonist-induced NMDA receptor activation 
and finally provides evidence of megakaryocytic glutamate release mechanisms. 
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4.2 Materials and Methods 
4.2.1 Cell culture 
MEG-01 and HEL cell lines were cultured as previously described (chapter 2.1.2). 
MK-801 (Tocris; Bristol, UK, 50µM unless otherwise stated) was added to cells at the 
same time as PMA and cultured for a period of 72 hours. Human CD34+-derived 
megakaryocytes were cultured as previously described (chapter 2.1.3) and 50µM MK- 
801 added 15 minutes prior to the addition of TPO at day 0 and day 7 of culture. 
4.2.2 Glutamate binding assay 
Prior to each glutamate binding experiment, MEG-01 cells were removed from normal 
culture medium, washed three times in PBS and transferred to glutamate/aspartate-free 
medium (NeurobasalTM) containing N2TM supplement for four hours. Cells were then 
washed twice in cold binding buffer (100mM NaCl, 5mM KC1.2mM CaCl2 in Hanks' 
balanced salt solution (HBSS)) and cell number adjusted to lx106 cells /ml. Cells were 
then incubated with 250µCi [3H]-glutamate (Amersham Pharmacia) with or without 
non-radioactive glutamate, at concentrations ranging from 1x 10-3M to 1x 10-8M and 
with or without MK-801 (50µM) in 500µl of cold binding buffer for 4 hours at room 
temperature. Cells were washed twice in cold binding buffer and solubilised in 0.1 % 
sodium dodecylsulphate (SDS) before the extract was diluted with scintillant 
(Ultragold. Packard) and relative remaining radioactivity counted using a Coulter 
counter (LS-60001 C; Beckman Coulter). 
4.2.3 MEG-O1 fibronectin adhesion assay 
4. '. 3.1 Fibronectin-mediated cellular adhesion and NR1 immunolocalisation 
1 3mm glass coverslips were immersed in 100% ethanol for 30seconds, to ensure 
sterilisation, and washed in sterile distilled water (dH, O) and allowed to air dry. The 
co\'erslips were then placed in 24-well culture plates and 200µl of 25n`/inl fibronectin 
(I'N, sigma : \ldrich). diluted in dH, O and allowed to coat the coverslips overnight at 
4°C. Fibronectin solution was then removed and the bound substrate washed 3 time 
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in dH2O and blocked in 0.1% BSA solution for 1 hour at 37°C before being removed. 
Cells were then plated directly onto FN coated coverslips in 24-well plates at an initial 
cell concentration of 1x105 cells/ml. 500µ1 of cell suspension was added to each well 
and incubated for 72hrs in the presence of I OOnM PMA, with or without 50µ1e1 
MK-801. Media and non-adherent cells were then removed and remaining cells 
washed 3 times with PBS, fixed in 4% paraformaldehyde for 5 minutes and blocked in 
10% goat serum (diluted in PBS) for 30 minutes. Cells were then incubated overnight 
at 4°C with mouse anti-active ß-1 integrin (1: 500; Pharmingen) and antibody binding 
was identified by incubation with FITC-conjugated goat anti-mouse secondary 
antibody for 45 minutes. Following washing (3x PBS). coverslips were mounted with 
Vectorshield mountant (Vector Laboratories) on microscope slides and fluorescence 
viewed under UV illumination. Antibody controls were performed using identical 
antibody concentrations of non-specific mouse IgGs instead of primary antibody. 
4.2.3.2 Adhesion assay 
Fibronectin coating of well bases of 96-well culture plates was performed as described 
above (chapter 4.3.3.1). MEG-01 cells were seeded at a density of lx 104 cells/well 
and cultured the absence or presence of 100nM PMA and 50µM MK-801 and cultured 
for a period of 72 hours. Culture media and non-adherent cells were removed by 
gentle washing with PBS and remaining adherent cells were fixed in 4% 
paraformaldehyde for 5 minutes at room temperature and washed three times in PBS. 
Adherent cells were stained with 0.5% crystal violet in 70% ethanol for 30 minutes at 
room temperature and all non-bound dye was removed by washing thoroughly with 
PBS. Cells were lysed by adding 20Oµ10.01 % Triton-X in MM sodium hydroxide 
and incubated for 30 minutes at room temperature until all bound dye was eluted. 
,, \bsorbance was measured using a 
Dynex MRX5000 plate reader (Dynatech, 
Billinghurst, UK) at a wavelength of 570nm. Relative absorbance was compared 
between control and treated cells and background absorbance from an average of 
"blank" wells, subjected to identical treatment in the absence of cells, removed from 
each sample. 
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4.2.4 Immunoisolation of NR1-positive MEG-01 cells 
MEG-01 cells were cultured as previously stated (chapter 2.1.2) in the absence and 
presence of 100nM PMA. Following 72 hours of culture, adherent cells were removed 
by the addition of 5mM EDTA and all cells were washed three times with PBS. Cell 
concentration was altered to lx 107 cells /ml and resuspended in 2 ml magnetic 
activated cell sorting (MACS) buffer (PBS (pH 7.2), supplemented with 0.5% BSA 
and 2mM EDTA). Cells were then incubated with anti-NMDARI monoclonal 
antibody (Pharmingen; 1µg/ml) for 30 minutes at 4°C. Cells were washed three times 
(by adding l Ox volume MACS buffer to cell suspension, centrifuged for 5 minutes at 
400g and supernatant removed) and subsequently incubated for 15 minutes at 4°C in 
horse anti-mouse biotinylated secondary antibody (Vector Laboratories; 1: 200) diluted 
in MACS buffer. Following three washes, cells were resuspended in 80µ1 of MACS 
buffer and 20µl of MACS anti-biotin microbeads (Miltenyi Biotec), mixed well and 
incubated at 4°C for 15 minutes. Cells were washed three times and resuspended in 
500µl of MACS buffer prior to magnetic separation by applying the cell suspensions 
over a MACS MS+ column (Miltenyi Biotec). Negative cells were allowed to pass 
through and collected along with the effluent from three subsequent column washes 
(NR1-negative). The column was then removed from the magnetic source and 
positive fraction flushed out by application of 1 ml MACS buffer (NR 1-positive). 
4.2.5 MTT assay 
To determine cell viability, the methylthiotetrazole (MTT) assay was used. Four 
parallel populations; -PMA NR1-negative, -PMA NR1-positive, +PMA NR1-negative 
and +PMA NR1-positive isolated by MACS were plated into 96-well culture plates at 
a concentration of lx 10` cells/ml and cultured in RPMI 1640 without phenol red with 
10% FBS, 100U/ml penicillin. 100µg/ml streptomycin and 2mM L-glutamine for 72 
hours. MTT (Sigma) was then added to each well at a final concentration of 1 niLl/ ml 
and the cells incubated at 37°C for a further 3 hours. Cells were 1v-sed using 0.05M 
HCl containing l 00'o SDS and the absorbance measured at 570nm on a plate reader 
(Dv-natech NIRX5000). 
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4.2.6 Primary megakaryocyte morphological characterisations 
4.2.6.1 Total cell and proplatelet counts 
Human CD34+-derived megakaryocyte cell numbers were determined after 14 days of 
culture, by counting the number of visible cells (magnification x200) in eight 
randomly selected fields of view / well using a Leica DMIL inverted light microscope 
(Milton Keynes, UK). All available wells were counted, for MK-801 treated and 
untreated cells. One proplatelet forming cell was identified by one cell body, forming 
at least 2 cytoplasmic proplatelet extensions in each randomly selected field of view 
taken for cell number counting. Relative proplatelet formation was quantified by 
percentage of proplatelet forming cells compared to total cell number. Experiments 
were carried out blind to treatment and control cell groups. 
4.2.6.2 Cell size quantification 
CD34+-derived megakaryocytes were cytospun onto microscope slides following the 
method described in chapter 2.4.1. Cells were fixed in 4% paraformaldehyde for 5 
minutes at room temperature and stained with Mayer's haematoxylin solution (Sigma) 
for 5 minutes before washing gently in tap water and counter-stained with 1% eosin 
(Sigma) for 10 minutes. Eosin was then removed by washing slides in tap water and 
mounted in PBS containing 10% glycerol. The cell area was digitally quantified using 
Leica Quantimet image analysis system (Leica Q500win standard version 2.2 Leica 
Imaging Systems) and the area of the cells in six random fields determined using a 
Leica DMLA light microscope. 
4.2.6.3 Transmission electron niicroscoply 
Day 14 megakaryocytes were washed twice in PBS before fixation in 4% 
paraformaldehyde/ 2.5% glutaraldehyde in 100mM phosphate buffer (pH7.0) for 90 
minutes at room temperature. Cells were then washed three times for 10 minutes in 
PBS and subjected to secondary fixation in 1% osmium tetroxide (Os04) for 1 hour on 
ice and washed twice for 10 minutes in PBS. The cells were dehydrated through 
graded ethanols. dried over a molecular sieve and washed twice in epoxvpropane for 5 
minute,, each. Embedding was performed by adding 60% epoxypropane 1400 o epon 
araldite for ý0 minutes and left to desiccate with silica gel overnight. Fresh cpon 
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araldite was added the next day. and was allowed to polymerise for 48 hours at 60°C. 
Sections were cut and stained with saturated uranyl acetate in 50% ethanol with 
Reynolds lead citrate and viewed using a transmission electron microscope (JLJEM 
1200 EX; Tokyo, Japan). 
4.2.7 Antigen expression determination by flow cytometrs 
Following media removal, cells were washed 3 times in buffer A (see chapter 2.1.3) to 
prevent clumping. 100µl (1 x 105) of cell suspension was used per sample. and non- 
specific binding blocked by incubating with normal relevant IgGs (Pharmingen) at a 
concentration of 1p g/ml for 10 minutes and washed. All washes were performed by 
adding 1 ml of buffer A to the cell suspension, followed by centrifugation at 400g for 5 
minutes at 4°C and removal of supernatant from the cell pellet. Primary-FITC 
conjugated antibodies, raised against CD61, CD41 (both Pharmingen) and CD42a 
(Sigma) were added to the cells (10µl per 106 cells) and incubated at 4°C for 30 
minutes in the dark. Negative controls were treated with non-specific-FITC 
conjugated antibodies. Cells were washed and remained at 4°C in the dark until 
analysis on a Coulter XL flow cytometer emitting an excitation light at 488nm from an 
argon laser. FITC signal was detected by FL 1 with an emission maximum of 520nm. 
Dead cells and doublets were excluded by light scatter properties and positive staining 
for propidium iodide (PI) after a 30 second incubation. The percentage of live cells 
expressing the different antigenic markers was determined by setting a positive gate at 
1% on negative control samples. 
4.2.8 Apoptosis detection by flow cytometry 
Apoptotic cells were identified using an Annexin V-FITC apoptosis detection kit 
(Oncogene, MA). The kit works on the principle that phosphatidyl serine (PS) is 
exposed on the surface of cells undergoing apoptosis. In the presence of calcium. PS 
binds rapidly to the anti-Annexin V-FITC conjugated antibody, indicating the early 
stages of apoptosis. PI is used as an indicator of late apoptosis by its ability to enter 
cells only through porous membrane and stain DNA red, enabling the identification of 
various stages of apoptosis. The procedure was carried out according to the 
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manufacturer's protocol. Cell suspension concentration was adjusted to lx 106 
cells/ml, without removing media, therefore preventing the onset of apoptosis by 
serum starvation. 500µl of cell suspension was transferred to microcentrifuge tubes 
and l0µ1 of media binding reagent added, followed by the addition of 1.25µl of 
Annexin V-FITC antibody. Cells were incubated in the dark at room temperature for 
15 minutes. The cell suspension was then centrifuged at 400g for 5 minutes at room 
temperature and the media removed. The cells were then gently resuspended in cold 
Ix binding buffer and 10µl of PI added. Samples were kept on ice in the dark and 
analysed by flow cytometry immediately, using a Coulter XL flow cytometer with an 
argon laser exciting at 488nm. The FITC signal was detected at 520nm on FL 1 and 
the PI at 620nm on FL2, adjusting to ensure minimal overlap between the two 
measurements. Log of annexin V-FITC was plotted on the x-axis and log of the PI 
readings on the y-axis. 
4.2.9 Ploidy analysis by flow cytometry 
Megakaryocyte aneuploidy was analysed using a PI DNA staining solution (Quest 
Biomedical, Solihull, UK), according to the manufacturer's protocol. Cells were 
removed from media and washed 3 times in buffer A and the cell concentration 
adjusted to 1x106 cells in a volume of 200µl of buffer A. 500µl of PI solution 
containing 25U/ml of RNase H and detergent was added and the cells were incubated 
in the dark at room temperature for 10 minutes in a horizontal position. The cells were 
then passed through a 25-gauge needle to ensure only single cells were counted and 
were kept on ice and in the dark until flow cytometric analysis. Single cells only were 
analysed by their light scatter properties and PI positive readings were taken on the 
FL2log setting. 
4.2.10 Intracellular calcium measurements 
Intracellular calcium measurements were recorded according to established methods 
developed specifically to cell suspensions (Nelemans: Calcium Signalling Protocols, 
Methods in N lolecular Biology: Volume 114). MEG-O 1 cells were treated with 
IOOnN1 PM: \ for 72hrs and washed 3 times in PBS to remove media and PNL\ before 
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being transferred to NeurobasalTM media containing 1% N2 supplement and incubated 
overnight. Cells were washed 3 times in HBSS (without M(`-. containing lmN1 Ca`-) 
and cell concentration adjusted to 5x106/ml. Cells were then loaded with 1µNI indo-l- 
acetyloxymethyl ester (AM) (Molecular Probes, Oregon) for 30 minutes at 37°C. 
Excess dye was removed by washing 3 times in HB SS and resuspended at acell 
concentration of 5x105 cells/ml. Indo-l-AM fluorescence was analysed using an LS55 
luminescence spectrometer (Perkin Elmer, Cambridge. UK). 2.5m1 of cell suspension 
was added to each cuvette with the ambient temperature kept at 37°C and continually 
agitated by magnetic stirring. Following the addition of 1-10µM NMDA with 100nM- 
1 p. M glycine calcium influx was monitored with an excitation wavelength of 3 3Onm 
and emission wavelengths at 405nm for calcium bound dye and 485nm for calcium 
free dye with 5nm slit width. Relative changes in fluorescence were expressed as a 
ratio of bound and free indo-l-AM. 500nM ionomycin (Calbiochem, Nottingham, 
UK) was added to achieve a maximum figure for bound dye and 5mM EDTA to 
chelate free calcium, thereby determining fluorescence for calcium free dye. [Ca]; can 
be calculated by measuring fluorescent intensity using the following equation; 
[Ca2+1 = Kd X [(R - Rmin) / (Rmax - R)1 X (Sf2/Sb2) 
Where R is the experimentally measured ratio of fluorescent intensities; Rmjn is the 
measured fluorescence ratio intensity in the absence of calcium; Rmax is the measured 
fluorescent ratio of Cat saturated dye; the term (Sf2/Sh2) is the signal ratio of 
fluorescence measured at emission wavelength 485nm in the absence of calcium (f`2) 
and at calcium saturation (b2); and Kd is the dissociation constant for indo-l-AM 
(=0.23). NMDA and AMPA receptor-mediated changes in [Ca, -]; by adding N\IDA 
and glycine or the AMPA receptor antagonist CFM-2 (Tocris) at varying 
concentrations at recorded time points. 
4.2.11 Glutamate release assay 
Glutamate release from NI[: G-O1 cells was determined using an cnizv one-linked 
fluorimetric assay. This assay has previously been employed in the study of neuronal 
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glutamate release (Nicholls et al., 1987; Bezzi et al., 1998) and has recently been 
modified for the study of glutamate release from osteoblastic cells (Genever and 
Skerry, 2001). The assay is based on the principle that addition of glutamate 
dehydrogenase (GDH) and 3-nicotinamide adenine dinucleotide phosphate (NADPt: 
both Sigma) will result in released glutamate being oxidised to a-ketoglutarate. 
resulting in the formation NADPH that can subsequently be determined 
fluorimetrically. MEG-O 1 cells were grown as previously stated (chapter 2.1.2) in the 
absence and presence of 100nM PMA for 72 hours. Following culture, cells were 
washed three times in PBS to remove any traces of exogenous glutamate and replated 
in blacked 96-well plates (µclear, Greiner Labortechnik Ltd., Stonehouse, UK) at 
various cell densities ranging from 1-5 x 104 cells/ml. Cells were incubated in release 
buffer (NaCI (120mM), KC1 (3mM), NaH2PO4 (1.25mM). HEPES-Na (25mM). 
glucose (4mM), MgCl2 (1mM), CaC12 (2mM) and NADP+ (1mM), pH7.4)) 
prewarmed to 37°C prior to use and the reaction initiated by the addition of GDH 
(40U/ml). Fluorescence was then measured using a Dynex MFX fluorescent plate 
reader (Dynatech) at 37°C, at an excitation wavelength of 355nm and emission 
wavelength of 460nm. Standard curves were created by the application of known 
concentrations of glutamate for each assay and protein concentrations determined by 
the BCA protein assay (Pierce). 
4.2.12 VGLUT2 immunolocalisation 
MEG-01 cells and cytospin preparations, rat tibiae cryosectioning and 
immunolocalisations were performed as previously stated (chapter 2.3.3). Rabbit anti- 
VGLUT2 primary antibody (Synaptic Systems, Gottingen, Germany) was used at a 
1: 500 dilution with anti-rabbit biotinylated secondary antibody (1: 200 dilution; Vector 
Laboratories). For co-immunolocalisation of VGLUT2 and NRI in rat 
megakaryocytes. VGLUT2 immunodetection was performed prior to incubating with 
mouse anti-NMDARI (1: 400; Pharmingen) overnight at 4°C and antibody binding 
detected following a 45 minute incubation using FITC-conj ugated goat anti-mouse 
secondary antibody (1: 100; sigma). 
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4.3 Results 
4.3.1 Glutamate binding by MEG-O1 cells 
The ability of NMDA receptors on MEG-01 cells to bind glutamate was determined 
by radioactive binding assay. The addition of increasing concentrations of 
non-radioactive glutamate resulted in the competitive inhibition of specific 
[3H]-glutamate (Fig. 4.3.1 A). Glutamate competed for binding with [3H]-glutamate 
with an IC50 of approximately 5x10-3M, a higher concentration than that observed in 
both osteoblastic cells (Laketic-Ljubojevic et al., 1999) and neuronal cells (Davies et 
al., 1981). Pre-incubation of MEG-01 cells with 50µM MK-801 prior to application 
of non-radioactive and [3H]-glutamate, significantly reduced the levels of specific 
glutamate binding (Fig. 4.3.1 B). 
4.3.2 Functional importance of NMDA receptor activity in megakaryocyte 
differentiation 
4.3.2.1 Function of NMDA receptors in MEG-01 cells 
Some of the morphological characteristics of MEG-O1 cells treated with the NMDA 
receptor antagonist MK-801 were previously characterised (Genever et al., 1999). 
Fibronectin, a substratum glycoprotein, has been shown to greatly increase MEG-01 
adhesion and elongation by the stimulation of cytoskeletal actin reorganisation 
(Yamazaki et al., 1999). PMA-mediated adhesion of MEG-01 cells to fibronectin was 
reduced to basal levels following MK-801 (50µM) treatment. MEG-O1 cells grown in 
the absence of PMA and fibronectin, displayed only low levels of adhesion (Fig. 
4.3.2). Megakaryocyte adhesion to fibronectin is mediated through the integrin u5ß1 
(Schick et al., 1998). Using an antibody directed against the activated conformation of 
ßI integrin, immunoreactnvity was most prominent at the s«Vol len terminals of 
pseudopodia in ME(I-01 cells adhered to fibronectin in the presence of P IA only 
(Fig. 4.3.3). Hox\, c\-er. MK-801 treatment prevented the formation of pseudopodia by 
Nl l-: G-01 cells and reduced the activity of ß-1 integrin expression b%- these cells (1= ig. 
-ý. 1.! /" 
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Figure 4.3.1. Glutamate binding by MEG-O1 cells. The binding of 
glutamate by MFG-O1 cells Evas competed against increasing concentrations of 
non-radioactive glutamate. The levels of bound glutamate are similar to those 
t0und in neuronal cell cultures (A). Glutamate binding kinetics was altered 
following the application of the NMDA receptor antagonist MK-801 (50µM; B). 
Results are representative of two independent experiments. 
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Figure 4.3.2. Effect of MK-801 on MEG-O1 adhesion to fibronectin. Adhesion 
assays were used to determine the effect of NMDA receptor inhibition MEG-O1 
adhesion to fibronectin-coated substratum. Adhesion was increased by the addition 
of PMA and the presence of fibronectin, however MK-801 (50µM) dramatically 
reduced levels of MEG-O1 adhesion to fibronectin (*=p<0.05; one way ANOVA). 
Results represent two independent experiments. 
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Figure 4.3.3. Effect of NMDA receptor inhibition on localisation of active ß-1 
integrin in fibronectin adhered MEG-O1 cells. Immunolocalisation of activated 
ý-1 integrin by MEG-01 cells grown on fibronectin in the absence and presence of 
MK-801. PMA-treated MEG-O1 cells displayed extensive cytoplasmic elongations 
with active P-1 integrin expression highly expressed at the rounded ends of these 
structures (arrows. A). MK-801 treated cells lacked cytoplasmic extensions and ß-1 
integrin appeared to be significantly weaker (B). Results are representative of two 
independent experiments. 
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To determine the effect of NR1 expression on MEG-O1 viability, 'N1EG-01 cells grown 
in the absence and presence of l 00nM PMA were separated into NR 1-positive and 
NR 1-negative expressing populations by MACS. The MTT-assay was then performed 
following continued culture of the separated cell populations for 72-hours. The PNIA- 
treated population revealed basal levels of viability, as did the PMA-untreated NR 1- 
positive population. Only the NR1-negative population in the absence of PMA 
exhibited significant levels of viability, similar to those found in unseparated MEG-01 
cells (Fig. 4.3.4). As PMA is not thought to cause cell death in MEG-O1 cells, (P. G. 
Genever, personal communication of unpublished data) it is likely that the decrease in 
viable cells observed in this experiment is due to reduced levels of proliferation. 
4.3.2.2 Effect of NMDA receptor inhibition on morphological characteristics of 
primary human megakaryocytes 
The primary megakaryocyte undergoes a great number of morphological 
transformations during differentiation, some of which were investigated in this section. 
Increases in cell size, indicative of megakaryocyte differentiation, were studied by 
image analysis of human primary megakaryocytes cytospin preparations (Fig. 4.3.5). 
All cells were cultured in the presence of TPO (25ng/ml) and in the absence or 
presence of 50µM MK-801 for 14 days. MK-801 almost halved the average 
megakaryocyte cell surface area, from approximately 500µm2 to 300µm2. 
The formation of proplatelets by primary megakaryocytes is an indicator of normal 
terminal megakaryocyte differentiation. Indeed, by the latter stages of in vitro 
megakaryocyte differentiation (>10 days of culture), proplatelet structures can be 
clearly observed. The percentage of megakaryocytes producing these structures in the 
absence and presence of 50µM MK-801 was analysed blind and by two independent 
experimenters at day 11 and day 14. After 11 days, MK-801 had no significant effect 
on cell number (Fig. 4.3.6 A), but reduced the percentage of cells producing 
proplatelets from an average of 3.5% to less than 1% in MK-801-treated cells (Fig. 
4.3.6 B). Following 14 days of culture, MK-801-treatment significantly reduced cell 
number (Fig. 4.3.7 : A) and reduced the number of proplatelet forming cells from an 
average of 8.5% to ?% (Fig. 4.3.7 B and C). 
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Figure 4.3.4 Proliferation of MEG-O1 cells following MACS for NR1-positive 
cells in the absence and presence of PMA. MTT assay was used to investigate the 
effect of the NMDA receptor expression on MEG-01 cell proliferation. NR I -positive 
isolated MEG-01 cells failed to proliferate following 72 hours of culture, whilst both 
NR I -negative and unseparated (Unsep. ) cells exhibited significantly (* *= p<0.01, 
one wav ANOVA) greater levels of proliferation. PMA-treatment resulted in both 
NRl-negative and positive cells failing to proliferate. Results are representative of 
two independent experiments. 
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Figure. 4.3.5 Cell area of human primary megakaryocytes with and without 
MK-801 following 14 days of culture. Cytospin preparations of human 
megakaryocytes cultured in the absence and presence of MK-801, were digitally 
analysed for cell surface area (gm2). Cell surface area was almost halved compared 
to control following MK-801 treatment (A, p< 0.001; students t-test ). Example of 
haematoxylin/eosin stained cytospin preparations are displayed in (B). Results are 
representative of 2 independent experiments. 
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Figure 4.3.6. Effect of NMDA receptor inhibition on megakaryocyte number 
and proplatelet formation after 11 days of culture. MK-801 treatment had no 
significant effect on cell number (A), but significantly (p<0.005; students t-test) 
reduced the percentage of cells displaying proplatelet structures (B). Results 
represent two independent experiments. 
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Figure 4.3.7 Effect of NMDA receptor inhibition on megakar', ocyte number 
and proplatelet formation after 14 days of culture. MK-801 treatment 
signit scantly reduced megakaryocyte number (A. **= p<0.01; students t-test ). and 
proplatelet formation after 14 days of culture (B and C (arrowheads). *** = p<0.005. 
students t-test). Results represent two independent experiments. 
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The identification of certain ultrastructural characteristics displayed by 
megakaryocytes, makes it possible to determine the platelet producing capabilities of 
the cells. Therefore, primary human megakaryocytes. following 14 days of culture in 
the presence and absence of MK-801 (50µM), were analysed by TEM. Control 
megakaryocytes exhibited multi-lobed nuclei, a dilated demarcation membrane system 
forming platelet territories towards the cell periphery, dense platelet cytoplasmic 
a-granules and proplatelet structure formation on the outside edge of the cell (Fig. 
4.3.8). In contrast, MK-801-treated cells presented rounded, single-lobed nuclei, they 
lacked demarcation membranes and a-granules and proplatelet structures were absent 
(Fig. 4.3.9). These cells also displayed significant cytoplasmic abnormalities, in the 
form of large open cisternae. 
4.3.2.3 MK-801 induced inhibition of megakaryocyte differentiation marker 
expression 
The expression of megakaryocyte-specific cell surface markers reveals the extent of 
TPO-induced expression by primary megakaryocytes. By quantifying the levels of 
differentiation markers by flow cytometry it is possible to document the process of 
megakaryocyte differentiation. MK-801 treatment reduced the level of expression of 
the early megakaryocyte marker, CD61 from an average of 72% of cells in control 
samples to around 50% of cells (Fig. 4.3.10). Similar figures were also observed for 
the expression of the intermediate megakaryocyte differentiation marker CD41, which 
was reduced from an average of approximately 76% of control cells, to 54% of cells 
treated with MK-801 (Fig. 4.3.11). The most profound reduction in expression was to 
the marker for terminally differentiated megakaryocyte/platelet specific marker 
CD42a, from an average of 40% of control cells to 23% of cells following MK-801 
treatment (Fig. 4.3.12). Annexin V/ PI flow cytometric analysis confirmed that 
MK-801 had no significant effect on cell viability, with approximately 91% and 89% 
of cells remaining viable following 14 days of culture with TPO and TPO with MK- 
801 respectively (Fig. 4.3.13). In addition, MK-801 had no significant effect on 
necrosis and early/late apoptosis. 
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Figure 4.3.8. tlltrastructural morphology of human primary megakarvocytes. 
t Jitrastructural analysis by TEM of human primary megakaryocytes cultured with 
TPO for 14 days. Cells displayed normal physiological characteristics, including 
multi-lobed nucleus (N). dilated demarcated membrane (arrowheads), a-granules 
(arrows) and proplatelet formation at the periphery of the cell (* ). Magnification 
x4000. 
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Figure 4.3.9. Ultrastructural morphology of human primary megakarg ocytes 
treated with MK-801. Ultrastructural analysis by TEM of human primary 
nme`gakaryocytes cultured with TPO and 50µM MK-801 for 14 days. Cells lacked 
multi-lobed nuclei (N), dilated demarcation membrane, a-granules and proplatelet 
structures. Large open cisternae were also identified within the cell cytoplasm (*). 
Magnification x6500. 
109 
Chapter 4 
Original in colour 
lqt 
CO 
CO 
a) 
LLl 
CD 
1 
FL1 LOG 
Antigen % positivity control (SSD) 
CD61 78 (±7.6) 
% positivity MK-801(ýSD); 
50.9 (±3.6) 
4 
Figure 4.3.10. Expression of CD61 by human primary megakaryocytes following 
treatment with MK-801. Flow cytometry was used to determine expression of the 
cell surface marker CD61 by human primary megakaryocytes grown in the presence 
of TPO for 14days, with and without MK-801.78% (±7.6) of control cells (solid blue 
fill) were positive for CD61 expression, which was reduced to 50.9% (±3.6) in cells 
treated with 50µM MK-801(red outline). Positivity is gated at higher than I% of 
antibody control (black outline; Region R1) and data shown is typical of 3 
independent experiments. 
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Figure 4.3.11. Expression of CD41 by human primary megakaryocytes 
following treatment with MK-801. Flow cytometry was used to determine 
expression of the cell surface marker CD41 by human primary megakaryocytes 
grown in the presence of TPO for 14days, with and without MK-801.76.2% (±7.3) 
of control cells (solid blue fill) were positive for CD4lexpression, which was 
reduced to 54.8% (±5.2) in cells treated with 504M MK-801(red outline). Positivity 
is gated at higher than 1% of antibody control (black outline, Region R l) and data 
shown is typical of 3 independent experiments. 
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Figure 4.3.12 Expression of CD42a by human primary megakaryocytes 
following treatment with MK-801. Flow cytometry was used to determine 
expression of the cell surface marker CD42a by human primary megakaryocytes 
grown in the presence of TPO for l4days, with and without MK-801.40.7% (±9.5) 
of control cells (solid blue fill) were positive for CD42a expression, which was 
reduced to 23% (±3.8) in cells treated with 50µM MK-801(red outline). Positivity is 
gated at higher than I% of antibody control (black outline; Region R 1) and data 
shown is typical of 3 independent experiments. 
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Figure 4.3.13. Effect of MK-801 on apoptosis of human primary 
megakaryocytes. Megakaryocytes were labeled with annexin V and PI and analysed 
by flow cytometry to determine the effect of 50µM MK-801 on apoptosis. No 
significant differences were observed between control and treated cells, with 
approximately 90% cells remaining viable (annexin V-negative / PI-negative) 
following 14 days of culture. Results are representative of three independent 
experiments. 
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4.3.2.4 Effect of NMDA receptor inhibition on megakaryocyte polyploid'- 
In addition to cytoplasmic maturation, proplatelet formation and 
megakaryocyte-specific antigen expression. nuclear maturation is also a characteristic 
of normal megakaryocyte maturation and is essential for correct cell function. Flow 
cytometry was used again in this section, to determine the effect of NMDA receptor 
inhibition on megakaryocyte endomitosis. Initial studies were performed on HEL 
cells treated for 72 hours in the absence and presence of I OOnM PMA and 50µM 
MK-801. Untreated cells remained predominantly in the low-ploidy state, with 
approximately 78% of cells at the 2N stage, whilst 16% of cells were at the 4N stage 
and only approximately 3% in the high ploidy (>4N) stages. PMA treatment greatly 
increased the number of cells at stages of high ploidy with approximately 25% of cells 
at the 4N stage and over 7% of cells at >4N, whilst the percentage of cells at 2N were 
notably reduced. Combined treatment with PMA and MK-801 dramatically reduced 
the levels of PMA-mediated endomitosis. Percentages of cells at 2N, 4N and >4N 
were similar to those exhibited by control (-PMA) cells, at 77%, 15% and 3% 
respectively (Fig. 4.3.14). 
The levels of polyploidy were also analysed in human primary megakaryocytes 
following 14 days of culture with TPO with and without 50µM MK-801 (Fig. 4.3.15). 
MK-801 treatment reduced the percentage of cells at 4N from 20% to 12% and >4N 
from approximately 8.5% to 4%. Levels of low ploidy cells (2N) remained higher in 
MK-801-treated cells compared to control. 
4.3.3 Activation of the NMDA receptor by NMDA and glycine 
The response of the megakaryocytic NMDA receptor to its pharmacological agonist 
NMDA and co-agonist glycine has not been previously investigated. To address 
\v Nether the NMDA receptor is readily activated by varying concentrations of NMDA 
and glycinc. MEG-Ol cells were loaded with the calcium indicator indo-l-AM and 
intracellular calcium concentration monitored using a fluorimeter. Calcium 
concentration was measured prior to and following, agonist addition, assuming that any 
increase in concentration would be as a result of N IDA receptor activation and 
calcium influx. The addition of 1µN1 N\ID. \/100n\l glycine and 10µM NMI): \ llt%l 
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Figure 4.3.14 Effect of MK-801 on megakaryocytic cell ploidy. Pliody levels of 
1-IEL cells cultured with or without PMA for 72 hours and in the absence or presence 
of 50µM MK-801 analysed by flow cytometry. PMA treatment considerably 
increased the percentage of cells displaying levels of high ploidy (4N and greater), 
whilst MK-801 treatment reduced ploidy to levels comparable to those displayed by 
untreated cells. Results are representative of two independent experiments. 
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Figure 4.3.15 Effect of MK-801 on human primary mega karv ocyte ploidy. 
1'liody levels cif human primary megakaryoc}ytes cultured with TPO for 14 days and 
in the absence or presence of MK-801 analysed by flow cytometry. MK-801 
treatment almost halved the percentage of cells displaying levels of ploidy 4N and 
greater, whilst a greater percentage of cells remained at ploidv levels (2N). Results 
are representative of two independent experiments. 
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glycine made no significant difference to basal intracellular calcium concentration. 
whilst 100µM NMDA/10µM glycine did cause a slight increase from basal 
intracellular concentration (Fig. 4.3.16). 
The lack of receptor-mediated response to NMDA by MEG-01 cells led to the 
investigation of other possible glutamate receptors expressed by the cells. 
Unpublished data has previously identified the existence of AMPA receptor subunits 
expressed by MEG-01 cells (P. G. Genever, personal communication). Therefore, 
changes in intracellular calcium concentration on addition of the specific AMPA 
receptor antagonist CFM-2 was also investigated. Addition of 25µM CFM-2 
dramatically reduced the concentration of intracellular calcium from approximately 
45nM to 20nM (Fig. 4.3.17). Addition of 50 µM CFM-2 resulted in further reductions 
in intracellular calcium, whilst the addition of 100µM CFM-2 caused no significant 
differences. However, addition of 200µM CFM-2 produced a small increase in 
intracellular calcium concentration. In an attempt to confirm whether changes in 
intracellular calcium observed by the addition of CFM-2 were due to influx of 
extracellular calcium, identical experiments were performed in the absence of 
extracellular calcium (Fig. 4.3.18). Addition of 25µM CFM-2 did cause a slight 
decrease in basal intracellular calcium concentration, whilst further additions of 
CFM-2 resulted in no significant changes in calcium concentrations. The reduction in 
intracellular calcium, from approximately 18nM to 15nM following addition of 25µM 
CFM-2 was however considerably less than the reduction observed in the presence of 
extracellular calcium. 
4.3.4 Megakaryocytic glutamate release 
The identification of the glutamate recycling protein GLT-1 expression b}' unidentified 
cells in the bone marrow certainly indicates that a release and recycle mechanism may 
be present (Genever et al., 1999). However, the source of glutamate used by the 
megakaryocytic NMDf\ receptor remains unclear. The lack of agonist-induced 
effects, but clear antagonist effects with regards to intracellular calcium concentration 
(see chapter 4.3.3). suggests that there may be endogenous `glutamate release. 
The 
possibility of glutamate being released by the megakarvocyte itself was investigated. 
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Figure 4.3.16. Changes in intracellular calcium concentration in HEL cells 
following addition of NMDA and glycine. Intracellular calcium concentration [Ca], 
was monitored in indo- l -AM-loaded HEL cells using a fluorimeter. Average [Ca], 
(±SD), was measured prior to and following the addition of increasing concentrations 
oINMDA and glycine at known time points. Lower concentrations of NMDA and 
glycine made no significant difference to [Ca],. whilst 100µM NMDA. 10µM glycine 
slightly increased the [Ca],. Results are representative of three independent 
experiments. 
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Figure 4.3.17. Changes in intracellular calcium concentration in HEL cells 
following addition of the AMPA receptor antagonist CFM-2. Intracellular 
calcium concentration [Ca]; was monitored in indo- l -AM-loaded HEL cells using a 
tluorimeter. Average [Ca]; (±SD), was measured prior to and following the addition 
of increasing concentrations of CFM-2 at known time points. Upon addition of 
25µM CFM-2, [Ca], was dramatically reduced. Further reductions were also 
observed following addition of 50 and I00µM CFM-2, whilst 200µM CFM-2 
appeared to increase [Ca],. Results are representative of two independent 
experiments. 
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Figure 4.3.18. Changes in intracellular calcium concentration in HEL cells 
following addition of the AMPA receptor antagonist CFM-2 in a calcium-free 
environment. Intracellular calcium concentration [Ca], was monitored in indo- l- 
AM-loaded HEL cells in a calcium-starved environment using a fluorimeter. 
Average [Ca], (±SD). was measured prior to and following the addition of increasing 
concentrations of CFM-2 at known time points. CFM-2 addition in the absence of 
extracellular calcium caused no significant increase in [Ca],. Results are 
representative of two independent experiments. 
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using a glutamate release assay (Fig. 4.3.19). It was demonstrated that MEG-01 cells 
release low concentrations (around 300pM/µg protein) compared to neuronal (Nicholls 
and Sihra, 1986) and osteoblastic cells (Genever and Skerry. 2001). Glutamate release 
from PMA treated cells (B) was not significantly different to those cells cultured in the 
absence of PMA (A). 
Expression of the vesicular glutamate transporter VGLUT2 was confirmed in cytospin 
preparations of MEG-O1 cells (Fig. 4.3.20). MEG-O1 cells express VGLUT2 both in 
the absence and presence of PMA with expression located throughout the cytoplasm. 
VGLUT2 expression was also identified in rat bone marrow megakaryocytes (Fig. 
4.3.2 1). VGLUT2 immunoreactivity was observed with a cytoplasmic and prominent 
pericellular localisation in all NR1-expressing megakaryocytes. VGLUT2 also 
appeared to be expressed exclusively by megakaryocytes in the bone marrow. 
Antibody negative preparations demonstrated specificity and low background levels. 
VGLUTI expression was not identified in MEG-01 cells or bone marrow 
megakaryocytes (data not shown). 
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Figure 4.3.19. Glutamate release by MEG-O1 cells. Glutamate release assay 
identified that MEG-O1 cells release glutamate proportional to the number of cells in 
the assay. Control (A) and PMA-treated (B) cells displayed no significant 
differences in glutamate release. Results are representative of two independent 
experiments. 
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Figure 4.3.20 VGLUT2 expression by MEG-O1 cells. Immunocytochemical 
identification of VGLUT2 expression by MEG-O1 cytospin presparation in the 
absence and presence of PMA. MEG-01 cells with and without PMA exhibit 
cytoplasmic expression of VGLUT2 (brown staining). Antibody control (Ab 
control) displays background levels of staining. Results are representative of two 
independent experiments. 
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Figure 4.3.21. VGLUT2 expression by rat tibial megakaryocytes. 
Immunohistochemical examinations of rat tibial sections identified pericellular 
expression of VGLUT2 by bone marrow megakaryocytes (brown staining; A). 
Megakaryocytes were identified as being NR 1 positive (green FITC staining; Q. 
Peroxidase and FITC antibody controls (B and D respectively) displayed low levels 
of background staining. The experiment was performed once. 
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4.4 Discussion 
Previously. evidence concerning the function of the megakaryocytic NMDA receptor 
was scant. The original investigations regarding glutamate signalling in 
megakaryocytes identified that by inhibiting the NMDA receptor with MK-801. 
MEG-01 cell differentiation and adhesion was significantly inhibited (Genever et al., 
1999a). How this novel signalling system integrates with other, more recognised 
megakaryocytopoiesis-regulating cytokines, requires a greater understanding of the 
effects that NMDA receptor inhibition has on megakaryocytes. The aim of this 
chapter is to provide greater insight into NMDA receptor function in megakaryocytic 
cell lines, as well as human primary megakaryocytes. 
Evidence that glutamate binds to the megakaryocytic receptor with similar kinetics as 
identified in other cells, along with previous [3H]-MK-801 binding experiments 
(Genever et al., 1999a), support the evidence that the receptor is functionally 
comparable to that present in neuronal cells. The lower affinity of glutamate binding 
by MEG-01 cells compared to both neuronal and bone cells (Davies et al., 1981; 
Laketic-Ljubojevic et al., 1999) may demonstrate one of the differences of this 
receptor compared to that present in other cell types. It is also of interest to note that 
MK-801, which does not directly block the binding of glutamate to its binding site, 
greatly alters the glutamate binding kinetics. The significant role of the NMDA 
receptor in LTP is widely acknowledged (for review see Dingledine et al.. 1998). One 
such characteristic of LTP is clustering of the membrane NMDA receptors, mediated 
by PKC phosphorylation of a serine residue in the cytoplasmic domain of either the 
NR1 or NR2A subunit (Tingley et al.. 1997; Zheng et al.. 1999). Clustering of the 
receptor in the megakaryocyte membrane would therefore increase glutamate binding, 
an effect that is inhibited by NMDA receptor antagonism. Currently, it is only 
possible to hypothesise that this is the case and requires more focused investigation of 
receptor subunit phosphorv Tation and localisation 
Fibronectin (FN) is a key element of the extracellular matrix in bone marrow. The 
role of FN has also been shown to be of major importance in 1ISC differentiation 
(Weiss and Reddy. 1981. Vertaillie et al., 1991). providing anchorage by which HI-"Cs 
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can migrate to specific regions of the bone marrow that promote maturation (Hamilton 
and Campbell, 1991). Megakaryocytes can produce, and in the presence of thrombin. 
secrete FN (Schick et al., 1996), the role of which is believed to be in the formation of 
pseudopodia resembling proplatelet structures (Schick et al.. 1998: Yamazaki et al.. 
1999). The principle integrin involved in the adhesion of megakaryocytes to 
fibronectin is a5ß1, which binds megakaryocytes to fibronectin both "resting" and 
``active" (+ thrombin) state (Schick et al., 1998). The data provided here demonstrated 
that the activation of ß1 integrin was decreased following NMDA receptor blockade 
offering one explanation as to why MEG-01 adhesion to FN was significantly reduced 
by MK-801. MEG-01 adhesion to fibronectin is induced through PMA-mediated PKC 
activation. This suggests that integrin activation could occur either as a direct or 
indirect result of active PKC, possibly via the receptor for activated C-kinase I 
(RACK1), which interacts with the ßl integrin subunit (Liliental and Chang. 1998). 
These findings however, suggest a role for NMDA receptors in the normal process of 
integrin activation. Similar investigations regarding J31 integrin activation in human 
polymorphonuclear leukocytes, identified that increased intracellular calcium 
concentration in synergy with direct PKC activation was required for ßI integrin 
activation (Rowin et al., 1998). Therefore, it is conceivable that increases in 
intracellular calcium concentration induced by the activation of the functional NMDA 
receptor, provides the source of calcium that, in conjunction with activated PKC, 
activates integrin-mediated FN binding. Inhibition of the NMDA receptor-mediated 
calcium influx would thus prevent integrin activation. How PKC and calcium interact 
in the modulation of integrin activation however, remains unknown. These findings 
have major implications not only on cytoskeletal reorganisation, but also on the 
possible effects of integrin signalling (for review see Giancotti and Rouslahti. 1999). 
Adhesion of megakaryocvtes to FN has been shown to directly activate the 
intracellular signalling molecule ERK1/2 (Mizutani et al.. 2002), in turn promoting the 
formation of proplatelet structures (Jiang et al.. 2002). 
In addition to being important in the adhesion of MMEG-01 cells, it is also possible that 
NNIDA receptor activity modulates their proliferative capacity. The role of the 
NNIDA receptor in megakaryocyte differentiation remains unclear. Work described in 
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this chapter demonstrated that NMDA receptor antagonism caused an inhibition of 
human primary megakaryocyte differentiation on several levels. The reduction in 
expression levels of CD61, CD41 and CD42a by primary megakarvocvtes in the 
presence of MK-801 implies that these cells were of a less differentiated phenotype. 
However morphological studies, confirm that megakaryocv tic NMDA receptor 
activity also has key roles in other aspects of normal megakaryocyte functions. It may 
be that the NMDA receptor activity is able to modulate the activity of intracellular 
signalling molecules that are known to promote differentiation. This hypothesis will 
be addressed in Chapter 5. However, if the receptor expressed by megakaryocvtes and 
neuronal cells is comparable it may be possible to draw analogies, which may have 
functional implications. One such example is in the dramatic antagonism of 
proplatelet production in vitro brought about by inhibition of the NMDA receptor. 
The formation of proplatelets is in many ways similar to the process of neuronal 
outgrowths. Axonal growth is of central importance both during the development of 
the adult nervous system and the regeneration of neuronal systems following injury. 
The process of neurite elongation followed by extensive branching (similar to the 
structures observed by ultrastructural analysis of proplatelet formation (Italiano et al., 
1999)) relies upon reorganisation cytoskeletal proteins including microtubules and 
actin. Indeed, depolymerisation of actin and tubulin reduces the ability of 
hippocampal neurones to develop the characteristic extensive branching (Allison et al., 
2000). The NMDA receptor has recently been demonstrated to modulate neuron 
outgrowth. MK-801 application to cultured chick neurones inhibits neurite initiation 
outgrowth and branching in a dose dependent manner, resulting in a reduction of the 
"neurite tree" complexity (Cuppini et al., 1999). It is possible that the NMDA 
receptor achieves this by controlling the action of the axonal growth-associated protein 
GAP-43, with MK-801 significantly reducing the levels of GAP-43 mRNA in 
hippocampal granule cells (Cantallops and Routtenberg. 1999). Other evidence also 
suggests that the NR1 and NR2B NMDA receptor subunits directly bind to ß-tubulin 
and modulate microtubule formation (van Rossum et al., 1999). 
It is also of interest to note that the recently characterised NR, subunit has a role in the 
formation of normal dendritic spines and branches (Das et al., 1998). As NR3A has 
been sho\\n to decrease the conductance of the NNIDA receptor both in vivo and in 
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vitro, the expected increase in dendritic spine branching was exhibited in NR3A 
knockout mice. It is therefore a distinct possibility the megakaryocytic NMDA 
receptor is also of great importance in the formation of microtubules from ß1 tubulin 
and actin polymerisation, both of which are key to the formation of normal proplatelet 
structures. The inhibition of proplatelet formation has not only been confirmed by 
examination of cells in vitro, but also by ultrastructural analyses which indicate the 
profound differences in cytoplasmic maturation between control and MK-801 treated 
cells. As shown in chapter 3, the expression of the NR3 subunit is restricted to 
immature cells, therefore providing a possible control mechanism to ensure that 
proplatelet formation occurs only in mature cells. 
These findings are of particular significance when considering that no haematopoietic 
cytokine has currently been identified that directly promotes the formation of 
proplatelets in vitro. Although these data provide the first evidence of a cell surface 
receptor with the ability to regulate proplatelet formation, the connections with the 
other factors involved in proplatelet production, such as the transcription factor NF-E2 
and cytoskeletal proteins, need to be investigated. However, if these links are 
confirmed, the implications to the understanding of how platelets are formed will be 
significant. 
Ultrastructural analyses also confirmed that other characteristics associated with the 
production of normal platelets are affected by NMDA receptor inhibition. The 
apparent lack of a-granules in the cytoplasm is of particular interest, as this is a 
characteristic displayed by peripheral blood CD34+-derived megakaryocytes from 
patients suffering the rare congenital bleeding disorder, gray platelet syndrome (GPS, 
Drouin et al., 2001). It would appear that this condition results from molecules vital 
for platelet function, especially vWF, being released elsewhere in the cell rather than 
the platelet a-granule, explaining the presence of vWF in GPS megakarv ocytes but 
absence in GPS platelets. As a-granules are only identifiable by TEM due to their 
dense packaging, empty granules cannot be identified. \'1hhether the pathology of GPS 
is caused by a lack of or mutation in the megakaryocytic NM DA receptor and how 
NMD. -\ receptor-mediated signalling may promote a-granule formation warrants 
further investigation. 
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Possibly the most striking cytoplasmic abnormality observed in MK-801 treated 
megakaryocytes is the formation of large open cisternae displayed by many of the 
cells examined in this study. Since this work was performed, similar characteristics 
were identified in megakaryocytes treated with monoclonal CD9 antibody (Clay et al., 
2001). The function of CD9 is unknown, even though it is expressed on numerous 
different haematopoietic cells (Boucheix et al., 1985), although it is postulated that it 
may play a role in several different cellular events including proliferation, adhesion 
and maturation (Maeker et al., 1997; Langaudriere-Gesbert et al.. 1997). In addition to 
the cytoplasmic abnormalities, suggestive of dysfunctional membrane remodelling, 
treating megakaryocytes with the monoclonal CD9 antibody increased the levels of 
proliferation whilst reducing expression of CD41. The apparent morphological and 
immunological similarities in MK-801 and CD9 antibody-treated megakaryocytes may 
be coincidental, indirectly linked though other signalling pathways or directly 
associated in normal megakaryocyte differentiation. However, both lines of work are 
still in their relative infancy and associations between the two systems warrant further 
investigation. 
In addition to providing essential evidence regarding cytoplasmic maturation, 
ultrastructural analyses also identified that MK-801 treatment reduced the levels of 
nuclear maturation. This subsequently led to the quantitative analysis of 
polyploidisation, which confirmed that the NMDA receptor has the ability to modulate 
megakaryocytic endomitosis. The mechanism by which this is attained is likely to be 
via an extensive signalling mechanism downstream of the NMDA receptor, such as 
the ERK 1 /2 pathway (Miyazaki et al., 2001), which is able to affect various aspects of 
the cell cycle that underpin endomitosis. The effect of NMDA receptor inhibition on 
intracellular signalling will be addressed in chapter 5. 
The lack of agonist response in MEG-O 1 cells was intriguing. The addition of NMDA 
with the co-agonist glycine to cells expressing the functional NNIDA receptor could be 
expected to induce recordable increases in intracellular calcium concentration. This 
response underpins many of the functions of the NNIDA receptor in the C'\S. 
However. it should be appreciated that the function of the receptor in the 
megakaryocyte is highly unlikely to be identical to that in the CNS. It is possible that 
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the activation of the megakaryocytic NMDA receptor actually causes very small 
increases in intracellular calcium, which cannot be measured using, the methods 
described in this chapter. It may be the case that the calcium influx is only required 
for the activation of the NMDA receptor in the locality, and it is the activated NNIDA 
receptor that directly influences downstream signalling events rather than large 
increases in intracellular calcium. The presence of the AMP. a and kainate receptors 
has not been studied since their expression was identified by RT-PCR in N IEG-0 l 
cells (P. G. Genever, personal communication). It would appear that MEG-01 cells 
express the AMPA receptor subunit GluR1, as well as the kainate receptor subunit 
KA2 (for review see chapter 1.6.2.1). The existence of AMPA/N NID: A receptor cross- 
talk is now well established and AMPA receptor activation has been shown to 
modulate NMDA receptor activity (Bai et al., 2002). As one of the key roles of the 
AMPA receptor is in depolarisation-induced Mg 2+ removal from the NMDA receptor. 
application of the specific AMPA antagonist CFM-2 may indirectly prevent the 
activation of the NMDA receptor. Therefore, the reduction of intracellular calcium 
concentration observed in the presence of CFM-2 might either be through inhibition of 
an uncharacterised functional megakaryocytic AMPA receptor. or by the prevention of 
Mg 2+ removal from the NMDA receptor. This is in great need of further investigation. 
One requirement is to perform more accurate techniques of measuring receptor 
activation and changes in calcium influx, for example, patch clamping, which has 
previously been used for the characterisation of the osteoblastic glutamate receptor 
(Laketic-Ljubojevic et al., 1999). However, the lack of agonist response has since led 
to the investigation of megakaryocytic glutamate release, which may provide an 
explanation as to why NMDA and glycine application has very little apparent effect on 
receptor activation. 
The release of glutamate from MEG-O1 cells in addition to the identification a protein 
involved in packaging of glutamatergic vesicles in MEG-01 cells and bone marrow 
megakaryocytes, is an extremely exciting finding. It may therefore be the case that 
MEG-01 cells are under constant stimulus of glutamate and starving the cells of 
glutamate to induce a large response to NMDA and glycine application may therefore 
not be viable. It may indeed be the case that the cells will have to be treated with the 
glutamate release inhibitor (such as riluzole) in conjunction with glutamate starving, to 
allow a detectable agonist response. The glutamate release findings also have 
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significant implications regarding the bone marrow microenvironment. It is possible 
to imagine a situation in which megakaryocytes release glutamate primarily for their 
own use (due to their relative sparseness in the bone marrow) and glutamate is 
recycled via the GLT-1 positive cells in the vicinity of the megakarvocvte. The fact 
that megakaryocytes express VGLUT2, which is expressed only by differentiated 
neuronal cells, and not VGLUTI, suggests that glutamate release may only occur in 
differentiated megakaryocytes. However, undifferentiated NIEG-0l cells do express 
VGLUT2 and release glutamate at similar levels to differentiated MFG-01 cells. It 
may therefore be the case that megakaryocytes release glutamate throughout 
differentiation, possibly mediating other cells in the bone marrow. but the high level of 
expression of NR3 by the undifferentiated cells prevents the activation of the 
megakaryocytic NMDA receptor. Currently, this situation is only speculative. 
However, further investigation, along the same lines as that performed on osteoblastic 
cells (Genever and Skerry, 2001 a), would provide a greater understanding of glutamate 
signalling in the bone marrow microenvironment with regards to the regulation of 
megakaryocytopoiesis. 
The data in this chapter provides a greater understanding of the functional effects of 
the megakaryocytic glutamate receptor. Inhibition of the NMDA receptor appears to 
have profound control over many aspects of megakaryocy'te differentiation and 
function and may provide a degree of control similar to the more established 
haematopoietic cytokines. However, to determine if this is indeed true, a greater 
understanding of downstream signalling events is required and will be addressed in the 
next chapter. 
1 Il 
Chapter 5 
ýI 
*%I 
P-4 
I 
(p 
t 
I 
il 
aw 
10 
401 
'Oft .I 
NMDA Receptor-Mediated 
Signal Transduction in 
Megakaryocytes 
Effects of PKC activation by PMA on MEG-01 cells. Untreated cells (left) 
are small and rounded compared to the large, multinucleated cells 
PMA-treated cells (Magnification x400) 
Chapter i 
Chapter 5 
NMDA Receptor-Mediated Signal Transduction 
in Megakaryocytic Cells 
5.1 Introduction 
Since TPO, the key cytokine regulating megakaryocytopoiesis became commercially 
available, intracellular signal transduction studies in megakarv-ocvtes have 
predominantly focused on the events following TPO application (Ievviewt-ed in chapter 
1.3.1). The subsequent findings have defined the action of TPO and provided 
compelling evidence as to its role in megakaryocyte survival, proliferation and 
differentiation. When characterising any membrane receptor signalling system, it is 
essential to define the downstream intracellular effects of receptor activation and/or 
inhibition. Doing so will identify how the signalling systems brings about cellular 
responses as well as potentially allowing pharmacological manipulation of these 
mechanisms. This chapter determines the effects of NMDA receptor activation and 
inhibition on intracellular signalling events in megakaryocv tic cell lines, by 
investigating both established megakaryocytopoiesis-promoting pathways and more 
"neuronal" NMDA receptor mediated signal transduction. 
The signal transduction studies in this chapter use the mcgakaryocvtic cell lines 
MEG-01 and HEL, which are described in depth in chapter 3.1. B using these cell 
lines, it is possible to investigate the effect of PMA-induced differentiation that occurs 
in both cell lines, as well as determining the effects of TPO signalling in the c-Mpl 
expressing HEL cells (Zauli et al.. 1997; Kalina et al. 2001). : gis \ 1I'G-O1 cells do not 
express c-Mpl (Rollinger-Holzinger et al.. 1998). the PKC-activ'atingagent P 1: \ is 
used to trigger differentiation, demonstrating the importance of PKC in 
megakaryocyte differentiation. The phorbol ester PNL\ competes for the same binding 
site on PKC as diacylglycerol (D: AG) and the reversible kinase activity of PKC relies 
on the binding of either DAG or phorbol esters (Sharkey and Blumbcrg. 1985). The 
region of the PKC regulatory domain responsible for the inhibition ot'catalytic activity 
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of PKC is known as the pseudosubstrate site (House and Kemp, 1987) and is inhibited 
by the binding of DAG or phorbol ester, therefore "activating" the catalytic activity of 
PKC. Some PKC isoforms, including PKCa that has been shown to have particular 
importance in megakaryocytopoiesis and platelet production (Rojnuckarin and 
Kaushansky, 2001), also have a calcium specificity domain that is believed to 
influence the translocation of PKC to various regions of the cell, such as the plasma 
membrane and the nucleus (Luo and Weinstein, 1993; Haller et al.. 1994). PKCa has 
also been shown to translocate to the plasma membrane following small increases in 
intracellular calcium concentration just under the plasma membrane. known as 
"calcium sparks", which have local intracellular effects (Haller et al.. 1989: Berridge 
and Dupont, 1994; Maasch et al., 2000). By translocating to the plasma membrane, 
active PKC is able to interact with Raf and stimulate the MAPK pathway. 
Compelling evidence now exists that both PMA and TPO-mediated megakaryocytic 
differentiation is via active PKC, which, initiated by stimulation of Raf, directly leads 
to the activation of the MAPK pathway that comprises ERK1/2, in addition to stress 
activated kinases p38 and Jun kinases (Rouyez et al., 1997: Fichelson et al., 1999, 
Avarham and Price, 1999). In megakaryocytes the effects of inhibiting the ERK1/2 
pathway with the specific inhibitor PD98059 are profound. Even in the presence of 
TPO, megakaryocyte differentiation from HSCs is significantly reduced and the 
number of immature cells greatly increased following PD98059, indicating that the 
ERKI/2 pathway is involved in differentiation rather than lineage determination 
(Fichelson et al., 1999). However, Hong and co-workers have indicated that inhibition 
of PKC with the bisindolylmaleimide GF109203X promoted erythrocvvte 
differentiation of HEL cells in the presence of PMA, indicating that another non- 
FRK 1 /2 PKC downstream signalling mechanism controls megakarvocy'te lineage 
determination (Hong et al., 1996). The application of GF 109203 X to primary 
megakaryocytes has also been shown to significantly reduce the levels of TPO- 
induced nuclear maturation (Rojnuckarin et al., 1999). However the interaction of the 
ERK 1 t'2 pathway and DNA synthesis in unknown. 
The ERK 1/2 pathway is also essentially involved in various aspects of neuronal cell 
function. The stimulation of neuronal NNID: \ receptors leads to the 
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calcium-dependent activation of ERK1/2 (Kurino et al., 1995: Xia et al., 1996). which 
is of great importance in LTP in hippocampal cells and LTD in cerchcllar cells (for 
review see Sweatt, 2001). It is thought that ERK1/2 is able to modulate transient LTP 
by the regulation of voltage-gated potassium channels (Adams et al.. 2000) and late 
LTP via the activation of transcription factors such as cA\IP response element (CRE) 
binding protein (CREB; Huang et al., 2000). CREB is the best-characterised CRE 
binding protein, which on activation by the phosphorylation of the scrine 133 residue, 
directly interacts with TFIIB, an essential constituent of the transcriptional machinery 
(Chrivia et al., 1993). CREB has also been implicated in the promotion of neuronal 
cell survival (Han and Holtzman, 2000), however, it appears that the PI3-K/AKT 
pathway may play a more important role in cell survival (Hetman ct al.. 2000). 
Interestingly, the CREB transcription factor has also been implicated in the lineage 
determination and possibly the differentiation of both megakaryocytic cell lines and 
human primary cells (Zauli et al., 1998). TPO application to FIEL cells results in the 
rapid dose-dependent phosphorylation of CREB in HEL cells, which is not mimicked 
by the erythrocyte lineage stimulants erythropoietin and heroin. This suggests that 
CREB activity promotes megakaryocytopoiesis over ervthrocvtopoiesis and may even 
be involved in megakaryocyte lineage determination. By the use of pharmacological 
inhibitors of PKA, PKC and MAPK, it has also been demonstrated that CREB 
activation in megakaryocytes appears to be MAPK dependent. In human primary 
cells, high levels of phosphorylated CREB were identified in the nucleus following 
TPO application, which corresponded with increases in CD61 expression. These data 
provides significant evidence that CREB may regulate TPO-mediated gene expression, 
which determines entry to the megakaryocyte lineage from ervthrocytc megakaryocyte 
bi-potential cells. 
Considering the profound effects mediated by ERKl/? and CREB pathways in both 
neuronal and megakaryocytic cells, it becomes of great importance to determine 
whether the NMDA receptor has the ability to modulate these path\t av-s in 
megakaryocytic cells. 
Changes in intracellular calcium concentration are common in the malorlty of cell 
types. In neuronal cells, [Ca2+]; is regulated by of various means, including: ligand- 
gated ion channels (such as the NMDA receptor). voltage gated ion channels. Ca 
2+ 
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pumps and exchangers as well as from intracellular stores via ry anodine and IP, - 
sensitve channels. [Ca2+]; increases stimulate the activation of a wide range of 
signalling events from localised areas, for example "calcium sparks" through to the 
modulation of gene transcription. An increase in intracellular calcium concentration is 
detected by calcium sensing proteins, of which the most common is calmodulin 
(CaM). The binding of Ca 2+ to CaM to form a Cat-/CaM complex. results in the 
functional adaptation of numerous proteins, possibly the most important of which is 
the serine/threonine kinase CaM kinase (CaMK; for review see Soderling. 2000). 
CaMK remains in a non-active state by interacting with an autoinhibitorv sequence via 
its catalytic domain. CaMK becomes active by Cat-/CaM binding adjacent to the 
autoinhibitory site, disrupting its interaction with the catalytic domain, which results in 
CaMK switching to its active conformation (Braun and Schulman, 1995). 
Autophosphorylation of active CaMK results in Ca 2+ independent prolonged 
activation. Therefore a transient increase in [Ca`+]; can lead to autonomous CaMK 
activity. 
CaMKII is by far the most widespread member of the CaN 1K protein family. CaMKII 
is comprised of one or more of its 10-12 subunits, of, \hicli there are four isoforms, a, 
ß, y, and b and it appears that subunit expression regulate CaMKII function in various 
tissue types (Brocke et al., 1999). Although the aCaN I KI I subunit isoform appears to 
be restricted to the CNS, the ß, y and b isoforms are expressed in a 'wide range of 
tissues (Tombes and Crystal, 1997). The isoform present in any given cell is subject 
to which of the four genes encoding the protein is transcribed and which of a 
substantial number of alternatively spliced forms of each primary transcript is 
translated (Means, 2000). Although CaMKII signalling is not restricted to the CNS. it 
is of interest to note that tissues expressing both a and ß CaMKII subunits also 
express glutamate signalling components. Interaction of CaMKII with the NMDA 
receptor in the CNS has been documented (Leonard et al.. 1999). It has been 
hypothesised that the ß CaMKII subunit binds to F-actin and on NNID: \ receptor 
activation, can translocate to the PSD (Shen and Nlever. 1999). Once in the PSD, 
CaMKII can act on signalling substrates located in the vicinity of the N\1D: \ receptor. 
One such substrate is the novel Ras-GTPase-activating protein SenG: \P. which is 
phosphorylated and potently inhibited by CaNIKIl. which leads to the potentiation of 
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the MAPK pathway (Chen et al., 1998). It is therefore probable that the Ca`1KII 
enzyme links the activated NMDA receptor to the MAPK pathway, via SynGAP and 
plays an essential role during LTP in neuronal cells. It is also believed that CaNIK. II 
can lead to the activation of CREB. although whether this activation is direct or via the 
ERKI/2 pathway remains elusive (Sheng et al.. 1991: Tabuchi et al.. 2001). 
However, Wu and McMurray have also suggested that CaMKII can inhibit the 
function of CREB in neuronal cells by phosphorylating the serine 142 residue. which 
attenuates the mechanism of CREB once bound to DNA (Wu and %Ic\1urray, 2001). 
Another tissue location where CaMKII activity appears to be of particular importance 
is in bone (G. J. Spencer, personal communication). Osteoblasts express the 
neurospecific CaMKII isoforms a and ß and on application of glutamate and glycine 
significantly increase CaMKII activity, demonstrating glutamate receptor-mediated 
activation of CaMKII in osteoblasts. CaMKII inhibition with KN-62 resulted in a 
significant reduction in osteoblast differentiation, whilst mechanical loading of clonal 
osteoblastic cells, which stimulates osteogenesis, produced a rapid increase in CaMKII 
activity. These findings imply a significant role of CaMKII in osteoblastic 
differentiation and owing to the expression a and ß CaMKII isoforms that are thought 
to interact with the NMDA receptor, can be triggered by NMDA receptor activation. 
The NMDA receptor-associated activity of CaMKII in bone leads to similar questions 
being posed about the signalling mechanisms of the megakaryocytic NMDA receptor. 
No evidence exists as to whether CaMKII is expressed by megakaryocy'tes, probably 
due to the signalling system still being regarded as "neurospecific". Therefore the 
aims of this chapter were to determine whether megakaryocytes expressed CaMKII, to 
identify the association between CaMKII and NMDA receptor activity and determine 
the functional importance CaMKII in megakaryocyte differentiation. The effects of 
NMDA receptor activation on adhesion and downstream signalling pathways (ERK I /-, 
and CREB) were also determined in megakaryocytic cells to identify how ligand 
binding may be transformed into a cellular response. 
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5.2 Materials and Methods 
5.2.1 Cell culture 
MEG-O1 and HEL cell lines were cultured as previously described (see chapter 2.1.2). 
PMA (100nM), TPO (25ng/ml), KN-93 (5µM, Tocris) and KN-92 (5µM. Tocris) 
treatments were performed for 72 hours unless otherwise stated. For experiments 
determining ionomycin-induced signal transduction, cells were preincubated with 20µl 
DMSO, KN-92 or KN-93 for 15 minutes prior to the application of 500nM ionomycin 
(Sigma) or DMSO. Following 5 minute incubations, media was removed and cells 
were washed twice with PBS prior to cell lysis. For experiments investigating the 
effects of NMDA and glycine treatment, MEG-01 cells were incubated with PMA for 
72 hours, washed three times to remove exogenous glutamate and cultured overnight 
in glutamate-free NeurobasalTM media containing 1% N2 supplement (Gibco). Cells 
were then treated with various concentrations of NMDA and glycine dissolved in PBS, 
for 15 minutes before media was removed and the cells was twice in PBS prior to 
lysis. 
5.2.2 Western blot analysis 
5.2.2.1 Protein extraction 
Megakaryoblastic cell lines were plated at an initial concentration of 1x 105 cells/ml 
and were exposed to treatments for a maximum of 72hrs. Cells were then removed 
from media and washed 3 times in PBS. Cells were lysed with cold kinase lysis buffer 
(New England Biolabs; l Ox = 25 mM Tris-HCl (pH 7.5). 5 mM beta- 
glycerophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4,10 mM MgC12) for 5 
minutes at 4°C. Lysates were centrifuged at 12,000g for 10 minutes to remove cell 
debris and protein concentration determined using a 96-well microplate version of a 
BCA protein assay kit (Pierce). 25µl of BSA standard at concentrations ranging from 
25µg/ml to 2,000 pg'ml and unknown samples were mixed wt ith 200µ1 of working 
reagent 50: 1, Reagent A: Reagent B). mixed thoroughly and incubated at 37-C 
for 30 minutes in a shaking incubator. The plate was allowed to cool to room 
temperature before absorbance was measured at 570nm using Dynex N1RX microplate 
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reader. Unknown protein concentrations were calculated from the standard curve 
given by the known BSA protein concentrations. All samples were plated in triplicate 
and blanks wells, containing only lysis buffer and working reagent. were subtracted 
from the sample averages. 
5.2.2.2 Polyacrylamide gel electrophoresis and protein translcr" 
10-20µg protein lysates were added to SDS loading buffer and denatured at 100°C for 
5 minutes. Protein samples and molecular mass standards were loaded on a 5% 
stacking gel and separated using a 10% SDS-polyacrylamide resolving gel in running 
buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH8) at 200V, 100mA until the dye- 
front ran to the bottom of the resolving gel. Gels were removed from the running 
plates, equilibrated in transfer buffer (25mM Tris, 193mM glycine. 20% methanol) for 
10 minutes and separated proteins electroblotted onto PVDF membrane (Amersham 
Pharmacia Biotech. ) at 100V, 250-350mA for ihr. Membranes were washed twice for 
5 minutes in TBS-T (20mM Tris, 137mM NaCl, 0.1% Tween20, pH 7.6) with gentle 
agitation before immunodetection. 
5.2.2.3 Immunodetection 
Membranes were incubated in blocking buffer (4% (w/v) skimmed milk powder or 5% 
(w/v) BSA in TBS-T, according to manufacturer's recommendation) for either 15 
minutes at room temperature with gentle agitation and 4°C overnight, or for 1 hr at 
room temperature with gentle agitation. Membranes were then rinsed twice and 
washed for 15 minutes before incubating with primary antibodies diluted in blocking 
buffer at the following concentrations; rabbit anti-ERK 1 /2, rabbit 
anti-phosphoERK l /2, mouse anti-CREB, mouse anti-phosphoCREB (all 1: 1000, New 
England Biolabs), CaMKII and phospho-CaMKII (both 1: 2000, Santa Cruz 
Biotechnologies) and GAPDH (1: 800, Immunodetection Laboratories), and incubated 
for I hr at room temperature or overnight at 4°C with gentle ag itatioii. The membranes 
were then rinsed twice quickly, once for 15 minutes and twice for 5 minutes in TBS-T 
to remove excess antibody. Peroxidase-conjugated secondary antibodies were diluted 
in blocking buffer (1: 2000. Santa Cruz Biotechnoloýgies) and incubated with the 
membrane for 1 hr at room temperature. t Inbound antibody was removed by 2 quick 
rinses, one 15-minute wash and tiOur 5 minutes washes and the membrane developed 
1 38 
Chapter 5 
by incubation in ECL chemiluminescent solution (Amersham Pharmacia Biotech) for 
1 minute. Membranes were exposed to Hyperfilm (Amersham Pharmacia Biotech) at 
room temperature, initially for 5 minutes before adjusting exposure time according to 
clarity of positive results. Hyperfilm was developed using a X-ograph automated 
developer. Membranes were kept at 4°C in TBS-T until stripped (see below) and re- 
probed. All washes were performed at room temperature with gentle agitation. 
5.2.2.4 Membrane stripping 
Bound antibodies were removed from the membrane by incubation with pre-warmed 
stripping buffer (62.5mM Tris, pH6.8,0.7% ß-mercaptoethanol. -'° o SDS) at 60°C for 
30 minutes with vigorous agitation. Membranes were then washed twice for 10 
minutes in TBS-T before immunodetection was performed on the stripped blots. 
5.2.3 DNA profiling of cell cycle by flow cytometry 
Cells were grown in the absence and presence of PMA. KN-9-2 and KN-93 for 72 
hours. Cells were then washed three times in PBS. fixed in 70% ethanol for 5 
minutes, washed twice in PBS and DNA stained as previously described (chapter 
4.2.9). To determine the cell cycle phase, cells were analysed b' flow cytometry and 
positive readings taken on the FL2 setting with the first peak being GO/G 1 phase, 
second peak G2/M phase and the trough in between the peaks being S phase. 
5.2.4 Bone marrow megakaryocyte NR1 expression by c-Mpl-'- knockout mice 
Frozen tibiae sections from c-Mpl- - and c-Mp10+'' mice were a kind gift from Dr. M. 
Perry, University of Bristol, UK. To avoid non-specific binding and high background 
caused by using the monoclonal mouse anti-NR1 antibody on mouse tissue, the mouse 
on mouse (MOMTM) staining kit was used (Vector Laboratories) according to the 
manufacturer's protocol. Prior to application of primary antibody. sections were 
incubated for 1 hour in M. O. N11-" mouse I`g blocking reagent ('_' drop 2.5ml PBS), 
washed three times in PBS and incubated for 5 minutes is M. O. M'-" diluent. Excess 
diluent was removed and subsequent antibody incubations: mouse anti-NR1 (3() 
minutes: 1: 400. Pharmingen) and biotinvlated anti-mouse secondary (220 minutes: 
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1: 200, Vector Laboratories), were performed in M. O. MT'" diluent. All other steps 
were performed as previously described (see chapter 2.2.2). 
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5.3 Results 
5.3.1 NMDA receptor-mediated modulation of ERK1/2 activation in 
megakaryocytic cells 
Changes in NMDA receptor-mediated ERK1/2 activation in the megakaryoblastic 
MEG-01 and HEL cells were determined by western blot analysis of cell protein 
lysates using a phospho-ERK1/2 monoclonal antibody. ERK1/2 activation, stimulated 
by PMA (l 00nM), was reduced dose dependently by increasing concentrations of the 
NMDA receptor antagonist MK-801 (Fig. 5.3.1). Decreased levels of ERK1/2 
phosphorylation were determined by comparing to levels of total ERK 1 /2. 
MEG-O1 cells were treated with increasing concentrations of' NMD: \ and glycine in 
order to clarify the effect of agonist-mediated NMDA receptor activation on F RK 1 /2 
phosphorylation. Addition of 10µM NMDA /1 ýtM glvcine resulted in a small 
increase in ERK1/2 activation compared to cells treated with PMA only. Howw, ever, 
cells treated with 100µM NMDA / 10µM glv'cine and 1mM NMDA / 100µM glvvcine 
resulted in significant decrease in levels of' ERK1/2 phosphorvlation. Levels of total 
ERK1/2 demonstrated equal loading (Fig. 5.3.2). 
5.3.2 NMDA receptor-mediated activation of CaMKII in megakaryocytic cells 
Western blot analysis of MEG-0l whole cell lv'sates identified expression of the 50kD 
a isoform as well as the slightly larger ß isoform of CaNIKII (Fig. 5.3.3). PMA 
treatment of MEG-0l cells did not appear to increase levels of CaMKII 
phosphorylation. However increasing concentrations of NIK-801 seemed to decrease 
the phosphorylation of both isoforms. Due to high background levels, it is not 
possible to accurately determine levels of activated CaN1KII. 
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Figure 5.3.1. Western blot analysis of NMDA receptor inhibition-mediated 
expression of phosphorylated ERK by MEG-01 cells. PMA-mediated 
phosphorylation of ERK (PERK, A) was significantly reduced by treating cells with 
increasing concentrations of MK-80 1. Treatment of MEG-01 cells with 100µM 
MK-801 reduced levels of pERK by over a half compared to PMA-only treated 
controls. Equal loading was demonstrated by total levels of unphosphorylated ERK 
(ERK, B). Results are representative of three independent experiments. 
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Figure 5.3.2 Western blot analysis of NMDA receptor activation-mediated 
expression of phosphorylated ERK by MEGO1 cells. PMA-mediated 
phosphorylation of ERK (pERK, A) was altered in glutamate starved MEG-Olcells 
by treating cells by increasing concentrations of NNIDA and glycine. 10µM NMDA 
with I µM glycine slightly increased expression of pERK, whilst treatment of 
MEG-01 cells with 100µM NMDA / 10µM glycine and 1 mM NMDA / 100µM 
glycine dramatically reduced pERK expression levels. Equal loading was 
demonstrated by total levels of unphosphorylated ERK (ERK, B). Results are 
representative of two independent experiments. 
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Figure 5.3.3. Western blot analysis of NMDA receptor-mediated activation of 
CaMKII in MEGO1 cells. Levels of CaMKII activation in MEG-01 cells with and 
without PMA and MK-801 were analysed by western blotting using an antibody 
specific to phosphorylated CaMKII isoforms (A). Both a and ß isoforms were 
identified whilst 10 and 100µM MK-801 appeared to reduce levels of CaMKII 
phosphorylation (pCaMKII) compared to total CaMKII (B). Results are 
representative of two independent experiments. 
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5.3.3 CaMKII signalling in megakaryocytes 
The identification of megakaryocytic CaMKII expression initiated subsequent 
investigation of CaMKII-mediated signalling and subsequent effects of Ca IKII 
inhibition on megakaryocyte differentiation. Treating MEG-01 cells with the calcium 
specific ionophore ionomycin, lead to the activation of ERK 1 i2 compared to DMSO 
control. Calcium-mediated ERKI/2 activation was however significantly reduced in 
cells treated with the CaMKII inhibitor KN-93 compared to DMSO control and the 
inactive KN-93 isoform, KN-92 (Fig. 5.3.4). 
To determine the effect of CaMKII inhibition on TPO-mediated activation of ERK 1 /2, 
HEL cells were used as they express the TPO receptor. c-Mpl. TPO greatly increased 
basal levels of ERKI/2 activation, which, unlike PMA-mediated activation in MEG-01 
cells, was not reduced by MK-801 treatment (Fig. 5.3.5). However, KN-93 did reduce 
ERKI/2 activation compared to cells treated with TPO and KN-92. Indeed. KN-93 
treatment lowered expression of phospho-ERK 1 /2 to approximately basal levels. 
CaMKII also plays a significant role in the cell cycle, possibly by the activation of 
cdc25-C at the G2/M phase of the cell cycle (Patel et al., 1999). To investigate a 
possible role of CaMKII in megakaryocytic G2/M phase transition. HEL cells were 
treated with PMA in conjunction with either KN-92 or KN-93 and the cellular DNA 
content analysed following 72 hours of culture. PMA treatment leads to a small 
increase in the percentage of cells in the G2/M phase, whilst decreasing the number of 
cells in GI and S phases (Fig. 5.3.6). KN-93 treatment in conjunction with PMA 
caused an increase in the percentage of cells found with a G2/M DNA content, from 
approximately 19% to 41%. Whilst performing DNA profiling experiments, it was 
also observed that KN-93 severely inhibited HEL cell adhesion. PMA-mediated 
increases in cellular adhesion were totally prevented by treatment with KN-93. whilst 
KN-92 had no clear effect (Fig. 5.3.7). 
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Figure 5.3.4 Western blot analysis of CaMKII-mediated ERK phosphorylation 
in MEG-O1 cells. lonomycin-mediated activation of ERK in the presence of the 
specific CaMKII antagonist KN-93 (5µM). KN-93 significantly lowered the levels 
of ERK phosphorylation compared to the inactive control KN-92 (A). Equal loading 
was demonstrated by total levels of unphosphorylated ERK (B). Results are 
representative of three independent experiments. 
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Figure 5.3.5 Western blot analysis of NMDA receptor and CaMKII-mediated 
ERK phosphorylation in HEL cells. TPO-mediated expression of phosphorylated 
ERK was dramatically inhibited by the specific CaMKII antagonist KN-93 (5µM) 
compared to KN-92 (54M) control (A). MK-801 (50µM) made no significant 
difference to ERK phosphorylation. Equal loading was demonstrated by total levels 
of unphosphorylated ERK (B). Results are representative of three independent 
experiments. 
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Figure 5.3.6 Effect of CaMKII inhibition on HEL cell cycle. Flow cytometry 
DNA profiling was used for the investigation of PMA-mediated changes in the 
percentage of HEL cells in different stages of the cell cycle following addition of 
KN-93. KN-93 dramatically increased the percentage of cells in the G2/M phase of 
the cell cycle, whilst decreasing the percentage of cells in the GO/GI phase. These 
affects were not observed in KN-92-treated cells. although KN-92 did appear to 
lower the number of cells in the G2/M phase whilst increasing the number in the S 
phase. Results are representative of three independent experiments. 
148 
0 
0 0: 3 
0 
0 1023 
0 1023 011II11111111 Iýý ýý -- - 0 1023 
Chapter 5 
HEL -PMA HEL +PMA 
Figure 5.3.7 Effect of CaMKH inhibition on HEL cell adhesion. PMA-induced 
increases in HEL cell adhesion was dramatically reduced following inhibition of 
CaMKII with KN-93 compared to cells treated with PMA only and KN-92. 
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5.3.4 NMDA receptor-mediated modulation of CREB activity in 
megakaryocytic cells 
TPO-mediated activation of CREB transcription factor has recently been identified as 
being important in the transcription of genes with various roles in megakaryocytic 
differentiation (Zauli et al., 1998). The NMDA receptor has also been identified as a 
potent activator of CREB in neuronal cells (Mao and Wang et at., 2002). leading to the 
investigation of NMDA receptor-mediated activation in MEG-O1 and HEL cells. Here 
it was demonstrated that TPO increased the expression levels of phosphorylated 
CREB in HEL cells (Fig. 5.3.8). The NMDA receptor antagonist MK-801 failed to 
affect CREB phosphorylation whilst the CaMKII inhibitor KN-93 caused a significant 
reduction in CREB activation. Interestingly, although MEG-01 cells express CREB, 
the activated phospho-CREB isoform was not identified and was not affected by 
PMA-stimulation (Fig. 5.3.9). 
5.3.5 Expression of NR1 by c-Mpl-/- bone marrow megakaryocytes 
Mice lacking the gene for the TPO receptor c-Mpl display aberrant 
megakaryocytopoiesis (Gurney et al., 1994; Alexander et al.. 1996). Mice lacking 
normal TPO-mediated megakaryocyte signalling also display greatly reduced levels of 
other proteins that are involved in the regulation of megakaryocyte differentiation and 
proliferation. With this in mind, immunohistochemical analysis of NMDA receptor 
expression by c-Mpl-'- bone marrow megakaryocytes was determined. 
Megakaryocyte number was greatly reduced in c-Mpl- - bone marrow, however all 
remaining megakaryocytes expressed NRl at a similar level as wild type (c-Mpl +ý{) 
controls. This indicates that the NMDA receptor is expressed in megakaryocvtes in 
the absence of TPO-mediated signalling (Fig. 5.3.10). 
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Figure 5.3.8 Western blot analysis of NMDA receptor and CaMKII-mediated 
CREB phosphorylation in HEL cells. TPO-mediated phosphorylation of CREB 
(pCREB) and associated transcription factor 1 (pATF 1) was reduced to basal levels 
by KN-93 (5µM) treatment, but remained unaltered by treatment with MK-801 
(50µM, A). Equal loading was demonstrated by total levels of unphosphorylated 
CREB and ATF (B). Results are representative of two independent experiments. 
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Figure 5.3.9 Western blot analysis of NMDA receptor and CaMKII-mediated 
CREB phosphorylation in MEG-O1 cells. PMA-mediated expression of 
phosphorylated CREB and ATF Iwas not identified in MEG-01 cells (A). Total 
CREB and ATF 1 were however identified, confirming megakaryocytic expression of 
the transcription factors (B). Results are representative of two independent 
experiments. 
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Figure 5.3.10 Immunohistochemical analysis of NR1 expression by c-Mpl' 
mouse bone marrow megakaryocytes. NR1 expression by bone marrow 
megakaryocytes was compared in c-Mpl Wildtype (c-Mpl "`) and knockout (c-Mpl ) 
mice. NR 1 was maintained in megakaryocytes from knockout mice, compared to 
wildtypes. Antibody controls (Ab -ve) low background levels. Results are 
representative of three independent experiments. 
153 
t: 
Chapter 5 
5.4 Discussion 
This chapter provides the first evidence of NMDA receptor-mediated signal 
transduction in megakaryocytes. The confirmation of signalling pathways that have 
previously been identified as being of key importance in mc``akaryocvte 
differentiation, are modulated by megakaryocytic NMDA receptors which is 
significant to our understanding of glutamate signalling in this cell type. 
The dose-dependent reduction in PMA-stimulated ERK 1 /2 phosphorylation (see 
section 3.1 for discussion on the possible drawbacks of using PMA) in MEG-01 cells 
by MK-801 would explain the inhibition of megakaryocyte differentiation as described 
by Genever and co-workers (1999) and observed in chapter 4. The fact that MK-801 
inhibits ERK1/2 activation in the presence of PKC activating agent PMA could 
indicate that the NMDA receptor is either downstream of PKC, possibly involved in 
the regulation of Raf. It is also possible that the activated NMDA receptor provides 
the "calcium sparks" required for the translocation of PKC isoforms with Ca 2+ 
specificity domains, such as PKCa, to the cell membrane. The latter hypothesis is 
further supported by the fact that ERK 1 /2 phosphorylation, although significantly 
decreased, was not abolished by MK-801 application. This implies that the NMDA 
receptor does not have absolute control of ERK 1 /2 activation and PKC retains the 
ability to activate Raf, possibly by binding with other sources of Ca 2+ enabling PKC to 
activate the MAPK pathway. It would be advantageous to confirm the interaction of 
the megakaryocytic NMDA receptor with PKC, by analysing changes in PKC 
regulation in the presence of MK-801 and/or NMDA and glycine (Goldfarb et al., 
2001), and also determining whether inhibition of NMDA receptor can alter the 
translocation of PKC from the cytoplasm to the plasma membrane (Hong et al.. 1998; 
Racke et al., 2001). 
The effect of NMDA and glvcine application on the levels of phospho-ERKI/2 was 
extremely intriguing. The small increase in phospho-FRK1%' in response to low 
concentrations of NMDA and glv cine are encouraging. implying that the activation of 
the NNIDA receptor does increase FRKI12 activation in the presence of P\1. -ß. The 
relatively low levels of NMD: \ and `glv'CIne-stimulated L' Rlt l i, phosphorylation may 
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be due to endogenous glutamate released from \IEG-01 cells as described in chapter 4 
and consequently, these cells were not starved of glutamate. which may mask agonist 
responses. The effect evoked by high concentrations of N\ IDA and glvcine may 
demonstrate bi-directional control of ERK1/2 activation by the megakaryocytic 
NMDA receptor, as observed in neuronal cells (Chandler et al.. 2001). In primary 
cortical neuronal cells the addition of 100µM NN IDA reduced the basal levels of 
active ERKI/2, with 50µM NMDA identified as the optimal concentration for NNIDA 
receptor-mediated ERK1/2 activation. This work perfectly demonstrates the 
complexity of NMDA receptor interactions with ERK 1 /2 in the CNS. It appears that 
the receptor is able to both activate and inhibit the MAPK pathway, depending on the 
concentration of extracellular glutamate, which may have implications in cell 
signalling pathways regulating cell survival follo\v-ih g pathological extracellular 
glutamate concentrations as a result of neuronal injury. The NMDA receptor pathway 
involved in inhibiting ERKI/2 remains unknown. It may therefore be possible that the 
megakaryocytic NMDA receptor has the ability to act in a similar fashion and is able 
to modulate rather than just activate the ERKI/2 pathway. It seems unlikely however, 
that concentrations high enough to inhibit the neuronal ERK 1 /2 activation mediated by 
the NMDA receptor exists in the bone marrow and the concentration of glutamate 
released from MEG-01 cells would only be enough to activate the receptor. 
The work by Chandler et al. (2001) also raises interesting points regarding how the 
neuronal NMDA receptor activates ERK1/2. They demonstrated that the NMDA- 
induced ERKI/2 activation still occurs in the presence of the PKC inhibitor 
GF 109203X, indicating that activation could take place independently of PKC. They 
also showed that CaMKII and P13 )-K antagonists do inhibit NMDA-mediated ERK1! 2 
activation, suggesting that these pathways are involved in \ IAPK activation in the 
CNS. The modulation of the NIAPK pathway- by the megakaryocytic NMDA receptor 
requires greater definition. If it w ere the case tliLit the receptor does mediate bi- 
directional regulation of the MAPK pathway. it could provide a unique level of control 
over megakarv-ocyte differentiation. 
The expression of the Ca\ IKII ct and ß isoforms by \ 11-( 1-0 1 cells further increases 
the complexity of the mcoakan ooc}tic ; ß\1D: \ receptor and prov-idcs an alternativ e 
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means by which the \IAPK pathway can be activated. independent of PKC. This 
finding also allows comparisons to be drawn between the receptor found in the CNS to 
that expressed by the megakaryocyte. Whether the NMD: \ receptor directly activates 
CaMKII, despite MK-801 possibly lowering the levels of activated Cah1KIl. is 
unclear. This can be confirmed by performing a radioactive kinase assay. to determine 
the activity of CaMKII following application of NMDA and MK-801 to 
megakaryocytic cells. The function of CaMKII in megakarvocytes is clearer. Ca 2+ 
induced ERKI/2 activation, as demonstrated by ionomvcin application, is reduced h\ 
the CaMKII inhibition. This demonstrated the regulative ability of Ca 2+ in 
megakaryocytic cells, in addition to providing evidence indicating that signalling 
mechanisms influenced by changes in [Ca2+]; can be mediated by CaMKII. 
Interestingly, TPO-induced activation of ERK1/2 in HEL cells was profoundly 
inhibited by CaMKII inhibition, reducing ERK 1 /- activity to approximately basal 
levels. The fact that MK-801 appeared to have no effect on TPO-mediated ERK 1 /2 
activation in these cells, suggests that TPO. unlike PMA treatment in MEG-01 cells, 
has the ability to activate ERK1/2 signalling independently of PKC, probably via 
adaptor proteins as described in chapter 1.3.1. The dramatic inhibition of the MAPK 
pathway caused by KN-93 suggests that the target of CaN I KI l in megakaryocytic cells 
is downstream to that of TPO signalling events. One possible target of CaMKII, as in 
neuronal cells, is SynGAP. The phosphorylation of SvnG. -\P by CaMKII relieves its 
inhibitory restraints on Ras. therefore inhibition of CaMKII function could prevent 
TPO-mediated Ras activation. Whether megakaryocytes express SynGAP requires 
investigation. However, it has recently been shown that osteoblasts do express 
SynGAP, demonstrating for the first time that this molecule does exist outside the 
CNS (G. J. Spencer, personal communication). It is also possible that megakaryocytic 
CaMKII can interact with other megakaryocytic GAPs. thereby having a profound 
effect of MAPK activation. 
The cellular effects of CaMKII inhibition in mcgakarvocytic cells included 
interruption of the cell cycle and reducing PM. N-induced adhesion. KN-9; induced a 
cell cycle block at G2 phase. an effect previously reported to also occur in IIcLa cells 
(Patel et al., 1999). Patel and colleagues demonstrate that the changes in the cell cycle 
were caused by CaNIKII-mediated phosphorvlation and activation of the tyrosine 
phosphatase cdc25. which in turn 
dephosphorvlates the protein klnase cdc2. which has 
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been identified as the key mediator of G2/M cell cycle phase transition (reviewed in 
Morgan, 1995). Therefore, by inhibiting the function of CaMKII, the cdc25-mediated 
dephosphorylation of cdc2 does not occur and phase transition is prevented. This may 
be of central importance in the endomitotic cell cycle of megakaryocytes, in which 
highly polyploid cells have been identified as having lowered levels of activated cdc2 
(Zhang et al., 1998; Matsumura et al., 2000). The data in this chapter therefore 
suggests a role for CaMKII in megakaryocytic endomitosis. This role could be one of 
applying a break to endomitosis and ensuring that normal mitosis progresses during 
megakaryocytic proliferation. It has now been established that megakaryocytic 
endomitosis is of fundamental importance in the production of normal platelets (for 
review see chapter 1.2.2). Therefore, the potential role of CaMKII in the cell cycle of 
megakaryocytes may also be of great importance in thrombocytopoiesis. 
The reduction in megakaryocytic cell adhesion caused by CaMKII inhibition raises 
other possible functions of this enzyme in these cells. CaMKII has previously been 
identified as a modulator of (x5 p1 integrin adhesion to FN in addition to integrin- 
mediated inside-out signalling (Bouvard et al., 1998). Interestingly, these 
investigators showed, by using Chinese hamster ovary (CHO) cells transfected with 
the a and ß isoforms of CaMKII, that CaMKII inhibition maintained the high affinity 
state of a5ß1 integrin, whilst addition of CaMKII to cell lysates inhibited binding to 
fibronectin in vitro. They also demonstrated that CaMKII did not affect integrin 
expression, implying that integrin activity was the target of CaMKII in these cells. 
With regards to the effects of CaMKII inhibition observed in this chapter, the findings 
of Bouvard and co-workers are intriguing, as they appear to be completely opposite to 
those found in megakaryocytes. Presently, the effect of CaMKII inhibition on 
megakaryocyte adhesion remains an interesting observation and requires further 
analysis before comparisons to the work by Bouvard and colleagues can be accurately 
drawn (Bouvard et al., 1998). It is also important to recognise the possible limitations 
of KN-93 as a CaMKII antagonist. KN-93 is a quinolonesulfonamide is thought to act 
as a CaMKII-specific ATP antagonist (Tokumitsu et al., 1990), although subsequent 
reports have suggested doubts regarding the specificity of this antagonist (Means, 
2000). This work indicates that KN-93 also acts as an antagonist to other members of 
the CaMK family of enzymes, namely CaMKI and CaMKIV. It is therefore important 
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to take into consideration that if KN-93 has any cellular effects on megakarvocytes. 
they may not necessarily be CaMKII-specific. 
Published data regarding the action of CREB in megakaryocvte differentiation is 
scarce. However, recent evidence suggests that this transcription factor is activated by- 
TPO binding to the c-Mpl receptor and subsequently has elects on megakaryoc\ to 
lineage determination and possibly also differentiation (Zauli et al.. 1998). We 
confirmed the findings that TPO results in CREB phosphorvlation in HEL cells, but 
also found that blocking the action of CaMKII can inhibit this effect. This 
phenomenon is common in neuronal cells (Huang et al.. 2000; Han and Holtzman, 
2000), where by blocking CREB activity with CaMKII inhibitors can result in changes 
in LIP and cell survival. Interestingly, as MK-801 appeared to have no effect on 
CREB activation, this may be an NMDA receptor-independent effect, implying that 
CaMKII activation occurs via another calcium source. Although CREB exists in 
MEG-O1 cells, the application of PMA did not result in its activation. Two clear 
hypotheses emerge from these findings. The first is that CREB activation in 
megakaryocytes may be PKC independent and occurs following TPO addition via 
adaptor proteins described previously. The second supports the theory by Zauli and 
co-workers (1998) that the role of CREB is in me`gakaryocvte lineage determination. 
As MEG-01 cells are already of the megakaryocytic lineage, unlike HEL cells that are 
erythrocyte/megakaryocyte bipotential, there may not be a requirement for CREB 
activation. 
The interaction between-TPO mediated signal transduction through the c-Mpl receptor 
and NMDA receptor expression is unclear. However, it would appear that expression 
of the NMDA receptor is unaltered in the absence of c-Mpl-mediated signalling, 
which has certain implications regarding both signalling mechanisms. The findings 
that c-Mpl-'- mice produce normal me`gakarvocvtes and platelets suggest that other 
systems are able to influence differentiation in the absence of TI_PO (Buntin`g et al.. 
1997). As the findings in this and previous chapters demonstrate that the N`11). \ 
receptor possesses a level of control over the normal nlegakarvocvte maturation, it is 
possible that megakaryocytic N JDA receptor signalling can compensate for the 
absence of I'PO effects, ensuring that the remaining me`gakarv ocytes do differentiate 
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normally. This theory is strongly supported by the findings in this chapter. which 
demonstrate that many of the signalling systems activated by TPO that are important 
for megakaryocytic differentiation, are also modulated by the NMDA receptor. 
The aim of this chapter was to bridge the gap between the expression of a functional 
NMDA receptor and the cellular effects observed when the receptor was antagonised. 
It has now been demonstrated that the NMDA receptor inflicts control over ERK 1 /2 
activation, possibly in both an inhibitory and excitatory manner, explaining the less 
differentiated phenotype observed in MK-801 treated cells (chapter 4). The 
identification of CaMKII expression by megakarv-ocv tes is a significant finding of its 
own accord, as it appears to influence various aspects of normal megakaryocv tic cell 
maturation. This finding may have implications on megakaryocytic signalling as a 
whole and with further investigation, could be implicated in megakaryocyte lineage 
selection, endomitosis, adhesion and inside-out inte`(rin signalling. As the CaMKII 
isoforms expressed by megakaryocytes were considered to be neuronal and interact 
with the NMDA receptor in the postsynaptic cell. it is a distinct possibility that the 
megakaryocytic NMDA receptor may modulate CaMKII function. Currently. this link 
is tenuous, as the western blot analysis is not clear enough to directly identify the 
effect of NMDA receptor inhibition on levels of active CaN I KII. These studies 
warrant further investigation, and it may be that if the NMD1 receptor is able to 
activate CaMKII, its influence could have widespread implications for megakaryocvte 
differentiation. To fully establish the exact signalling downstream of the 
megakaryocytic NMDA receptors requires focused and dedicated investigation, which 
due to time restraints was not possible in this study. Ho%\ev er. this chapter does 
provide explanations as to how the NMDA receptor modulates megakarvocyte 
differentiation, as well as presenting other possible routes for further analysis. 
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6.1 Introduction 
The study of transgenic animals with receptor gene ablation can often provide a 
definitive characterisation of receptor function in vivo. One such example, frequently 
cited in previous chapters, is that of TPO and c-Mpl knockout models (Gurney et al., 
1994; Alexander et al., 1996, de Sauvage et al., 1996, Bunting et al., 1997). Indeed, 
until the development of these knockouts, the process of megakaryocytopoiesis in 
addition to the function of TPO and its receptor was poorly understood. Similar 
studies have also been performed on the NMDA receptor to provide greater insights 
into the mechanisms by which it is able to affect animal behaviour, with most of the 
studies understandably focusing on learning and memory. This chapter concentrates 
on the changes evoked by NMDA receptor gene ablation on megakaryocytes and 
platelets. 
Changes in the expression of individual NMDA receptor subunits add to the clarity of 
function. Several types of NMDA receptor subunit-specific transgenic mice exist, 
including, global knockouts, in which expression of a functional product of the gene of 
interest is abolished, conditional knockouts, in which receptor expression is knocked 
out in only certain regions of the brain, point mutations. which produce complex 
phenotypic and functional changes in the receptor and knock-ins, in which the receptor 
protein is over-expressed. These trans'genic animals have provided substantial 
evidence regarding the function of specific NMDA receptor subunits in the CN. S. 
These include demonstrating the importance of the NR2B subunit in synaptic targeting 
of the receptor (Ito et al.. 1997), that NR2D expression is implicated in juvenile 
epilepsy (Bengzon et al.. 1999) and also identifying the role of the tiR3A subunit as 
an NNIDA receptor "volume control" (Das et al.. 1998). As important as these 
findings are, the majority of N\1D: \ receptor subunit knockouts are targeted at the 
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essential NR1 subunit. NR1 knockout animals have demonstrated that the subunit is 
fundamental for the function of the receptor. In these animals. NMDA receptor- 
mediated Ca2+ influx is totally abolished (Forrest et al., 1994) and several groups have 
also demonstrated that NR1 is implicated in the formation of somatosensory maps 
formation, which are involved in the sensing of external stimuli in the foetal brain (Li 
et al., 1994; Iwasato et al., 1997; Messersmith et al., 1997). However, as much as the 
NR1 transgenic animals provide insight into subunit and receptor function in vivo, the 
diseases in which NMDA receptor dysfunction has been implicated cannot be 
investigated, as the animals usually die within 10 hours of birth. The reasons behind 
neonatal death are believed to be due to defective breathing and suckling mechanisms 
(Sprengel and Single, 1999). 
This fact has frustrated the use of transgenic animals in the research of NMDA 
receptor related psychotic diseases such as schizophrenia. However, recently a 
genetically altered mouse line was produced that expressed lowered levels of the NR 1 
subunit protein (Mohn et al., 1998). The creation of these animals involved using a 
vector targeted to integrate in to the NR1 locus (designated Grin 1) and insert a 
neomycin (neo)-resistant gene into intron 20. The impact of this insertion was to 
reduce the expression of NR1 mRNA and protein to an average of 8.1% and 7.3% 
respectively. It was also demonstrated that insertion of the neo gene did not produce 
any point mutations or novel transcripts, indicating that the NRlneo mutation produced 
a hypomorphic allele. Importantly, although NR1 expression was greatly lowered, it 
appeared that expression of the receptor was at high enough levels for the animals to 
progress from the neonatal stage and develop into normal adults. The adult mice were 
physically normal compared to control (albeit smaller than average, they were still in 
the normal range) and displayed no obvious abnormalities outside the CNS (although 
detailed studies have not been performed on peripheral tissues). The NR 1 ne° mice 
do however have severe psychological abnormalities. The general behaviour of these 
mice including; increased motor activity, stereotypic behaviour (fixed response to 
external stimuli, indicative of learning not taking place), abnormal social behaviour 
and deficient sexual interactions are typical of those seen in animal models of 
drug-induced schizophrenia (Moghaddam and Adams, 1998). Indeed, drugs 
previously shown to induce schizophrenia in mice. such as phencyclidine (PCP) and 
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MK-801, did not have any additional effect on NR1"e0 mice. This psychotic 
behaviour of NR1"'- was prevented by the administration of the widely used anti- 
psychotic drugs, clozapine and halperidol. The expression of functional receptors 
present in the pre-frontal cortex was also determined by [3H] MK-801 binding assay. 
Competition curves demonstrated that the IC50 for both NR I"""' and NR 1 "` °- - were 
identical, demonstrating that the remaining receptors were functionally normal, 
however the maximal binding was only 10% of that of the wild type. The findings by 
Mohn and colleagues support the importance of NMDA receptor function in 
schizophrenia and reveal the action by which anti-psychotic drugs may evoke their 
effects. Further studies using these animals will lead to a greater understanding of the 
role of the NMDA receptor in other diseases of the CNS. 
Currently, no investigations have been performed on these animals with regard to the 
effect of NR1 gene ablation on peripheral tissues. These animals provide an 
unparalleled opportunity to investigate glutamate signalling in peripheral tissues due to 
the fact that they survive to adulthood. Not only would the extraction and 
experimentation on organs and tissues from 10-hour-old neonates prove extremely 
challenging, age-related defects regarding dysfunctional NMDA receptor signalling in 
peripheral tissues cannot be determined in NRI global knockouts. The NRlneo 
transgenic mouse is the only viable model on which to study the effect of NR1 gene 
ablation on megakaryocytopoiesis and platelet production for several reasons. Firstly, 
the site of haematopoiesis changes during foetal development from the yolk sac, to the 
aorta-gonad-mesonephros (AGM) and finally to the liver (Zon, 1995; Traver et al. 
2001). Indeed it is not until 4-7 days after birth that haematopoiesis, including 
megakaryocyte and platelet production appears in the bone marrow. Secondly, many 
of the experiments performed to determine the level of platelet production involves the 
bleeding of the animals and measuring the clotting time (see chapter 6.2.3) and also 
taking a comparatively large amount of peripheral blood for automated or histological 
analysis (see chapter 6.2.4 and 6.2.5). Such procedures would be impossible to 
perform on neonates. 
This chapter is the first to determine the effects on peripheral tissues observed in the 
NR1"e°-, /- mouse by focusing on megakaryocytopoiesis and platelet production. The 
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experiments performed on these animals are comparable to those carried out in the 
c-Mpl and TPO knockout models to determine effect on megakaryocyte and platelet 
function. These investigations should provide a penetrating insight into the role of the 
NMDA receptor in the proliferation and maturation of megakaryocytes and also the in 
the production of functional platelets in vivo. 
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6.2 Materials and methods 
6.2.1 Generation of NR11eo-/- mice 
Transgenic animals were generously provided by Dr. Bev Koller (University of North 
Carolina). These mice were generated as described previously (Mohn et al.. 1999). 
Briefly, cells were transfected with JNS2 vector containing neo gene and positive 
selection markers. Targeted clones were identified by Southern analysis and injected 
into blastocysts to generate chimeras, which were then bred to B6D2 animals, 
obtaining NRIne0+1 animals. Intercrossin`ý between the wild type and heterozygous 
colonies generated NRI"'O+I animals and a breeding colony established. All mice used 
in the following experiments were generated from intercrossing the first 2 
heterozygous animals. The NR1"e°-'- mice expressed 5 -10% of the normal levels of 
NRI compared to wild type, suggesting a hvpomorphic NRl allele enabling the neo 
homozygous mice to survive to adulthood. 
6.2.2 Acetylcholinesterase staining of NR1"`°-l- megakarvocvtes 
Tibiae, femora and spleen were removed from NR 1 "eO+i+ NR 1 neo+l- and 
NRlneo 1 mice, frozen in liquid nitrogen and sections collected and stored as method 
2.4.4.1. Acetylcholinesterase (ACNE)-positive cells within these tissues were 
identified as megakaryocvtes. Substrate was prepared freshly' before use by adding 
5mg of acetylcholine iodide (ACI: Sigma) to 6.5m1 0.1 M Na, -11P04 
(pH6.0). The 
following was added, in order to the substrate whilst stirring; 
0.5m1 0.1M C(, IT; Na307. 'l I, O (sodium citrate) 
1. Oml 30mM CuSO4 
1. Oml H2O 
1. Oml 5mM K Fe(CN)(, 
= IOrni ACIhE staining solution 
\Ch1 staining solution was applied to the slides and incubated for ' firs at room 
temperature in a humidified chamber. Aides were rinsed with 0.1 \1 \aI 1P04 and 
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fixed in 4% paraformaldehyde for 5 minutes, washed 3 times for 5 minutes in PBS and 
counterstained for 5 minutes in Mayer's haematoxylin. Slides were mounted in 90% 
v/v. glycerol/PBS and viewed using a Leica DMLA microscope. Spleen sections used 
were approximately of the same size (15mm x 5mm) and all positively stained splenic 
megakaryocytes were counted for each section. Counts were performed blind. 
6.2.3 Bleeding time assay 
Mice were anaesthetised by intraperitoneal injection of avertin, made by mixing equal 
volumes of tribromyl ethyl alcohol and tertiary amyl alcohol (2.5% dilution), at 
250mg/kg body weight. 5mm of the distal end of the mouse-tail was then removed 
and immediately placed in 0.9% saline solution maintained at 37°C. The bleeding 
time was measured as 15 seconds after the time taken for all traces of bleeding to 
cease. If bleeding continued for over 20 minutes, platelet plug formation was 
promoted by applying pressure to cut region using 3MM paper. 
6.2.4 Whole blood cell count 
200µ1 of blood was removed from anaesthetised mice via cardiac puncture of the left 
ventricle in syringes containing 2Oµ1 of 50mM EDTA to prevent clotting. 12µl of 
whole blood was then counted using a Heska's animal blood counter (Heska, CO). 
2Oµ1 remaining blood was used in the production of blood films, by spreading a thin 
layer of blood over polylysine slides and fixing in 70% methanol for 5 minutes and 
allowed to air dry and May-Wright Giemsa counter-stained. 
6.2.5 Transmission electron microscopic analysis of platelets and bone marrow 
Whole blood was collected by cardiac puncture as described in section 6.2.4 from 
NRlneo+/+, NRIne0+/-and NRlneo-' mice. Platelet rich plasnia (PRP) was collected 
from whole blood by centrifugation at 150g for 10 minutes and supernatant collected 
as PRP. To prevent platelet activation, platelets were firstly fixed lightly by adding 
l00µ1 of PRP to 1 ml of 0.2% glutaraldehyde in 0.1 M sodium cacodylate at pH 7.4 
and incubated at room temperature for 30 minutes. Platelet suspension was then 
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centrifuged at 800g for 10 minutes, the supernatant removed and the platelet pellet 
resuspended in 4% glutaraldehyde in 0.1 M sodium cacodvlate at pH 7.4. Samples 
were then kept at room temperature until TEM preparation. For bone marrow 
examinations, tibiae and femora were extracted from NR 1 "`'°+'+ and NR 1 neo '- and 
immediately fixed in 4% glutaraldehyde in 0.1 M sodium cacodylate at pH 7.4 and 
kept at room temperature until TEM sample preparation. 
TEM sample preparation was performed as previously described (chapter 4.2.6.3). 
Approximately 40 platelet clusters were analysed at various magnifications and 15 
photographs taken for each group at 12,000 and 25,000-x magnification. Due to the 
rarity of the megakaryocyte in the bone marrow, it was possible to examine every 
megakaryocyte in each sample and approximately 15 photographs of each sample 
taken at 4,000 and 10,000 X magnification. 
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6.3 Results 
6.3.1 Splenic megakaryocyte number in NR1"eo mice 
The generation of the NR1 hypomorph, NRl"eo, has made it possible to determine the 
effect of NR1 down-regulation in adult mice. With regard to possible affects on 
megakaryocyte number, spleens removed from wildtype (N R 1"" +/+) heterozygous 
(NR1"+I-) and knockout (NR1"-h'-) mice were snap frozen and 7µm cryosections of 
comparable size taken and stained for the megakaryocyte-specific marker AChE. 
Megakaryocyte counts, performed blind, demonstrated a significant decrease in 
megakaryocyte number, from an average of 82/section in NRI"e0'ß+ to 62/section in 
NRIne0 -'- (Fig. 6.3.1). Interestingly, megakaryocyte number was significantly 
increased to an average of 128/section in NR1ne0+'- animals. 
6.3.2 Bleeding time and platelet counts of NR1? wo mice 
As changes in megakaryocyte number may directly alter the number of circulating 
platelets, consequential variations in clotting time were established. In the following 
experiments, the tail cut assay was used as a method of quantifying clot formation in 
age-matched NR 1 "eO +'+ NR I neo +1- and NR I "eo -/- mice. Bleeding times of NR 1 "e°'- 
were increased nearly four-fold compared to NR 1 "eo +/+, from an average of 2 minutes 
47 seconds to 9 minutes 34 seconds (Fig. 6.3.2). The bleeding times of NRI"" 
mice were not significantly different to wildtype controls. 
As the common cause of increased bleeding time is a reduction in the number of 
platelets, platelet counts and subsequent histological examination of peripheral blood 
smears were performed. Peripheral blood was removed via cardiac puncture and kept 
in 10mM EDTA solution to prevent activation until platelet counts were performed. 
Whole blood counts in NR 1 neo +/+, NR 1 neo +'- and NR I""' -- revealed no significant 
difference in circulating red blood cell number, haemoglobin, haematocrit or platelet 
167 
Chanter 6 
140 
120 
äs 100 
E 
80 
60 
40 
20 
0 
Figure 6.3.1. Splenic megakaryocyte number in NR1"`'° wildtype, heterozygous 
and knockout mice. Megakaryocyte number was quantified by counting AC'hE- 
positive cells present in the spleen of wildtype, heterozygous and knockout mice. 
Experiments were performed blind and revealed a decrease in megakaryocyte 
number in knockout animals compared to wildtype , 
but interestingly a significantly 
increased in heterozygotes. (* p<0.05, ***p<0.001; one way ANOVA). 
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Figure 6.3.2. Bleeding times in wildt}ype (NR1m. ), heterozygote (NRl"'""-) and 
knockout (NR1"`~'-) mice. Average bleeding time, measured by tail cut assay, was 
significantly increased in knockout mice compared to wildtype and heterozygous. 
The average bleeding time of wildtype was 2.47 minutes (±S. D. 1.02 minutes) and 
2.17 minutes (±S. D. 1.10 minutes) in heterozygous, whilst bleeding time was 
increased to an average of 9.34 minutes (±S. D. 5.42 minutes) in knockouts. (*** _ 
p<0.001, Mann-Whitney rank sum test) 
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Figure 6.3.3. Complete blood counts from NR1""' mice. Peripheral blood taken 
by cardiac puncture was subjected to automated counting. Counts were performed on 
red blood cells (normal range 5-12x 10'/ml), haemoglobin (normal range 11-18g/L ), 
haematocrit (normal range 36-52%) and platelet number (normal range 140- 
600x 10'/ml). No significant difference was observed between xvildtype. 
heterozygous (hetero) or knockout in any of the selected counts (one-way ANOVA). 
Error bars = standard deviation. n=8 for «ildtpye. heterozygous and knockout. 
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number (Fig. 6.3.3). Counts for all other circulating blood cells were also similar in 
all three groups. 
Peripheral blood films were prepared from remaining blood and May-Wright Giemsa 
stained for histological evaluation. Each blood film was graded according to defined 
criteria determining film quality, platelet clumping, red blood cell number, platelet 
staining, platelet size and platelet number (Fig. 6.3.4). Three independent 
experimenters performed all examinations blind. Results were comparable to 
automated counts, with no significant difference between NR 1 neo +/+ and NR 1 neo -l- 
platelet counts and red blood cell number, whilst platelet size was not obviously 
different in any of the experimental groups. Platelet number was slightly higher in the 
NRlneo +/- group, which may be due higher quality platelet staining. The relatively 
high level of platelet clumping indicates that the experimental techniques employed to 
prevent platelet activation, were unsuccessful. 
6.3.3 NR1"eo megakaryocyte and platelet ultrastructure 
The functional role of the NR1 gene in the formation of normal megakaryocytes and 
platelets was determined by ultrastructural analysis of NR 1 "`'° +1+ and NR 1 neo -/- bone 
marrow megakaryocytes and circulating platelets by TEM. Wildtype megakaryocytes 
were characteristically normal, including being large in size, having a multilobed and 
indented nucleus, extensive cytoplasmic partitioning by demarcation membrane and 
containing many dense a-granule bodies (Fig. 6.3.5). Also, apparent cytoplasmic 
extensions resembling proplatelet structures were observed in many of the mature 
cells. In comparison, NR 1' -'- bone marrow megakaryocytes appear similar in size 
and nuclear maturation and cytoplasmic a-granules were clearly present (Fig. 6.3.6). 
However, the levels of demarcation membrane invasion into the cytoplasm appeared 
less perfuse in many mature cells leading to larger platelet territories. Proplatelet 
structures were also not observed in these cells. 
The ultrastructure of circulating platelets obtained via cardiac puncture and isolation 
of platelet-rich plasma were also analysed by TEM. The general morphology of all 
platelets indicated that they have been activated (non-activated morphology is a 
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uniform discoid shape), again indicating the technical failure to prevent platelet 
activation (Fig. 6.3.7). However. morphological differences between 
NR1'1e° +i+, NR1 "eo +/-and NR 1 "+'+ were not apparent, with normal numbers of 
a-granules and marginal bands of microtubules observed in all platelets observed. 
There was also no obvious difference in platelet size between groups. 
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Figure 6.3.4. Histological grading of peripheral blood smears from NR1""' 
wildtype, heterozygous and knockout mice. Histological examinations performed 
blind by three independent experimenters revealed no differences in red blood cell 
(RBC) number, platelet clumping, size or number in knockouts compared to 
wildtype. Platelet number may be slightly increased in heterozygous mice, although 
this could be due to the films being of a higher quality and better platelet staining. 
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A 
Figure 6.3.5. Ultrastructure of NR1"""" bone marrow megakaryocytes. 
Ultrastructural determination of NR I"""' bone marrow megakaryocyte morphology 
by TEM. Megakaryocytes display normal physiological morphology, including 
multi-lobed, indented nuclei (N), extensive demarcation membrane system leading to 
numerous small platelet territories (PT) and the presence of proplatelet structures (A: 
arrowheads) . 
Higher magnification images reveal normal platelet-territories and (I- 
granule formation (B; arrows). 
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Figure 6.3.6. Ultrastructure of NR I"' '- bone marrow mega kars ocytes. 
Ultrastructural determination ofNR1""--bone marrow megakaryocyte morphology 
by TEM. Megakaryocytes appeared to be of similar size to those found in wildtope 
bone marrow and exhibited multi-lobed, indented nuclei (N). However, the number 
of platelet-terratories (PT), formed by demarcation membrane, was less than wildtope 
controls (A). Higher magnification images demonstrated larger PTs although a- 
granule formation (B, arrows) appears normal. 
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Figure 6.3.7. Circulating platelet ultrastructure from NRI"`' mice. Circulating 
platelets taken from NR l neo wvildtype, heterozygote and knockout mice displayed 
similar cytoplasmic constituents, including a-granules (a) and microtubule 
formation (arrows). 
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6.4 Discussion 
NRIne0 transgenic mice have enabled the function of the NMDA receptor in the adult 
brain to be determined as, unlike other NR1 global knockouts, they survive to 
adulthood (Mohn et al., 1998). The NRIneo mice are able to survive because, rather 
than the expression of NR1 gene being totally abolished, the neomycin-resistance gene 
inserted into intron 20 of the Grin 1 gene, results in the formation of a hypomorphic 
NR1 allele, lowering NR1 expression by over 90%. As such, these animals are the 
ideal models with which to study the effects of greatly lowered NR1 expression on 
peripheral tissue glutamatergic signalling in vivo. This chapter describes changes the 
changes in megakaryocytopoiesis and platelet production observed in the NR 1 neo 1 
mouse. 
It appears that megakaryocyte proliferation in NR1"e. _ mice is significantly reduced 
compared to wild types. Interestingly, the reduction in splenic megakaryocyte number 
is of a similar degree to those observed in human primary cell cultures treated with the 
NMDA receptor antagonist MK-801 (see chapter 4.3.3.2). The effect of the NMDA 
receptor on megakaryocyte proliferation is perhaps not been given the attention it 
warrants in this study. This is probably due the fact that NMDA receptor inhibition 
appeared to have such profound effects on megakaryocyte differentiation and platelet 
production that the less pronounced changes in cell number were not focused on 
initially. However, NMDA receptor-mediated changes in proliferation and possibly 
lineage determination in vivo and in vitro may well be an attractive line of study. It is 
significant that the heterozygous animals display significantly greater number of 
megakaryocytes than wild type. This could demonstrate that the method of counting 
ACNE-positive cells in spleen sections of similar size is not sufficiently accurate 
enough to determine cell number and a more precise method would be to extract the 
bone marrow and count all CD61 -positive cells by flow cytometry. 
To complement the in vitro data described in chapter 4, it was demonstrated that 
bleeding times displayed by NR 1"'0--"- mice significantly increased compared to 
heterozygotes and wild type animals. Indeed, the increased clotting time ofNRl"e° -"- 
compared to wildtype are comparable to that observed in c-Mpl- and TPO-knockout 
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animals, indicating the importance of the N IDA receptor in thrombopoiesis (Gurney 
et al.. 1994: Bunting et al.. 1997). However. increased clotting time can be indicative 
of several conditions in addition to decreased platelet production. One possibility that 
must be considered, following the work by Franconi and co-workers on the platelet 
NMDA receptor. is platelet function (Franconi et al., 1996). Unfortunately, the data 
shown in this chapter cannot provide a tangible explanation as to why clotting, was 
inhibited by NR1 under-expression. The ultrastructure of bone marrow 
megakaryocytes in NR1"e0 _Z_ compared to wild type imply that the demarcation 
membrane system has not developed throughout the cytoplasm, therefore reducilig, tile 
number of platelets being released. Demarcation membrane abnormalities were also 
observed in the ultrastructure of human primary megakaryocytes following \1 K-801 
treatment (chapter 4.3.2.2), which appears to confirm the role of the NN IDA receptor 
in megakaryocyte cytoplasmic fragmentation. However, a reduction in the number of 
circulating platelets was not demonstrated by automated \\-hole blood counts, a findin1-1 
that favours platelet dysfunction rather than reduced platelet production. Platelet 
abnormalities, for example in platelet diseases such as GPS and von \? l'illebrand 
disease, can often be identified from ultrastructural characteristics (Smith et al., 1997). 
The platelets extracted from the peripheral blood of NR l ""-Z- mice however, appear to 
be morphologically similar to those from wildtype and heterozygotes animals, 
suggesting that the observed clotting abnormalities may not be a result of platelet 
dysfunction. 
The findings from the NRlneo transgenic studies underline the complexity of this 
newly-identified signalling mechanism. I lowever, the data presented in this chapter 
was the result of experiments performed over an extremely short period of time. It is 
of integral importance that further experiments are performed on these animals. 
focusing on determining whether the clotting abnormalities are as a result of lowered 
platelet production, or platelet dysfunction. For example, platelet function can be 
determined by platelet adhesion assay (Bunting et al., 1997) or assays determining 
platelet activation (Newsman and Chong, 2000, Falles et at.. 2002) from peripheral 
blood. It would also be possible to culture bone marrow megakaryocytes by 
immunoslecting CD61-positive cells and determining the extent of proplatclct 
production in response to TPO and plasma (Rojnuckarin et al.. I9(f9). It would also he 
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of interest to record the concentration of circulating TPO and other cytokines in the 
NR 1 `e°-1- mouse, to determine whether the haematopoietic system compensates for the 
lack of NMDA receptor-mediated effects. It may also be the case that the low levels 
of NRl expression displayed in NRl"e0 -1- mice, remain high enough to not affect 
certain aspects of the NMDA receptor-mediated megakaryocytopoiesis, or that unlike 
neuronal cells, the role of the NRl subunit is not essential to receptor function. 
From these encouraging preliminary studies it is possible to state that mice exhibiting 
decreased levels of the NRl subunit display significant bleeding abnormalities. 
Unfortunately, it was not possible to determine the role of the NMDA receptor in this 
condition because of the contradictions presented with regards to platelet production 
and platelet function. By performing the further experiments described above, it 
would be possible to clarify the cause of the bleeding abnormality and also the role of 
the megakaryocytic NMDA receptor in vivo. 
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General Discussion 
Comparison of human bone marrow trephines from a normal patient (left) 
and a patient suffering from myelfibrosis (right), a condition in which increased 
numbers of megakaryocytes leads to excessive fibrosis of the 
bone marrow (magnification x40) 
(Bristol Biomedical Image Archive, University of Bristol) 
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General Discussion 
Haematopoiesis is tightly regulated by numerous cytokines. N 1e`gakarvocvtopoiesis is 
no exception, with cell survival, proliferation and differentiation all rigidly modulated 
by a large number of growth factors and cytokines (reviewed in chapter 1.3) ensuring 
that the number of platelets released into the circulation is within physiological limits. 
However, since the characterisation of TPO. the key positive regulator of 
megakaryocyte differentiation, a great deal of research has focused on increasing the 
volume of knowledge on the effects of this particular cytokine. Indeed, since the 
cloning and characterisation of TPO and c-Mpl in 1994 (de Sau\-a(., e et al., 1994: Lok 
et al., 1994; Kaushansky et al., 1994, Wendling et al., 1994). studies attempting to 
identify novel regulators of megakaryocytopoiesis have been scarce. This seems 
particularly surprising in view of the findings by Bunting and colleagues that normal 
platelets and megakaryocytes are produced in vii'o in the absence of TPO (Buntin`g ct 
al., 1997) and the acknowledgment by Kaushansky that mouse primary 
megakaryocytes require a component of blood plasma in addition to TPO, to produce 
platelets in vivo (K. Kaushansky. personal communication). The data presented in this 
thesis not only characterises a novel signalling system that regulates megakaryoc}'te 
differentiation and platelet production, but also enhances the field of peripheral 
glutamatergic signalling. 
The principal aim of this \vork was to advance the preliminary findings regarding the 
expression of the NMDA receptor by megakaryocytes and its role in the differentiation 
of megakaryocytic cell lines (Genever et al., 1999). The findings described in this 
thesis clarifies the expression of NMDA receptor expression and its role both in 
megakaryocytic primary cells and cell lines. in addition to determining the function ot- 
the receptor in primary cells. identification of NN1D: \ receptor-mediated intracellular 
signalling lýýlillwa vs anthe effect of lowering NRI gene expression on 
nlegakaryocytopoiesis and platelet production in viva. Howe ever, it was he \ and the 
capacity of this study to concisely determine the action of the receptor in every aspect 
of megakaryocyte differentiation and function. Indeed, the apparent nmultilaceted 
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action of the megakaryocytic NMDA receptor has lead to numerous lines of study 
undergoing preliminary investigation, many of which warrant concise analysis. 
To continue the advances made during this study, it is imperative that certain aspects 
attain further investigation. The selective expression of NMDA receptor subunits by 
megakaryocytes during differentiation suggests that certain adaptations in receptor 
function may alter the effect they have on the cell (Fig. 7.1). It is of key importance to 
determine the full-length sequence of the NMDA receptor subunits NRI, NR2A, 
NR2C, NR2D and NR3 expressed by cell lines and primary cells. Once this is 
determined, it would be possible to compare the sequence with that of human neuronal 
NMDA receptor subunits and this may reveal the expression of splice variants or 
novel megakaryocyte-specific isoforms that modulate the conductivity of the receptor. 
It would then be possible to co-transfect MEG-01 and HEL cell lines with different 
combinations of the full-length cloned NMDA receptor subunits. This would result in 
megakaryoblastic cell lines stably transfected with diheteromeric (for example 
NR 1 /NR2A) and triheteromeric (for example NR 1 /NR2A/NR3) receptors. In 
conjunction with these studies, it would also be possible to transfect the 
megakaryoblastic cells with small interfering RNAs (siRNAs), which would result in 
the knocking down of endogenous NMDA receptor subunit expression. These 
molecular techniques would allow the manipulation of NMDA receptor subunit 
expression in megakaryoblastic cell lines and by performing functional experiments, 
comparable to those described in chapter 4, it would be possible to characterise the 
cellular effects of specific NMDA receptor subunit expression. 
The megakaryocytic NMDA receptor has a number of roles during 
megakaryocytopoiesis and platelet production (Fig. 7.2). Several of these aspects 
warrant fuller examination to accumulate a greater understanding of how the receptor 
imposes such changes on the megakaryocyte. One such experiment would be to 
determine the effect of activation and antagonism of the megakaryocytic NMDA 
receptor on the activity of the transcription factors GATA-1 and NF-E2 (for review 
see chapter 1.3.4), both of which have specific key roles in megakaryocytopoiesis and 
platelet production. By establishing whether there are changes in the action of these 
transcription factors, for example by electromobility shift assay (EMSA), which 
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detects the binding of transcription factors to their DNA recognition sequences 
(Freson et al., 2001), the cause of the NMDA receptor-mediated effects would then 
become clearer. Indeed, considering the effects of modulating the transcriptional 
activity of NF-E2 has on the expression of ß 1-tubulin (Lecine et al., 2000), a reduction 
of NF-E2-mediated gene transcription may account for the profound deficits observed 
in the production of proplatelets by human primary cells in vitro following MK-801 
exposure. 
The likelihood of the megakaryocytic NMDA receptor mediating gene transcription is 
supported by the findings reported in chapter 5. Seemingly, the NMDA receptor can 
modulate the activation of the MAPK pathway among others (Fig. 7.3), which directly 
impinges on gene transcription regulating megakaryocytopoiesis. However, as stated 
in chapter 5.4, the exact mechanism by which the NMDA receptor activates this 
pathway in megakaryocytic cells remains unclear. NMDA receptor-mediated 
translocation of PKC isoforms would prove an interesting subject of further study, as 
would the plausible interaction of the receptor with CaMKII, the megakaryocytic 
expression of which was identified for the first time in this study. However, a greater 
understanding of downstream signalling pathways relies upon the immediate effects of 
agonist-induced NMDA receptor activation being determined. The results presented 
in chapter 4.3.3 attempting to address this question are inconclusive. By performing 
patch-clamping experiments, it would be possible to clarify the conductance of the 
megakaryocytic NMDA receptor, by determining whether the receptor causes large 
intracellular increases in calcium, small local increases known as "calcium sparks" or 
possibly no recordable changes in calcium. Once these aspects have been resolved, it 
would then be possible to postulate how receptor-mediated signal transduction occurs. 
It would also be of interest to determine, again by patch clamping, the receptor 
conductance of the afore mentioned transfected cell lines, in addition to that of cells 
undergoing differentiation, particularly with regards to the expression of the NR3 
subunit. 
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As implied in chapter 4.4, the fact that megakaryocytes release glutamate could have 
significant implications on the modulation of NMDA receptor-mediated 
megakaryocytopoiesis, in addition to establishing interactions between the 
megakaryocyte and GLT-1 positive cells in the bone marrow microenvironment. 
Research on the subject of megakaryocytic glutamate release is in its relative infancy. 
However, with the current data, it is possible to establish a hypothesis on how 
glutamate release could have an autocrine action on megakaryocytopoiesis (Fig. 7.4). 
As the megakaryocyte is a rare cell in the bone marrow, it is likely that released 
glutamate would act predominantly on the cell from which it has been released and 
that it remains in the vicinity of the megakaryocyte by the recycling activity of GLT-1 
positive cells. Whether bone marrow megakaryocytes release glutamate throughout 
differentiation is unclear, although both immature and differentiated MEG-O1 cells 
release comparable concentrations of glutamate and express the glutamate vesicular 
loading protein, VGLUT2. It would therefore seem that megakaryocytes have a 
constant source of glutamate for NMDA receptor activation. However, as the NMDA 
receptor appears to positively regulate the latter stages of megakaryocyte 
differentiation and platelet release, constant receptor activation may unbalance 
megakaryocytopoiesis and possibly lead to a thrombocythaemic state. It is plausible 
that the NR3 subunit, expressed exclusively by immature megakaryocytic cell lines, 
prevents NMDA receptor activity in an undifferentiated state. It may be that in the 
presence of an externally produced differentiation stimulus, such as TPO, 
megakaryocyte maturation is initiated and NR3 expression down regulated, leading to 
the restoration of normal autocrine NMDA receptor signalling-mediated events. 
These interactions currently remain a hypothesis and require further study, however, if 
these events were confirmed to occur in vivo, it would provide an elegant means by 
which to regulate megakaryocytopoiesis. 
Further investigations regarding NR1"eo transgenic animals are covered in chapter 6.4. 
As these animals are currently only bred and kept at the University of North Carolina, 
USA, access to these animals to perform the required experiments raised logistical 
problems. However, all attempts should be made to further utilise these animals. as 
they represent a unique opportunity to investigate the effects of NRI gene reduction 
in 
adult megakaryocytopoiesis and also in platelet production. 
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It was not possible to address every aspect of NMDA receptor-mediated signalling in 
this study. If future studies suggested in this thesis were to be performed. that many 
identify the true functional role of the NMDA receptor and its role in the 
megakaryocyte. If, as implied by the findings in this study. these experiments confirm 
that the receptor does directly influence multiple aspects of megakaryocyte behaviour. 
the NMDA receptor could be considered as a key regulator of megakaryocytopoiesis. 
7.1 Implications of megakaryocytic NMDA receptor signalling 
It is difficult to predict the degree of impact that the data presented in this thesis will 
have on the current understanding of peripheral glutamatergic signalling, 
megakaryocytopoiesis and platelet production. Functional glutamate signalling has 
been identified in numerous tissues (for review see chapter 1.6. ), however the process 
of NMDA receptor-mediated signalling in megakaryocytes is unique in several 
respects. Unlike the majority of other sites of peripheral glutamatergic signalling, in 
which the tissues consist of a relatively homogeneous population of cells, the bone 
marrow is an extremely heterogeneous collection of cell types. These range from stem 
cells, able to differentiate into numerous different lineages, to mature cell types, such 
as megakaryocytes. Therefore, unlike other peripheral tissues in which glutamate 
signalling occurs within a large collection of cells or even an entire tissue, glutamate 
signalling in the bone marrow is largely restricted to the megakaryocyte, surrounded 
by non-glutamatergic cells. Therefore, as megakaryocyte/megakaryocyte interactions 
do not occur often in normal bone marrow, glutamate signalling is likely to be 
autocrine, as often discussed above, rather than paracrine, as described for example in 
osteoblasts. 
Although there are differences between the nature of glutamate signalling in 
megakaryocytes and other tissues, these are essentially due to the heterogeneous 
nature of the bone marrow. Indeed, the function of glutamate signalling in 
megakaryocytes is comparable to that in other tissues, especially osteoblasts, 
osteoclasts and keratinocytes, in which the primary role for glutamate signalling is in 
cellular differentiation and function (for review see Skerry and Genever, 2001). The 
NMDA receptor associated proteins, found to be expressed by megakaryocytes have 
also previously been identified in osteoblastic cells (G. J. Spencer, personal 
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communication), although whether these proteins are expressed in other tissues that 
utilise glutamate signalling has currently not been defined. However the a and ß 
CaMKII isoforms, identified in megakaryocytes, are also expressed in peripheral 
NMDA receptor expressing tissues (Inagaki et al., 1995; Krizbai et al., 1998). 
Peripheral glutamate receptor signalling is rapidly gaining credibility in a number of 
different fields. A recent report aimed at encouraging research into the role of 
glutamate signalling in cancer (which will be addressed with regards to 
megakaryocytes later in this chapter) and also possibly stem cell lineage selection and 
differentiation (Cavalheiro and Olney, 2001), suggests that studies of peripheral 
glutamate signalling is set to expand, perhaps focusing on aberrant signalling in tissue 
diseases. A minority still treat the role of the glutamate receptor outside the CNS with 
scepticism (Gray et al., 2001). However, the data presented by these authors would 
appear to be over-interpreted, due to the use of a competitive NMDA receptor 
antagonist D-APV, on osteoblastic and osteoclastic cells in high glutamate-containing 
media. The work described in this thesis will add to the escalating evidence 
demonstrating that glutamate may be considered as a more widely distributed 
"cytokine". 
Furthermore, the findings of this study also have significant implications regarding the 
current understanding of megakaryocytopoiesis. The action of TPO, although 
profound on many aspects of megakaryocyte differentiation, does not regulate platelet 
release. This thesis provides fundamental evidence of a signalling system previously 
uncharacterised in megakaryocytes, which is of considerable importance to platelet 
formation and release in vitro. Many cytokines that regulate megakaryocytopoiesis 
are involved in various aspects of cell proliferation and differentiation and also affect 
several different cell types in addition to megakaryocytes. However, current data 
suggests that haematopoietic glutamate signalling is restricted only to cells of the 
megakaryocyte lineage (with exception to osteoclast progenitor cells) and appears to 
affect distinct stages of differentiation. Exactly where the megakaryocytic NMDA 
receptor fits into the more established signalling mechanisms remains unclear. Various 
signal transduction proteins activated by the NMDA receptor are the same as those 
activated by c-Mpl, but it is unclear as to whether the two signalling systems are able 
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to directly interact. Although the tyrosine kinase c-Mpl receptor is far removed from 
the ligand-gated ionotropic NMDA receptor, it is possible that these receptors activate 
convergent signalling pathways that are important in the normal regulation of 
megakaryocytopoiesis. As far as the implications of future megakaryocyte research 
are concerned, the NMDA receptor should at least be recognised as an interesting 
addition to the complex signalling hierarchy controlling normal 
megakaryocytopoiesis. 
This thesis begins by identifying the continuing need for pharmacological agents with 
which to prevent thrombus-induced ischaemic disease. As acknowledged in chapter 1. 
current anti-thrombotic agents, such as the anti-coagulant aspirin and anti-platelet 
drugs, are to an extent, successful in lowering the incidence of CVD in high-risk 
patients. However, the direct prevention of platelet function can often have severe 
bleeding side effects and commonly a number of patients are resistant to these 
therapies. It is likely that by modulating platelet production rather than function, it 
would be possible to obtain a greater level of control over the blood clotting potential 
of high-risk patients. The data presented in this study suggests that, in the future, it 
may be possible to control platelet production by using therapeutic agents aimed at 
modulating the megakaryocytic NMDA receptor. 
MK-801, the pharmacological antagonist used in these studies, although being a 
highly specific NMDA receptor antagonist and having marked effects on 
megakaryocyte differentiation and platelet production, would not be suitable as a 
therapeutic agent due to its ability to easily pass the blood-brain barrier, preventing 
normal synaptic neurotransmission and causing severe psychoses (Leppik et al., 1988). 
However, due to the potentially wide range of therapeutic applications of NMDA 
receptor antagonists, especially with regards to the treatment of neurodegenerative 
diseases such as stroke, Parkinson's disease and Alzheimer's disease, has lead to the 
creation of clinically well-tolerated NMDA receptor antagonists (Parsons et al., 1998). 
One such drug, now widely used as a neuroprotectant in Parkinson's disease, is 
memantine (for review see Parsons et al.. 1999), a non-competitive NMDA receptor 
antagonist that displays minimal side effects (Riederer et at., 1991). How this is 
achieved is unclear, however it is thought that memantine and Mg 
2+ block the same or 
a similar site on the NMDA receptor channel. At pathological glutamate 
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concentrations, memantine remains in site and blocks the NMDA receptor ion 
channel. However at physiological concentrations, memantine dissociates from the 
receptor and allows the normal activation passage of calcium through the receptor 
channel (Blanpied et al., 1997; Sobolevsky et al., 1998), unlike MK-801 which can not 
be dislodged from the channel. Memantine would therefore prove a good candidate as 
an NMDA receptor antagonist in peripheral tissues, as it would not result in 
neurological abnormalities, although whether the high physiological concentrations of 
glutamate in neuronal cells is comparable to that of megakaryocytes is yet to be 
determined. 
A more desirable alternative would be a non-competitive NMDA receptor that does 
not cross the blood-brain barrier and will therefore not affect CNS receptors. The 
development of such compounds however is currently restricted as they are 
specifically designed as neuroprotective drugs with the ability to cross the blood-brain 
barrier. As a result, it can only be assumed that blood-brain barrier-impermeable 
drugs do exist, but were not completely developed and therefore are not commercially 
available. Consequently these "failed" compounds, may be exploited to rapidly 
advance the clinical relevance of the megakaryocytic NMDA receptor as a therapeutic 
target to control platelet numbers in high-risk patients. It may also be possible 
discriminate between glutamate receptor expressing tissues by gene therapy by using 
tissue-specific promoters to alter receptor function therapeutically without affecting 
neuronal and peripheral receptors. 
Considering the apparent importance of the NMDA receptor in normal 
megakaryocytopoiesis, it would also be of great interest to address expression of the 
receptor in myeloproliferative disorders (MPDs). As discussed in chapter 1.5, very 
few megakaryocytic disorders are as a result of aberrant TPO/c-Mpl signalling, 
making it increasing likely that such conditions occur as a result of yet unidentified 
dysfunctional signalling systems. It could be postulated that abnormal NMDA 
receptor expression and/or receptor function influences these conditions. For example, 
the considerable effects induced by point mutations of the NR I subunit, such as thosc 
induced in NRl transgenic (N598Q/R) mutants (Single et al., 2000) which completely 
prevent NMDA receptor function, may similarly prevent megakaryocytic NMDA 
receptor signal transduction. Interestingly. I did perform a small-scale study on human 
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bone marrow aspirates, comparing NR1 expression by megakaryocytes from control 
and ET patients. Only a few samples were studied, as ET is a relatively rare condition 
(largely due to the disorder being misdiagnosed or undiagnosed), it did appear that 
expression of NR1 was reduced in ET samples (data not shown). The implications of 
this are difficult to interpret, as the data presented here indicates that reduced NMDA 
receptor signalling should prevent platelet production, whilst the major characteristic 
of ET is a greatly increased number of circulating platelets. To address NMDA 
receptor dysfunction with regards to MPDs such as ET, PV and AMM would require 
extensive retrospective molecular and histological investigations, but may prove to be 
extremely interesting. 
7.2 The megakaryocytic NMDA receptor - Concluding remarks 
It is nearly 50 years since L-glutamate was first championed as a major 
neurotransmitter in the CNS (Hayashi, 1954) although its full importance in neuronal 
synaptic transmission was not realised until over 20 years later (Watkins and Evans, 
1981; Foster and Fagg, 1984). In the last decade, the key importance of glutamatergic 
signalling in memory and learning, in addition to the implications in 
neurodegenerative disorders has been realised. With glutamate now universally 
accepted as the major neurotransmitter in the brain, it seems strange that when the role 
of glutamate was first being postulated, there was considerable scepticism that a 
simple amino acid, abundantly available in the brain, would act as a neurotransmitter 
(for review see Watkins, 2000). However, with time and skilled research, the sceptics 
were overcome as the fundamental roles of glutamate in the CNS were revealed. 
Overall, glutamate signalling in peripheral tissues is at a similar developmental stage 
as the early days of neuroscience, with the signalling mechanism in megakaryocytes 
less well characterised than that in other cell types. This thesis significantly advances 
the understanding of the megakaryocytic NMDA receptor and puts it on a par with 
some of the better-characterised glutamatergic tissues. One question often posed with 
regards to peripheral glutamatergic signalling, is why these tissues require a receptor 
type specifically intended for rapid responses at the neuronal synapse? With reference 
to the megakaryocyte receptor, the high-speed response of the receptor is almost 
certainly not as important as the long-term effects of NMDA receptor-mediated 
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protein phosphorylation and gene transcription. Indeed, with mounting evidence of 
peripheral glutamate signalling. classifying the glutamate receptor as a 
"neuroreceptor" may be a misnomer. It appears that each tissue in which glutamate 
signalling has been identified express certain receptors types, subunits and associatcd 
proteins, of which the megakaryocyte is one such example. indicating that the each 
cell type only express the type of receptor required for its specific function. 
Only future work regarding the molecular characterisation and the detailed 1'unction of, 
the receptor will truly clarify the importance of the megakaryoc}-tic VNID1\ receptor. 
The data presented in this thesis provides a stable grounding on which to continue and 
expand such analyses. To borrow a line from `'Winston Churchill when he addressed 
the Lord Mayor's Luncheon, London in November 1942, "This is not the end. It is riot 
even the beginning of the end. But it is, perhaps. the end of the beginning"". 
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Abbreviations 
AA arachidonic acid (not the first time this is used) 
AChE acetylcholinesterase 
ACI acetylcholine iodide 
ADP adenosine diphosphate 
AGM aorta-gonad-mesonephros 
AMM agnogenic myeloid metaplasia 
AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolc propionate 
ANOVA analysis of variance 
ATCC American tissue culture collection 
ATF-1 associated transcription factor-1 
BFU-MK burst forming unit megakarvocvte 
BFU-E/MK burst forming unit-crvthroid / megakarvocv to 
BMEC bone marrow endothelial cells 
BMSC bone marrow stromal cells 
BNPI brain-specific Na+-dependent inorganic phosphate (Pi) 
transporter I 
BSA bovine serum albumin 
[Ca2+]; intracellular calcium concentration 
CaM calmodulin 
CaMKII Ca2+/calmodulin-dependent protein kinase II 
cAMP cyclic adenosine monophosphate 
CD cluster of differentiation 
cDNA complementary DNA 
CFM-2 1-(4'Aminophenyl)- 3,5-dihvdro-7.8-dimethoxv-411-2.3- 
henzodiazepin-4-one 
(FU-GM CFt U-granulocyte-macrophage 
CFU-MK Colony forming unit megakaryocy tc 
ehapsyn-110 channel associated protein of synapses- 110 
CHD coronary heart disease 
CHO Chinese hamster ovary 
('\IL chronic my cloid leukaemia 
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CNS central nervous system 
CNTF ciliary neurotrophic factor 
CREB cAMP response element binding protein 
CT-1 cardiotrophin-1 
CVD cardiovascular disease 
DAB 3,3'-diaminobenzidine 
DAG diacylglycerol 
D-AP5 D-(-)-2-amino-5-phosphonopentanoic acid 
dCTP deoxycytosine triphosphate 
dH2O distilled H2O 
Dig Disks large 
DMS demarcation membrane system 
DMSO dimethyl sulphoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
DNPI differentiation-associated BNPI 
dNTP deoxyribonucleotide triphosphate 
dpm dissintegrations per minute 
DTT dithiothreitol 
EAAT-1 excitatory amino acid transporter 
EDTA ethylenediaminetetraacetic acid 
EMSA electromobility shift assay 
EPO erythropoietin 
ERK1/2 extracellular signal regulated kinase 1 
ESPC excitatory posts\ naptic current 
ET essential thrombocythaemia 
FBS foetal bovine serum 
FGFß fibroblastic growth factor ß 
FITC fluorescein isothiocvanate I 
FN fibronectin 
FOG friend of G: \T: 
GAP GTPase activating protein 
(; A P-43 growth associated protein-4 
ý Kati 
Abbreviations 
G-CSF granulocyte colony stimulating factor 
GAPDH glyceraldehyde-3 -phosphate dehydrogenase 
GDH glutamate dehydrogenase 
GLAST glutamate/aspartate transporter 
GLT-1 glutamate transporter-1 
GM-CSF granulocyte macrophage colony-stimulating factor 
GP glycoprotein 
GPS grey platelet syndrome 
GTPase guanosine triphosphatase 
HBSS Hank's buffered salt solution 
HEK human embryonic kidney 
HEL human erythroleukaemia 
HSC haematopoietic stem cell 
IgG immunoglobulins G 
IL interleukin 
IMDM Iscove's Modified Dulbecco's Medium 
Indo-1-AM 1 H-Indole-6-carboxylic acid, 2-[4-[bis[2-[(acetyloxy)methoxy]- 
2- oxoethyl]amino]-3-[2-[2-[bis[2- [(acetyloxy)methoxy]-2- 
oxoetyl]amino]-5- methylphenoxy]ethoxy]phenyl]-, 
(acetyloxy)methyl ester 
IP3 inositol triphosphate 
ITP idiopathic thrombocytopenic purpura 
JAK Janus kinase 
KA kainate 
kainate [2S-(2a, 3b, 4b)]-2-carboxyl-4-(1-methylethenyl)-3- 
pyrrolidinaecetic acid 
kb kilobases 
kD kilodalton 
KN-62 (S)-5-isoquinolinesulfonic acid, 4-[2-[(5-isoquinolinesulfonyl)]] 
KN-92 2-[N-(4-methoxynemzenesulfnoyl)]amino-N-(4- 
chlorocinnamyl)-N-methyl-benzlamine 
KN-93 N-(2-[N- [4-chlorocinnamyl]-N-methylaminmethY-l]phenyl)-N- 
(2-hydroxymethyl)-4-methoxysulfonamide 
LIF leukaemia inhibitory factor 
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LTD long-term depression 
LTP long-term potentiation 
m meter 
µ micro 
M molar 
MACS magnetic activated cell sorting 
MAGUK membrane associated guan}-late cvclases 
MALS mammalian analogue LIN-7 
MAPK mitogen activated protein kinase 
mGIuR metabotropic glutamate receptors 
min minute 
MK-801 5-Methyl-10.11-dihydro-5H-dibenzo-[a. b] cyclohcpten-5. I0- 
imine 
ml millilitre 
MOPS 3-[N-morpholino] propanesulphonic acid 
MPD myeloproliferative disorders 
mRNA messenger-ribonucleic acid 
MTT methylthiotetrazole 
n nano 
NADP+ ß-nicotinamide adenine dinucleotide phosphate 
NADPH ß-nicotinamide adenine dinucleotide hydrogen phosphate 
neo neomycin 
NF-E2 nuclear factor-erythrocyte 2 
NMDA N-methyl-D-aspartate 
nNOS neuronal nitric oxide synthase 
NO nitric oxide 
NR NMDA receptor 
PAF platelet-activating factor 
PBS phosphate buffered saline 
PCP phencyclidine 
PDGF platelet-derived growth factor 
PDZ PS D-95, Dl `g/ZO- l 
PF4 platelet factor 4 
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Abbreviatioir. s 
PI propidium iodide 
P13-K phosphatidv, linositol-, -k* nase 
PKA protein kinase A 
PKB protein kinase B 
PKC protein kinase C 
PKD protein kinase D 
PLC phospholipase C 
PMA phorbol myristate acetate 
PP1 protein phosphatase 1 
PPDA cis- 1-[phenanthren-2vl-carbonyl] piperaxzin-2.3-dicarhoxvl'C 
acid 
PRP platelet rich plasma 
PS phosphatidyl serine 
PSD postsynaptic density 
PSD-95 postsynaptic density-9S 
PV polvcythaemia vera 
RACK-1 receptor for activated C-kinase-1 
RANK ligand receptor activator of NF-kB 
RNA ribonucleic acid 
RNase ribonuclease 
rpm revolutions per minutes 
RT-PCR reverse transcriptase polymerase chain reaction 
SAP-90 synaptic associated protein-90 
SCF stem cell factor 
SDS sodium dodecyl sulphate 
SEM scanning electron microscope 
SHANK SH -3 domain ankryin repeat 
siRNAs small interfering RNAs 
SNARE soluble N-ethyl maleimide-sensitive factor attachment protein 
receptors 
(v)-SNARE vesicle-SNARE protein 
(t)-SN: kIZF. target-"protein 
SIC sodium citrate 
STATs signal transducers and activators of transcription 
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-l bbreviation % 
SynGAP synaptic GTPase activating protein 
TBE Tris-borate EDT. - 
tbr-1 transcription brain-1 
TEM transmission electron microscopy 
TFIIB transcription factor IIB 
TGFß1 transforming growth factor ß1 
TPEN N, N, N',. '''-tetrakis-[2-pvvridmethvl]-ethvlcnediamine 
TPO thrombopoietin 
TRIS tri (hydroxy) methyl aminomethane 
TRITC tetramethyl rhodamine isothiocyanate 
UCB umbilical cord blood 
U. V. Ultraviolet 
VGLUTI vesicular glutamate transporter I 
VGLUT2 vesicular glutamate transporter 
2 
vWf von-Willebrand factor 
ZO-1 zona occludens protein I 
ýýýý 
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